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Abstract 
 
Colorectal cancer (CRC) is a serious health problem worldwide and current interventions 
combining surgery and chemotherapy are frequently ineffective at preventing cancer 
recurrence and progression in patients. This is largely due to conventional routes of 
administration of anti-cancer drugs, through which drugs that are administered 
intravenously often cannot reach target sites (especially tumours in the colorectal region) 
at therapeutic concentrations. Colon-specific delivery systems through oral administration 
are a promising means for improving treatment of CRC by increasing the local drug 
concentration in the colon. This approach can be further improved by encapsulating drug-
loaded nanoparticles in oral formulations that offer opportunities for targeted delivery and 
enhanced drug uptake specifically by cancer cells, thus minimising side effects on 
surrounding healthy cells in the colon. This thesis describes the development of a colon-
specific delivery system capable of releasing individual drug-loaded nanoparticles in the 
colorectal region to improve chemotherapy for CRC. Eudragit® RS nanoparticles were 
used as a model scaffold for formulation development of colon-specific delivery systems. 
Alginate-based carriers (Chapter 2), hypromellose capsules and chitosan-hypromellose 
microcapsules (Chapters 3 and 4), and chitosan-hypromellose microcapsules 
incorporating drug-loaded nanoparticles (Chapter 5) were investigated as vehicles for 
delivering nanoparticles or model drugs to the colon. 
Chapter 2 investigates the use of alginate microcapsules and pellets for delivering model 
Eudragit® RS nanoparticles and a small molecular drug (indomethacin) to the colon. 
Eudragit® RS nanoparticles were loaded into alginate microcapsules at a high loading 
(22%, w/w) but subsequent aggregation between Eudragit® RS nanoparticles and the 
alginate carrier impeded nanoparticle release from alginate microcapsules into the release 
medium, suggesting that the nanoparticle-carrier interaction may prevent correct 
presentation of individual nanoparticles at the tumour site for uptake by cancer cells. An 
alternative approach was then devised in which indomethacin-loaded Eudragit® S100 
nanoparticles (a pH responsive polymer) were loaded into alginate pellets (2 mm in 
diameter). This ultimately led to increased drug release in the colon compared to the drug 
delivered via Eudragit® S100 nanoparticles.  
To overcome the nanoparticle-carrier aggregation issue observed for alginate 
microcapsules, Chapter 3 presents the development of enteric-coated hypromellose 
capsules (product name: DRcaps® capsules) and chitosan-hypromellose microcapsules 
for colon-specific delivery of Eudragit® RS nanoparticles. DRcaps® capsules coated by 
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Eudragit® L100-55 and alginate released a majority of the nanoparticle load in simulated 
colonic fluid. Furthermore, detection of individual, non-aggregated nanoparticles in 
representative release samples by dynamic laser scattering suggest the potential of 
coated DRcaps® capsules for colon-specific delivery of Eudragit® RS nanoparticles. 
Eudragit® S100-coated chitosan-hypromellose microcapsules released less than 1 % of 
the nanoparticle load in simulated gastric fluid and simulated intestinal fluid, resulting in 
99% of the NP load potentially available for release in the colon.  
Chapter 4 assessed the efficacy of Eudragit® S100-coated chitosan-hypromellose 
microcapsules as vehicles for delivering nanoparticles to the colon in a mouse model. 
Nanoparticle and microcapsule components were labelled with two separate fluorophores 
and their movement along the mouse gastrointestinal tract after oral administration was 
monitored using multispectral optical imaging. Complete nanoparticle release from 
microcapsules was observed in the lower region of the mouse small intestine at 8 h post-
administration. Un-encapsulated nanoparticle suspension administered as a control 
formulation showed significant excretion of nanoparticles in faeces after 5 h. Overall, the 
encapsulation of nanoparticles in microcapsules resulted in a higher nanoparticle intensity 
within the colon from 8 h to 24 h post-administration compared to the control 
nanoparticles, thus indicating a prolonged nanoparticle residence within mouse 
gastrointestinal tract and decreased nanoparticle excretion in faeces.  
Finally, Chapter 5 describes encapsulation of therapeutic drug-loaded Eudragit® RS 
nanoparticles in Eudragit® S100-coated chitosan-hypromellose microcapsules for 
delivering therapeutics to the colon. The encapsulation efficiencies and in vitro release 
kinetics were compared for three model anti-colorectal cancer drugs fluorouracil (5-FU), 
indomethacin and curcumin, each with differing aqueous solubility. The encapsulation 
efficiency was higher for indomethacin and curcumin than 5-FU. In addition, the drug 
loading of nanoparticle-loaded microcapsules decreased with the pH of preparation 
medium of microcapsules, probably reflecting increased drug solubilities with increasing 
medium alkalinity. Incorporation of indomethacin-loaded nanoparticles into microcapsules 
resulted in slower drug release in vitro compared to un-encapsulated nanoparticles, 
whereas curcumin release from nanoparticles and nanoparticle-loaded microcapsules was 
negligible under all conditions investigated in this study. Release of Eudragit® RS 
nanoparticles from chitosan-hypromellose microcapsules was independent of the drug 
load. In general, Eudragit® RS nanoparticles enhanced the cytotoxic effect of curcumin on 
both NIH/3T3 mouse fibroblast cells and HT29 human colon adenocarcinoma cells, 
indicating a lack of specificity for the tumour cells. 
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In conclusion, these results have shown Eudragit® S100-coated chitosan-microcapsules 
are promising carriers for delivering anti-cancer drug and/or drug-loaded nanoparticles to 
the colon. The microcapsules can be utilized as a general platform for ultimately delivering 
targeting ligand-conjugated nanoparticles to the colon, and this strategy will combine 
localised delivery of a payload with specific release of chemotherapeutics within cancer 
cells for improved diagnosis and treatment of CRC. The development of different carriers 
systems described in this thesis form the basis for future design of oral carriers for 
treatment of colon cancer. 
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Chapter 1. Introduction and literature review 
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1.1  Overview  
Colorectal cancer (CRC), also known as bowel cancer, refers to cancer that forms in the colon or 
rectum. It is the fourth leading cause of cancer-related deaths for both men and women worldwide.
1
 
Fortunately, it is one of the most curable cancers if detected early. Surgery is the main and primary 
treatment for colorectal cancer and chemotherapy is often used in combination to kill residual 
cancer cells. In conventional treatments, chemotherapeutic agents are often administered by 
intravenous injection at the maximum tolerated dose to eliminate as many cancer cells as possible.  
Although this approach reduces cancer recurrence and prolongs patient survival, these powerful 
cytotoxic drugs cause damage to healthy cells and tissues, leading to severe side effects in patients. 
To balance efficacy and toxicity, chemotherapy is often discontinued for a 3-4 week interval to 
enable the damaged organs to recover. Nonetheless several cycles of drug administration extending 
over 6 months are generally applied leading to long term detrimental effects to normal tissue. The 
main obstacles to effective colorectal cancer chemotherapy is the difficulty in achieving sufficient 
drug concentrations in cancer cells to achieve therapeutic outcome, while minimising drug 
distribution in healthy tissues to avoid serious side effects.
2-5
  
Targeted drug delivery to the colon has provided benefits for colon related diseases such as 
inflammatory bowel disease (IBD)
6,7
 and has also shown potential for improving chemotherapy 
efficicacy for colonrectal cancer
8,9
. Nanoparticles (NPs) have been studied extensively for cancer 
diagnosis and targeted drug delivery to cancer cells, predominantly by intravenous administration 
(i.v.) due to their ability to control drug release kinetics and enhance drug uptake by cancer cells.
10-
13
 Surface conjugation of NPs with targeting ligands has shown exclusive interaction with cancer 
cells
14-16
 and has been widely recongnized as a promising strategy for enhancing delivery of 
anticancer drugs to tumour cells
17
. Thus, the incorporation of drug-loaded NPs in colon-targeted 
delivery systems has the potential for delivering drug specifically to colon cancer cells, reducing the 
required dose of chemotherapeutic agents and minimizing toxic effects to healthy tissues. The aim 
of this project is to develop a colon-targeted carrier system for delivering individual NPs to the 
colon to enable specific intracellular NP uptake and subsequent drug delivery to colorectal cancer 
cells at the tumour site. 
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1.2 Colon and colorectal cancer (CRC) 
1.2.1 Colon  
The colon constitutes the main part of the large intestine, and is located immediately after the small 
intestine in the human gastrointestinal tract. It is about 1.5 m long and 7.5 cm in diameter, 
consisting of four sections: the ascending colon, the transverse colon, the descending colon, and the 
sigmoid colon (Figure 1-1). The colonic mucosa has a surface area of 0.5~1 m
2
 as it does not have 
villi. In contrast, the villi and microvilli of the small intestine increase its surface area to 
approximately 120 m
2
, making the small intestine the site for absorption of most nutrients from 
ingested food. The function of the colon is to absorb water, salt and some fat-soluble vitamins from 
the remaining indigestible food after its transit through the small intestine, and also to eliminate 
solid waste from the body. A major feature of the colon is the numerous microflora (10
11
~10
12
 
CFU/mL compared to less than 10
3
~10
4
 CFU/mL in the stomach and the duodenum) consisting of 
400 different bacterial species,
18
 accounting for vitamin synthesis and metabolism of residual 
nutrients (e.g. carbohydrates and amino acids) in the colon luminal content. 
 
Figure 1-1 Anatomy of large intestine  
(reproduced with permission from Elsevier, Ref
19
) 
1.2.2 Incidence, mortality, diagnosis and staging of colorectal cancer (CRC) 
According to the Globocan 2012 database, about 1.36 million new colorectal cancer cases were 
diagnosed worldwide in 2012 and 0.7 million people died from the disease. CRC is ranked as the 
fourth leading cause of cancer-related mortality worldwide.
1
 Australia has one of the highest rates 
of bowel cancer in the world, with around 14,860 cases diagnosed and 4,047 fatalities every year.
20
 
Colorectal cancer has become Australia’s second biggest cancer killer after lung cancer and based 
on current trends, it is estimated that 1 in 12 Australians will develop bowel cancer before the age 
of 85.
20
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CRC is caused by malignant cell growth that starts within the inner layer of the large intestine and 
spreads to some or all of the other layers. The layers in the wall of the colon and rectum from the 
inner to the outer: the inner lining (mucosa), the fibrous tissue beneath the thin muscle layer 
(submucosa), the thick muscle layer and the thin, outermost layers of connective tissue (subserosa 
and serosa) that cover most of the colon but not the rectum.
21
 
CRC mostly develops from polyps which may be benign at the beginning but become abnormal 
under uncontrolled growth, and over time spread to form a solid tumour. Although the underlying 
mechanisms for the development of CRC are not clear, many risk factors have been identified
22
, 
such as age, family history and gene mutations between different races, diet high in red meat and 
processed meat, obesity and tobacco smoking. Early detection of colorectal polyps can minimize 
the chance of cancer developing and improve curability. The American Cancer Society 
recommends that women and men at average risk start a regular screen for CRC at the age of 50 and 
people with positive family history start at an earlier age.
23
 
Cancer diagnosis and staging guide clinicians in deciding treatment options for patients and also 
influence patients’ life expectancy. Tests for detecting colorectal polyps or cancer inside the colon 
and rectum include flexible sigmoidoscopy, colonoscopy, double-contrast barium enema, biopsy, 
lab test of samples (gene tests and microsatellite instability test) and imaging tests such as computed 
tomography colonography, ultrasound, magnetic resonance imaging (MRI) scan, chest x-ray, 
positron emission tomography (PET) scan and angiography
21,24
. Among these diagnostic methods, 
the only way to positively distinguish cancer from a benign growth is by biopsy, during which 
tissue sampled from the suspicious area is examined under a microscope. Imaging tests can be used 
for finding suspicious areas in many organs, so are particularly useful in detecting CRC metastasis 
and evaluating efficacy of a given treatment after CRC has been diagnosed. These tests are often 
used together by medical practitioners for diagnosing cancer, determining optimal treatment 
strategy for patients and monitoring cancer development after a treatment is given.
25
  
The stage of colorectal cancer depends on the extent of tumour spread through the layers of colon or 
rectum, nearby lymph nodes and distant organs and the most commonly used staging system is the 
TNM Staging system.
21
 CRC is staged by combining cancer spreading information from three 
aspects: T stands for the growth of primary tumour into the wall of colon or rectal and nearby areas; 
N for the extent of CRC spreading to nearby (regional) lymph nodes; M for cancer metastasis to 
other organs of the body.
26
 Details of each stage are shown in Table 1-1. In advanced cases, cancer 
cells which have penetrated through the colon wall would enter the bloodstream or reach 
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surrounding lymph nodes and can spread to other organs, most commonly the liver and lung. Over 
50% of patients who eventually die from CRC have developed liver metastasis.
27
 Other sites, such 
as bone, brain and peritoneum also form metastatic colorectal cancer (mCRC).
28
  
Table 1-1 Colorectal cancer TNM Staging System
26
 
Stage 0 
Abnormal cells have not grown beyond the mucosa of the colon or rectum wall. 
Stage 0 is also called carcinoma in situ. 
Stage I 
Cancer has grown through the mucosa into the submucosa or has reached the 
thick muscle layer.  It has not spread to nearby lymph nodes, organs or distant 
sites. 
Stage II 
 
 
Stage II 
A 
Cancer has spread to the outmost layers of the colon (serosa) or 
rectum but has not grown through them. It has not spread to nearby 
lymph nodes, organs or distant sites. 
Stage II 
B 
Cancer has grown through the wall of the colon (serosa) or rectum but 
has not spread to nearby lymph nodes, organs or distant sites. 
Stage II 
C 
Cancer has grown through the outmost layers of the colon (serosa) or 
rectum and has grown into nearby organs, but no nearby lymph nodes 
or distant sites. 
Stage III 
 
Stage III 
A 
Cancer may have spread through the mucosa to the submucosa and 
may have spread to the muscle layer. Cancer has spread to at most 3 
nearby lymph nodes or areas of fat near the lymph nodes, but no 
distant sites. 
Cancer has spread through the mucosa to the submucosa. Cancer has 
spread to at least 4 but not more than 6 nearby lymph nodes, but no 
distant sites. 
Stage III 
B 
Cancer has spread to or through the outmost layers of the colon 
(serosa) or rectum but not to nearby organs. Cancer has spread to at 
most 3 nearby lymph nodes or tissues near the lymph nodes, but no 
distant sites. 
Cancer has spread to the muscle layer of the colon or to the outmost 
layers of the colon (serosa) or rectum. Cancer has spread to at least 4 
but not more than 6 nearby lymph nodes, but no distant sites. 
Cancer has spread through the mucosa to the submucosa or to the 
muscle layer. Cancer has spread to 7 or more nearby lymph nodes, but 
no distant sites. 
Stage III 
C 
Cancer has spread through the outmost layers of the colon (serosa) or 
rectum but has not spread to nearby organs. Cancer has spread to at 
least 4 but not more than 6 nearby lymph nodes, but no distant sites. 
Cancer has spread through the muscle layer to the outmost layers of 
the colon (serosa) or rectum or has spread through the serosa but has 
not spread to nearby organs. Cancer has spread to 7 or more nearby 
lymph nodes, but no distant sites. 
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Cancer has spread through the outmost layers of the colon (serosa) or 
rectum and has spread to nearby organs. Cancer has spread to nearby 
lymph nodes or tissues near the lymph nodes, but no distant sites. 
Stage IV 
Stage IV 
A 
Cancer may have spread through the colon or rectum and have spread 
to nearby organs or lymph nodes. Cancer has spread to at least one 
distant organ, such as the liver, lung, or ovary, or to set of distant 
lymph node. 
Stage IV 
B 
Cancer may have spread through the colon or rectum and have spread 
to nearby organs or lymph nodes. Cancer has spread to at least one 
distant organ, such as the liver, lung, or ovary, or to set of distant 
lymph node, or it has spread to distant parts of the peritoneum (the 
lining of the abdominal cavity). 
1.2.3 Treatment of colorectal cancer  
Colorectal cancer is curable if detected at an early stage. Available treatment includes surgery, 
radiation therapy, chemotherapy and immunotherapy (e.g. monoclonal antibodies
29
). Depending on 
the stage of cancer development, a combination of two or more treatments is often needed to 
achieve the best results. Surgery is the main treatment and primary procedure for CRC wherein the 
tumour, surrounding healthy tissue and adjacent lymph nodes are removed. 5-year relative survival 
rate of patients with CRC metastasis to distant organs is much lower than CRC patients at earlier 
stages (Table 1-2).
30
  
Table 1-2 Stage distribution and 5-year relative survival rates at diagnosis of CRC
30
 
CRC Stage at Diagnosis 
CRC stages based on 
TNM Staging system 
Stage Distribution
a
 
(%) 
5-year Relative 
Survival (%) 
Localized (confined to primary site) Stage 0 to II 40 89.8 
Regional (spread to regional lymph 
nodes) 
Stage III 36 70.5 
Distant (cancer has metastasized) Stage IV 20 12.9 
Unknown (unstaged) N/A 5 33.2 
a
Stage Distribution: the stage distribution is based on SEER Summary Stage 2000. Based on data 
from 18 SEER geographic areas, all Races, both Sexes, 2004-2010  
1.2.3.1 Surgery  
The degree of cancer cell spreading to other organs is the main factor determining patients' long-
term prognosis after surgery. For CRC confined to the intestinal wall, surgery is often effective and 
the 5-year patients’ survival rate observed between 2004 and 2010 is 89.8%. In contrast, patients 
with stage IV CRC had a 5-year relative survival rate of only 12.9%.
30
 It is difficult to completely 
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remove cancer cells by surgery and tumour recurrence may occur in local or remote organs due to 
residual cells. Thus, surgery is usually combined with chemotherapy and radiation therapy. Despite 
improved treatment, approximately 35%-55% of patients with CRC will develop hepatic metastases 
during the course of their disease.
31
 For recurrent CRC, a repeat surgical resection has been shown 
to improve life expectancy, although the second and the third hepatectomy becomes more difficult 
than the first resection and this is not suitable for some patients because of severe complications or 
risks associated with repeat surgery.
31-34
  
1.2.3.2 Radiation therapy  
Radiation therapy employs X-rays produced by a linear accelerator to damage cellular DNA and 
inhibit cell proliferation. The energy and irradiated volume of X-rays determine penetration ability. 
It is often used combination with surgery and chemotherapy in treating CRC. The co-administration 
of 5-fluorouracil (5-FU) or its prodrug capecitabine with preoperative radiotherapy for rectal cancer 
increases the remission rate of rectal cancer compared to radiotherapy alone, but has no impact on 
survival or the incidence of distant metastases.
35
 The optimal treatment schedule is bolus 5-FU 
infusion for 4 cycles with continuous 5-FU infusion during 5-6 weeks of radiotherapy.
36
 
1.2.3.3 Chemotherapy 
Conventional chemotherapy for cancer treatment is defined as the use of cytotoxic drugs to inhibit 
cell proliferation and kill cancer cells. Chemotherapy used after surgery is termed adjuvant 
chemotherapy and numerous clinical studies have revealed its survival benefits.
37-40
 In a survey 
covering 929 stage III colon cancer cases over more than 5 years follow-up, Charles et al.
40
 reported 
that a 5-FU/levamisole combination reduced the recurrence rate by 40% and the death rate by 33%. 
Chemotherapy can also be used before surgery to shrink the tumour, when its size or location makes 
surgery difficult. This approach helps to assess tumour response to chemotherapy and to eliminate 
undetected microscopic cells in the body. Drugs approved for treatment of CRC by the FDA include 
5-FU, capecitabine, leucovorin (LV), irinotecan and oxaliplatin (chemical structures shown in 
Figure 1-2). These anticancer drugs have different mechanisms of action in treating CRC. 
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     Figure 1-2  Chemical structures of common drugs used for CRC treatment 
5-FU was initially synthesized in the 1950s and is an analogue of uracil and rapidly enters the cell 
using the same facilitated transport mechanism as uracil.
41
 5-FU is converted intracellularly to the 
active metabolite 5-fluoroxyuridine monophosphate (F-UMP) which incorporates into RNA in 
place of uracil and inhibits RNA processing, thereby inhibiting cell growth. Another active 
metabolite in cells is 5-5-fluoro-2'-deoxyuridine-5'-O-monophosphate (F-dUMP), which inhibits 
thymidylate synthase, resulting in the depletion of thymidine triphosphate, one of the four 
nucleotide triphosphates used in the in vivo synthesis of DNA. However, up to 80% – 85% of an 
administered dose of 5-FU is broken down to inactive metabolites in the liver by dihydropyrimidine 
dehydrogenase (DPD).
42
 The blood concentration of 5-FU after i.v. administration decreases rapidly 
and the half-life of 5-FU is normally approximately 10-15 minutes.
42
 Hence, various strategies have 
been developed to increase the anticancer activity of 5-FU by decreasing 5-FU degradation by DPD 
(e.g. by designing 5-FU prodrugs that avoid DPD-mediated degradation in the liver and co-
administration of 5-FU with DPD inhibitor or substrates), increasing 5-FU conversion to its active 
metabolite F-UMP (e.g. by administration of methotrexate before 5-FU) and stabilizing the binding 
of its metabolites to target enzymes.
41
 Leucovorin is an active metabolite of folic acid and enhances 
the activity of 5-FU and derivatives by stabilizing the binding of their metabolites to target enzymes, 
so it is often administered in combination with 5-FU. 
Capecitabine is a prodrug of 5-FU for oral administration. It is absorbed intact in the human 
gastrointestinal tract with a bioavailability of around 100% 
43
 and converted to 5-FU more actively 
in tumour and liver than other healthy tissues due to the higher expression levels of responsible 
enzymes in liver and tumour cells.
44,45
 In clinical trials, oral administration of capecitabine showed 
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a significantly higher tumour response rate and lower incidence of side effects than bolus 
intravenous injection of 5-FU plus leucovorin (5-FU/LV) in mCRC patients.
46
  
Irinotecan is a prodrug which can be converted to an active metabolite 7-ethyl-10-hydroxy-
camptothecin (SN-38) by a carboxylesterase-converting enzyme in the liver. It has shown survival 
benefits as a single agent in mCRC patients who had cancer progression within 6 months of 5-FU 
treatment.
47
  
Oxaliplatin is an organoplatinum complex in which the platinum atom is complexed with 1,2-
diaminocyclohexane and with an oxalate ligand as a ‘leaving group’. After displacement of the 
labile oxalate ligand leaving group, active oxaliplatin derivatives form both inter- and intra-strand 
platinum-DNA crosslinks, resulting in inhibition of DNA replication and transcription and cell-
cycle nonspecific cytotoxicity.  
Because these drugs act on different cellular targets, combinations of two or more drugs are 
generally superior to single-agent chemotherapy in prolonging progression-free survival of 
patients.
48,49
 For example, combinations of 5-FU/LV plus irinotecan or oxaliplatin increased the 
median overall survival of advanced CRC patients by 2-3 months.
50,51
 Table 1-3 lists the drug 
combinations currently used in CRC and drugs are often administered at high doses. Table 1-4 
shows the dose schedule of different FOLFOX regimens and each regimen repeats every 14 days to 
balance efficacy and toxicity of chemotherapy. 
Table 1-3 Drug combinations used for CRC treatment 
Drug combination name Drugs included 
CAPOX Capecitabine, Oxaliplatin 
FOLFIRI Leucovorin Calcium, 5-FU, Irinotecan Hydrochloride 
FOLFIRI-BEVACIZUMAB 
Leucovorin Calcium, 5-FU, Irinotecan Hydrochloride, 
Bevacizumab 
FOLFIRI-CETUXIMAB 
Leucovorin Calcium, 5-FU, Irinotecan Hydrochloride, 
Cetuximab 
FOLFOX Leucovorin Calcium (folinic acid), 5-FU, Oxaliplatin 
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Table 1-4 Dose schedule of FOLFOX regimens
52
 
Regimen Drug 
Total dose/cycle 
(mg/m
2
)
a
 
Administration route Time Term 
FOLFOX-4 
oxaliplatin 85  i.v.
b
 2 h Day 1 
LV 200  i.v. 2 h Days 1 and 2 
5-FU 400  i.v. bolus 2-10 min Days 1 and 2 
5-FU 600  i.v. 22 h Days 1 and 2 
 
FOLFOX-6 
oxaliplatin 100 i.v. 2 h Day 1 
LV 400 i.v. 2 h Day 1 and 2 
5-FU 400 i.v. bolus 2-10 min Day 1 and 2 
5-FU 2400~3000 i.v. 46 hours Day 1 and 2 
 
FOLFOX-7 
oxaliplatin 130 i.v. 2 h Day 1 
LV 400 i.v. 2 h Day 1 and 2 
5-FU 2400 i.v. 46 hours Day 1 
a 
The dose of drugs to be administered to a patient is calculated using estimated body surface area of 
the patient (m
2
), so the unit of dose is mg/m
2
.    
b
 i.v.:  intravenous injection.  
The outcome of chemotherapy is determined by many factors, including the drug(s) used and 
dosage, timing of chemotherapy, treatment schedule, the extent of cancer cell penetration through 
the bowel wall and other tissues, and the health condition of the patient. In conventional treatment, 
chemotherapeutic agents are usually administered at maximum tolerated dose, aiming to kill as 
many cancerous cells as possible. However, the chemotherapy efficiency is far from satisfactory 
due to the limited drug concentration at tumour sites. Moreover, anti-cancer drugs cause damage to 
healthy cells and tissues and patients suffer from severe side effects including nausea, easy bruising, 
nausea, hair loss and susceptibility to infections. To balance efficacy and toxicity, chemotherapy is 
often followed by 3-4 weeks without drug administration to enable the suppressed bone marrow 
cells to recover. The duration of chemotherapy influences the outcome of treatment and the quality 
of life of patients. In general, chemotherapy should be maintained to achieve the best survival but 
because of the severe toxicity of the drugs, different strategies have been developed to minimize the 
cumulative toxicity, including treatment breaks and restarts, shifts between less intensive therapy 
and more intensive therapy and minimising toxicity. Metronomic chemotherapy involves the 
administration of relatively low and nontoxic doses of drugs without a long-term drug-free break, 
but few clinical studies have evaluated the feasibility and efficacy of this approach.
53-55
 Most side 
effects were mild, but its ability to prolong patient survival time remains to be proven. Recently, the 
sequential use of active single drugs instead of combination regimens has been evaluated in clinical 
trials and shown to reduce the overall toxicity of therapy without compromising survival benefits.
56
 
Overall, the strategy of chemotherapy should be based on therapeutic performance, toxicity 
parameters, patient condition and preferences to achieve the balance between therapy efficacy and 
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toxicity. Clearly, there still exists significant scope for improving the mechanisms by which 
chemotherapeutics are delivered and internalised by tumour cells, including optimisation of 
methodologies to maximise localisation of the administered dose to the site of the tumour. 
1.2.3.4 Immunotherapy 
Rather than killing cancer cells directly, targeted therapies in CRC treatment hinder cancer 
progression and metastasis by inhibiting specific mediators such as vascular endothelial growth 
factors (VEGF) and epidermal growth factor (EGF) involved in these processes.
29
 Drugs approved 
by the FDA for CRC treatment are bevacizumab (Avastin
®
), aflibercept (Zaltrap
®
), regorafenib, 
cetuximab and panitumumab. Bevacizumab, ziv-aflibercept and regorafenib target VEGF pathway 
and cetuximab and panitumumab act on the EGF receptor (EGFR). 
Bevacizumab, a humanised recombinant antibody, has a high binding affinity to VEGF-A, such that 
it prevents binding of the growth factor to specific receptors on the endothelial cell surface, and thus 
blocks angiogenesis. The antibody has only modest single agent activity but, when used in 
combination with bolus 5-FU/LV or FOLFIRI (5-FU/LV/irinotecan), has been shown to increase 
the objective response, progression free survival and overall survival of these treatments in several 
phase III trials.
57
 The use of bevacizumab in combination with FOLFOX has been recommended in 
patients treated with irinotecan as a first-line treatment, with overall survival increased significantly 
from 10.8 months to 12.9 months.
58
 
Aflibercept is a novel recombinant fusion protein which blocks tumour angiogenesis by binding to 
VEGF-A, VEGF-B and placental growth factor. It was approved for use by FDA in 2012 for use in 
combination with FOLFIRI for the treatment of patients with metastatic colorectal cancer (mCRC) 
that is resistant to treatment with an oxaliplatin‑containing regimen.59  
Regorafenib is a novel orally administered small molecule which blocks several kinases (including 
VEGFR, tyrosine receptor kinases, platelet-derived growth factor receptor and fibroblast-growth 
factor receptor) involved in the regulation of tumour angiogenesis and oncogenesis.
60
 An 
international phase III trial covering 1052 patients in 16 countries has shown survival benefits for 
mCRC patients whose cancer has not responded to standard therapies.
61
 
Monoclonal antibodies cetuximab and panitumumab are anti-EGFR agents first introduced as a 
third-line treatment for patients in whom conventional chemotherapy failed. These antibodies have 
shown good results when used in combination with conventional treatments. For example, for 
patients resistant to irinotecan, irinotecan-cetuximab combinations prolonged both progression-free 
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and overall survival times. Van Cutsem et al.
62
 showed that a combination of cetuximab and 
FOLFIRI improved survival of mCRC patients bearing the wild type KRAS gene, although no 
benefits were observed in patients with the KRAS gene mutation. Similar results were found for a 
FOLFOX-panitumumab combination compared with FOLFOX alone.
63
 The mutation status of 
BRAF, NRAS and PIK3CA genes was also reported to influence the efficacy of cetuximab alone.
64
 
Thus, the presence of these mutations should be tested to determine whether patients can benefit 
from therapy with anti-EGFR agents. Such approaches are part of the trend towards more 
personalised treatments for CRC. 
1.3 Strategies to improve chemotherapy for colorectal cancer  
1.3.1 Challenges associated with CRC chemotherapy 
Chemotherapeutic treatments for CRC are not as effective as for some other cancers, because of the 
difficulty of delivering drug at effective concentrations to the target site. In order to maintain 
therapeutic concentrations at the tumour site, chemotherapeutic drugs must be administered at high 
doses and this causes serious toxicity to normal (non-cancerous) tissues and organs. In many cases, 
the failure to achieve effective doses at the tumour site leads to cancer recurrence and progression to 
advanced stages, with reduced patient survival. A survey of clinical data covering 17,381 stage II 
and III CRC patients showed that 32.9% experienced cancer recurrence after surgery alone or with 
5-FU based chemotherapy and the median time from recurrence to death was 13.3 months.
65
  
Intravenous injection is the most common administration route for chemotherapy, but unfortunately 
it often results in low levels of drug in the colon. With this route, drug is transported via the 
bloodstream to major organs (e.g. liver, lung, heart and kidney), leading to widespread drug 
distribution, metabolism and excretion; as a result with drug concentrations in the colon are too low 
to be effective. A clinical pharmacokinetics study of 5-FU administered to cancer patients by i.v. 
bolus injection at 500 mg/m
2
 showed that the elimination half-life of 5-FU was less than 15 min,  
metabolites were detected within 5 min post-injection and approximately 60-90% of the 
administered dose was excreted in urinewithin 24 h in the form of metabolites.
66
 Because of this, 
chemotherapeutic drugs are often administered by slow infusion over several hours or even days to 
maintain therapeutic levels of drugs in plasma. Studies showed that patients with disseminated 
carcinomas treated by continuous i.v. infusion of 5-FU over 96 h had constant levels of the drug in 
plasma and significantly (50- to1000-fold) less drug in bone marrow, compared to a rapid i.v. 
injection of 5-FU which gave high early levels of drug both in plasma and bone marrow followed 
by a rapid fall.
67
 Although this dosage regimen improves CRC chemotherapy to some extent and 
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shows reduced side effects compared to bolus injection, it cannot avoid the problematic wide 
distribution of drugs resulting from i.v. injection. Kovach and Beart showed that the 5-FU 
concentration ratios for tumour-to-healthy tissue, tumour-to-plasma and healthy tissue-to-plasma in 
CRC patients were near 1.0 following intravenous bolus injection (500 mg/m
2
) or infusion (1,000 
mg/m
2
 over 24 h), indicating a lack of preferential distribution of 5-FU in the tumour.
68
 Only a 
fraction of i.v. administered irinotecan is converted to SN-38, with the remaining drug metabolized 
by CYP3A4 (and possibly CYP3A5) or excreted via hepatic or renal transport.
69-71
 Graham et al.
72
 
reported that for cancer patients treated with oxaliplatin at 130 mg/m
2
 for a single 2 h infusion, 
approximately 54% of drug was excreted in urine. Besides, the long term i.v. injection of anticancer 
drugs necessiates the inconvenience of drug administration via an in-dwelling catheter and leads to 
serious and diverse side effects including hair loss, nausea, vomiting, loss of appetite and increased 
chance of infection. Therefore, novel drug administration strategies which both increase drug 
concentration at the tumour site and reduce systemic concentrations promise to improve efficacy 
and reduce the side effects of chemotherapy.  
In addition to delivering anticancer drugs specifically to the tumour site, there is a need to improve 
the efficiency of drug uptake by cancer cells. The tumour microenvironment is composed of 
connective tissue that contains a tumour-associated extracellular matrix and several different cell 
types, including endothelial cells which form new vas
73
culature, immune and inflammatory cells, 
bone marrow-derived mesenchymal stem cells that differentiate into various components of the 
stroma, smooth muscle cells and fibroblastic cells.
73,74
 Fibroblastic cells are activated in response to 
tumour progression, resulting in changes in the surrounding mesenchyme and promoting tumour 
development.
75
 The tumour microenvironment is complex and its pH is slightly acidic, in the range 
of 6.5 to 6.9, as tumour cells often use glycolysis rather than oxidative metabolism; high interstitial 
pressure causing poor perfusion reduces the clearance of the resulting acidic products.
75,76
 Most 
chemotherapeutics are membrane permeable in their neutral form and the protonation of some basic 
anticancer drugs (e.g. irinotecan, doxorubicin) in the acidic extracellular environment would reduce 
drug permeation through the cell membrane. In addition, molecular efflux pumps in cancer cells 
pump drugs out of cells, decrease intracellular accumulation and give rise to multidrug resistance 
(MDR).
77
 Multidrug resistance-related protein (MRP) belongs to the ATP-binding cassette 
superfamily of membrane transporter proteins. P-glycoprotein, also known as multidrug resistance 
protein 1, is a 170 kDa polypeptide shown to be involved in MDR in colon cancer.
78
 Gradilone et 
al.
79
 reported that celecoxib induced the over-expression of MRP in colon cancer cells and co-
administration of celecoxib with 5-FU and irinotecan in clinical trials resulted in an inferior 
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treatment, probably because of MRP-mediated efflux of 5-FU and irinotecan. Based on these 
studies, it can be concluded that enhancing drug cellular internalisation and retention in cancer cells 
would facilitate drug interaction with its cellular target sites, leading to a more efficient 
chemotherapy.  
Another problem in chemotherapy is that most drugs lack specificity towards cancer cells.
80
 
Following administration, they can be simultaneously uptaken by healthy cells in tissues 
surrounding the tumour, causing toxicity to the healthy cells and unwanted side effects. The poor 
specificity of anticancer drugs towards cancer cells needs to be addressed to improve 
chemotherapeutic efficacy. 
1.3.2 Strategies to improve CRC chemotherapy 
Nanoparticles (NP) have shown potential for delivering anti-cancer drugs or agents to colorectal 
cancer cells while reducing undesired drug distribution in healthy tissues.
81-83
 To date, most of the 
drug-loaded NPs have been designed for i.v. administration, aiming to accumulate in tumour sites 
during their circulation in blood vessels and subsequently kill cancer cells. Enhanced anti-tumour 
efficacy of drug-loaded NPs compared to the drug has been shown in animal models in which 
human or animal colorectal cancer cell lines are injected into animals subcutaneously
81,83
 or 
intravenously
84
 to mimic metastatic CRC. Orthotopic colon cancer models, in which cells or tissue 
are transplanted to the colorectal region
85
, simulate primary or localized CRC. Another method to 
induce tumours in colorectal region entails weekly intraperitoneal injection of azoxymethane over a 
period of six weeks. Choi et al.
86
 used this latter model to demonstrate effective tumour suppression 
by i.v. injection of irinotecan-loaded hyaluronic acid NPs due to their targeted accumulation in the 
tumour through the enhanced permeation and retention effect and strong receptor binding to the 
hyaluronic acid receptor, which is over-expressed in colorectal cancer cells. 
Despite these promising advances in design of nanomedicines, NPs administered by i.v. injection 
often showed high distribution in major organs with high blood flow (e.g. liver, lung, spleen, 
kidneys) compared to tumour tissue.
81,87-91
 The non-specific distribution of NPs decreases the 
amount available for accumulation in the tumour site and long-term i.v. administration could result 
in impairment of major organs. Hence, researchers have investigated other administration routes, in 
particular oral formulations for treating CRC, especially for the localised (in situ) cancer. Oral 
administration avoids the inconvenience and discomfort of intravenous injection, and targeted drug 
delivery to the colorectal region has potential for achieving higher dosing with reduced systemic 
toxicity. Various carrier systems (e.g., tablets
92
, pellets
93
, hydrogel
8
, NP-loaded pellets
94
) have been 
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shown to increase drug delivery to the colon and improve chemotherapeutic efficacy. One 
disadvantage of these colon-specific delivery systems is that they are designed to release the anti-
cancer drugs in the colorectal region, but as the drugs lack of selectivity towards cancer cells, 
healthy cells are also damaged. This issue has not been well addressed by studies to develop oral 
formulations for CRC chemotherapy.
95
 Instead of direct loading of anti-cancer drugs, one possible 
solution is the incorporation of drug-loaded nanoparticles (NPs) into colon-specific carrier systems. 
An example of this approach was the encapsulation of oxaliplatin-loaded NPs in alginate 
microspheres reported by Urbanska et al.
96
 and they demonstrated that this ‘particle-in-particle’ 
system reduced the tumour progression in CRC orthotopic mouse model. A similar NP-in-
microsphere system was the poly(epsilon-caprolactone) microspheres loaded with gelatine NPs 
reported by Bhavsar et al.
97
, which were shown to deliver plasmid DNA to rat small and large 
intestine more effectively than un-encapsulated gelatine NPs, due to protection of the plasmid from 
the harsh environment in the digestive tract.  
NPs developed for targeted drug delivery to cancer cells are often evaluated by tissue distribution 
studies which look at concentration of encapsulated drugs in collected tissues. Usually NPs are 
regarded as drug carriers only and their in vivo fate following oral administration has not been well 
investigated, but would provide significant insight into the effectiveness of the oral delivery 
vehicles for CRC chemotherapy. However, Pinkerton et al.
98
 reported that incorporation of 
poly(styrene) NPs in poly(ethylene glycol) (PEG) gel microparticles improved distribution of the 
NPs in the lungs following i.v. injection in mice, thus demonstrating the potential of this approach 
for lung cancer imaging and targeted drug delivery. The delivery of therapeutic NPs to the 
colorectal region may similarly overcome the barriers to successful CRC chemotherapy.  
Thus this thesis investigates the hypothesis that the incorporation of drug-loaded NPs within a 
colon-targeting carrier system (suitable for oral administration) will 1) protect drug-loaded NPs 
from release in the upper gastrointestinal tract and 2) release them in the colon where NPs will 
promote drug uptake by cancer cells and thus improve the efficacy of CRC chemotherapy. There 
have been few studies combining advantages of colon-specific delivery systems and NPs for 
improving the uptake of chemotherapeutic drugs by CRC cells. The following two sections will 
review previous research into colon-specific delivery systems and NP-based targeted delivery 
systems. The advantages and disadvantages of the two approaches for improving CRC 
chemotherapy will be compared. 
Chapter 1 
 
 16 
1.3.3 Colon-specific drug delivery systems – drawing insight from delivery vehicles for 
diseases beyond cancer 
The colon has been widely investigated as a target site for drug delivery for topical treatment of 
local diseases (e.g., ulcerative colitis, Crohn’s disease and irritable bowel syndrome). The harsh pH 
conditions in the stomach and the intestinal enzymatic metabolism limit drug availability for 
systemic absorption and result in low bioavailability of proteins or poorly permeable drugs.
99
 
Compared to the stomach and small intestine, the colon has a near neutral pH, reduced digestive 
enzyme activity, susceptibility to absorption enhancers and long transit time (from 6 to 48 h).
100
 
These features have been taken into account to improve oral bioavailability of some active 
molecules (e.g., insulin, salmon calcitonin)
101,102
 by developing oral formulations which prevent 
drug release in the stomach and small intestine but allow drug release upon arrival in the colon. 
These oral drug delivery carriers are termed ‘colon-specific carrier systems’. 
Most of the colon-specific drug delivery systems described in the literature are based on four 
primary strategies: 1) prodrug-based approach, 2) time-dependent systems, 3) pH-dependent 
devices and 4) microflora-activated systems. Among these, the pH-dependent systems are the most 
widely used commercially.
103
 Novel systems, such as intestinal pressure-controlled capsules, pectin-
galactomannan coatings and azo-hydrogels. have recently been developed.
104
 The latter two systems 
utilize the combinined pH-dependent and microflora-activated mechanisms for achieving colon-
specificity.
104
 
1. The prodrug-based approach 
A prodrug is a pharmacological substance administered in an inactive or much less active form of a 
parent drug to modulate pharmacokinetic properties of the parent drug. After administration, the 
prodrug is metabolised in vivo to an active metabolite. For colon-specific delivery, prodrugs are 
normally designed to be hydrophilic or bulky by conjugating drug molecules to hydrophilic small 
molecules (e.g., sulfate, amino acids and sugars) or polymers (e.g., cyclodextrin, poly(L-aspartic 
acid) and dextran). This limits the absorption of prodrugs in the upper gastrointestinal tract and the 
intact prodrugs can release active drug in response to the altered pH or specific enzyme activity in 
the colon. Enzymes such as azoreductase, glycosidase, polysaccharidases and cyclodextrinase 
produced by colon microflora have been successfully exploited for activation of colon-targeted 
prodrugs, including azo-bonded prodrugs, glycoside-, glucuronide-, cyclodextrin-, dextran- and 
amino acid conjugates.
105
 For example, sulfasalazine, ipsalazine, balsalazine and olsalazine are 
prodrugs based on azo linkages for the delivery of 5-amino salicylic acid to the colon.
106
 Around 60% 
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of a dexamethasone-glucose prodrug was found to reach the cecum after oral administration in 
rats.
107
 Mcleod et al. 
108
 conjugated dexamethasone to dextran for treatment of experiment colitis in 
rats and reported that the drug was released in the cecum and the colon. Despite these promising 
results, the clinical application of prodrugs is quite limited since their manufacture depends on the 
availability of functional groups within the drug molecule suitable for chemical linkage. Moreover, 
since prodrugs are new chemical entities, regulatory approval requires substantial evaluation to 
confirm their function and safety. 
2. Time-dependent systems  
Time-dependent systems are designed to achieve colon specific delivery by utilizing the transit time 
for the formulation to pass through the upper GI tract as a timing mechanism to engineer colonic 
releaseof the drug. Various coating layers which erode over a predetermined time are employed to 
protect drug from being released in the stomach and small intestine. Krogel et al.
109
 placed an 
erodible compressed tablet as a plug in the opening of a drug-containing impermeable capsule and 
determined release specificity by the composition and thickness of the erodible tablet. A novel Time 
Clock
®
 system used a coating composed of hydrophobic polyoxyethylene sorbitan monooleate and 
water soluble hypromellose.
110
 The coating disintegrated in an aqueous environment at a rate 
proportional to the coating thickness and gradually exposed the drug core for dissolution. However, 
a major limitation of these time-dependent systems is the variation in their transit time through the 
human gastrointestinal. Gastric emptying time is highly variable; influenced by food intake, dosage 
form, size and density of the formulation. Studies have shown that enteric-coated tablets can remain 
trapped in the stomach for over 12h.
111,112
 Although mean transit time through the small intestine  is 
3 ± 1 h, the range is from 30 min to over 9 h.
113
 After passing through the small intestine, large 
single-unit dosage forms were found to stay in the ileocaecal junction for 2 to 10 h before they 
reached the caecum.
114
 All these variations make the time-dependent systems unreliable, despite 
their capable to release their load precisely after a pre-set lag time. 
3. pH-dependent devices  
pH-dependent devices utilize the pH changes along the GI tract to control drug release. In healthy 
volunteers, luminal pH increases from the duodenum (pH 6.6±0.5) to the terminal ileum (pH 
7.5±0.4), decreases in the cecum (pH 6.4±0.4), and then slowly rises from the right colon to the left 
colon to a final pH at 7.0±0.7.
115
 Coatings made of pH-responsive polymers, such as Eudragit
® 
L100-55, Eudragit
® 
S100, cellulose acetate trimellitate, hydroxypropyl methyl cellulose phthalate 
(HPMCP), (Figure 1-3) have been widely used alone or together in the past for site-specific drug 
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delivery to the lower GI tract.
105
 These polymers have a high threshold pH (at least 5.0) for 
dissolution, and are capable of withstanding gastric acid and small intestinal fluid for several hours 
to protect drug from exposure to these conditions. For example, TARGIT™ 116 capsules which use 
a Eudragit
®
L/S (3:1) mixture as a coating on starch capsules were shown that around 90% of 
TARGIT capsules delivered their contents to the target site of the terminal ileum and colon in 
healthy volunteers. Schroeder et al.
117
 reported that 5-aminosalicylic acid tablets coated with 
Eudragit
®
S (which dissolves above pH 7.0) for delivering drug to the distal gut showed effective 
therapy in ulcerative colitis patients. However, the site specificity of pH responsive dosage forms 
may be unsatisfactory in some individuals due to factors such as transit time, which would influence 
their exposure to luminal fluids.
118
  
 
Figure 1-3 Chemical structures of Eudragit
®
 L100-55, Eudragit
®
 S100, cellulose acetate 
trimellitate and hydroxypropyl methyl cellulose phthalate (HPMCP) 
4. Microflora-activated systems  
Microflora-activated systems usually refer to colon-specific carriers based on polysaccharides 
which can be digested by bacteria available in the colon. The enormous population (about 10
11
-10
12 
CFU/mL
18
) of colon bacteria produce a range of enzymes to act on specific substrates that are left 
undigested after passage through the small intestine. These enzymes present a more reliable feature 
of the colon for achieving site-specific drug delivery when compared to transit time or pH 
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change.
119
 Substrates for these enzymes include polysaccharides such as chitosan, amylose, 
cyclodextrins, pectin, guar gum and alginate which have been used as coatings or matrices in 
delivery systems.
105
 Degradation of these polysaccharides by enzymes produced by microflora in 
the colon subsequently activates drug release. Cummings et al.
120
 demonstrated in healthy 
volunteers that amylose/ethyl cellulose coating of glucose-microcrystalline cellulose pellets 
protected the pellets from breakdown in the upper gastrointestinal tract so that the glucose load was 
predominantly released in the large bowel. Carrier systems combining pH-dependent and 
microflora-activated mechanisms have been developed to prevent burst drug release in the stomach 
and small intestine and achieve improved colonic delivery. Rai et al.
121
 showed that oral 
administration of 5-FU-loaded dextran microspheres coated by Eudragit
®
 S100  to rats achieved 
specific drug release in the colon. Similarly, orally administered  HPMCP-coated chitosan capsules 
delivered insulin to the rat colon,
122
 and subsequently exhibited varying hypoglycemic effects 
depending on the protease inhibitors or absorption enhancers incorporated in capsules. Because of 
the interplay of gastrointestinal factors that influence drug release from colon-specific carriers, the 
most effective delivery systems in the future will likely combine the different characteristics of each 
of these processes to achieve colon specific delivery. 
1.3.4 Nanoparticles  
According to the standards developed by organizations like American Society for Testing and 
Materials and International Organization for Standardization, nanoparticles are generally defined as 
particles in the size range of 1~100 nm.
123
 This is in contrast to the literature, in which particles of 
nanoscale size (smaller than 1 mm) prepared from various materials such as lipids, inorganic 
materials, polymers and dendrimers have been referred as nanoparticles and been exploited for 
targeted drug delivery to cancer cells.
124-127
 NPs act as effective carriers of different types of drug 
cargo, including small molecules, peptides, proteins and nuclear acids which can be physically 
encapsulated or covalently conjugated to them. NPs can be fabricated from various materials and 
their size, shape and surface properties can be tuned to modify in vivo fate of both NP and loaded 
drug molecules. Hence, the application of NPs in cancer therapy has been widely investigated and 
their potential for improving chemotherapy by enhancing drug delivery to cancer cells has been 
demonstrated.
83,126,127
 The encapsulation of chemotherapeutic drugs in NPs has the potential to 
overcome problems such as insolubility of hydrophobic drugs, protect drug load from degradation 
in harsh physiological environments, control drug release kinetics, increase drug uptake by cancer 
cells and target cancer cells through passive or active targeting mechanism. 
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(1) Many anti-cancer drugs are hydrophobic and their low water solubilities limit anti-cancer 
efficacy, because only a small fraction of administered drug dissolved in biological fluids, thus 
limiting the drug availability to cancer cells. The high surface-to-volume ratio of NPs enables a 
sustainable release of encapsulated hydrophobic drugs over time. In addition, NP composition can 
be tailored to overcome pharmacokinetic limitations of the free drug. Jie et al.
128
 reported that the 
successful loading of camptothecin, a water-insoluble drug, into mesoporous silica nanoparticles 
resulted in negligible drug release in phosphate-buffered saline (PBS) and increased drug uptake 
and apoptosis in human colon cancer cells (SW480). SN38, an active metabolite of the 
topoisomerase I inhibitor irinotecan
129
, cannot be used clinically due to its poor solubility and high 
toxicity. However, Sayari et al.
130
 showed that NPs, prepared from SN38-chitosan conjugates and 
attached to MUC1 DNA aptamer for active targeting of colon cancer, exhibited improved in vitro 
efficacy on human colon cancer HT29 cells. 
(2) Compared to conventional oral administration of drugs, NPs can protect drug from release and 
metabolism in the stomach and small intestine, thus increasing the amount of drug available for 
systemic absorption or localized delivery within the colon. Additionally, NP compositions can be 
tailored to provide effective delivery of loaded drug to the desired location. For example, Ray et 
al.
131
 synthesized poly(acrylic acid-co-acrylamide) by free radical polymerization and adjusted the 
monomer ratio for hydrogel swelling in rat caecal medium. When delivered orally, these 
poly(acrylic acid-co-acrylamide) NPs were capable of delivering 60% of the 5-FU load to the rat 
colon compared to less than 5% of unconjugated 5-FU solution. In another study, Khalil et al.
132
 
demonstrated that addition of polyethylene glycol to polylactic-co-glycolic acid NPs increased the 
oral bioavailability of curcumin in rats by 3.5-fold, enhancing curcumin release and absorption into 
the systemic circulation.  
(3) NPs can enhance drug uptake by cancer cells. Endocytosis is generally regarded as the uptake 
mechanism for NPs and multiple endocytic pathways can be involved in the uptake of a single type 
of particle.
133
 Upon internalisation, NPs localize in endosomal compartments which gradually 
mature as pH decreases and lysozymes are activated. Drug-loaded NPs will either be released into 
the cytoplasm or transported to lysosomes for degradation, depending on their physico-chemical 
properties. Drug-efflux pumps in cancer cells reduce intracellular drug concentration and 
accumulation, resulting in tumour resistance and chemotherapy failure.
77
 Thus, the internalization 
of NPs via endocytosis potentially allows them to reach the cytoplasm and enhance drug efficacy, 
thus preventing the drug cargo from being recognized and transported out of the cell by drug-efflux 
pumps.
134
 NP uptake by cancer cells has been reported to be influenced by many factors, including 
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surface charge, size, shape, hydrophobicity, surface modification and receptor affinity. Studies have 
shown that positively charged NPs are generally better internalised in cells than their respective 
negatively charged ones.
135-137
 Feng et al.
138
 demonstrated that the uptake of 100 nm polystyrene 
NPs by Caco-2 cells was higher than that for other sizes (50, 200, 500 and 1000 nm). Chithrani et 
al.
139
 reported that spherical gold NPs exhibited higher uptake in HeLa cells than their rod-shaped 
counterparts. Gratton et al.
140
 found that cationic PEG nanorods with a diameter of 150 nm and a 
length of 450 nm were internalized by HeLa cells more rapidly than NPs with a diameter and length 
of 200 nm, probably due to the stronger electrostatic interactions with cells as high length-to-
diameter ratio of the NPs resulted in larger surface area in contact with the cell membrane. These 
studies highlight the importance of considering and understanding the physicochemical properties 
of NPs when designing drug delivery systems. 
(4) NPs offer the potential to deliver drugs specifically to cancer cells and reduce their interaction 
with healthy cells or tissues for improved efficacy and safety. The mechanisms of NP targeting can 
be classified as either passive- or active-targeting. The passive-targeting mechanism is also called 
the ‘Enhanced Permeability and Retention (EPR) effect’, by which NPs circulating in normal blood 
vessels can selectively enter tumours through their leaky surrounding blood vessels and retain in the 
tumour interstitial space. It is believed that a NP size range of 10~100 nm is optimal for the EPR 
effect.
141
 To prolong NP circulation in the blood for better EPR effect, NP surface are often 
modified with poly ethylene glycol to reduce their recognition and clearance by the mononuclear 
phagocyte system. However, NPs that employ the EPR effect to deliver chemotherapeutic drugs are 
generally administered by i.v. injection, since absorption of oral administered NPs from the 
gastrointestinal tract into the systemic circulation is insufficient.  
Active targeting of NPs to cancer cells requires specific ligand-receptor recognition and interaction 
on the cell surface. Cancer cells express some cell-surface receptors at high levels compared to 
normal cells. This allows NPs conjugated with a targeting ligand to specifically interact with them 
via receptor-mediated molecular recognition. Available receptors for targeting colorectal cancer 
cells include folate receptor
142
, hyaluronan receptor
143
, transferrin receptor
144
 and epidermal growth 
factor receptor
145
. Antibody/ligand-conjugated NPs targeting these receptors have shown enhanced 
NP-cancer cell interaction in vitro and exhibited stronger anti-proliferative effects on cancer cells 
than unmodified NPs.
146-149
 Animal studies have illustrated the potential of this targeted drug 
delivery strategy for improved cancer chemotherapy. One example is the overexpression of 
hyaluronan receptor CD44 in colon tumour cells for targeted delivery of paclitaxel.
150
 Rivkin et 
al.
150
 demonstrated that i.v. injection of hyaluronan coated paclitaxel-lipid NPs into mice with colon 
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adenocarcinoma increased drug accumulation in the tumour by 10-fold, reduced drug accumulation 
in liver and spleen compared to the free drug formulation (Taxol
®
), and showed higher tumour 
suppression compared to Taxol
®
 or a non-targeted albumin NP formulation. In general, these 
studies have demonstrated the potential of nanotechnology for improving the efficacy of cancer 
treatment.  
1.3.5 Microcapsules and nanoparticles for colon-specific delivery: current status on 
preparation, characterization and evaluation  
Although colon-specific capsules and tablets have been commercialized successfully, drug delivery 
systems with smaller sizes (e.g. microcapsules (MCs) and NPs) have been recognized as more 
effective carriers than the large formulations, for they can enhance delivery of the drug load to its 
cellular targets.
99,151
 The proposed molecular mechanism of this is that micro- or nano- sized 
carriers can avoid drug contact with the multi-drug efflux pumps and metabolic enzymes (e.g. 
cytochrome P450 enzymes) which are present on the cell surface in gastrointestinal tract and result 
in limited drug absorption.
152,153
 Various polymers have been used for fabricating 
microcapsules(MCs)
120,121,154,155
and nanoparticles
94,151,156,157
 and they can be simply classified as 
synthetic and biodegradable natural polymers. Among these systems, MCs or NPs produced from 
chitosan, alginate and/or the Eudragit
®
 series of polymers have shown potentials for delivering 
drugs to the colon.
95,151
 However, their application on delivering individual NPs to the colon has not 
been well explored. 
1. Preparation of MCs from chitosan and/or alginate  
Chitosan and alginate are hydrophilic polysaccharides which are subjected to degradation by 
bacterial enzymes generated by colonic microflora.
105
 They are polyelectrolytes and can form a 
hydrogel in aqueous media at room temperature through ionic interactions with polyanions of 
opposite charges (e.g. chitosan with tripolyphosphate or gelatin and alginate with Ca
2+
). Methods 
for MC preparation include ionotropic gelation method, spray drying and emulsion method
158
.  
The ionotropic gelation method involves extruding polymer solution as droplets into cross-linking 
solution and hardening of polymer droplets to form MCs.
159,160
 This approach can prepare MCs of a 
small batch by only using several milliliters of polymer solution. Also, organic solvents are not 
included in this method, making sample collection really simple. One disadvantage of this process 
is that MCs may have irregular shape due to a high impact of polymer droplets with the surface of 
cross-linking solution.  
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Spray drying is based on atomization of a polymer solution containing active substances the in a 
drying chamber. The small droplets are converted into dried MCs during solvent evaporation in 
heated air. This technique is widely used in the food and pharmaceutical industry because of its 
reliability, reproducibility, and avoidance of the use of organic solvents. Small MCs with a diameter 
less than 10 µm can be produced.
161,162
 Due to the use of large volume of hot air to dry polymer 
droplets, spray drying is not suitable for microencapsulation of heat sensitive materials such as 
vaccines, proteins and NPs.  
In the emulsification technique, polymer solution containing drug is dispersed in an immiscible 
organic phase (e.g. isooctane, silicone oil, liquid paraffin
155
) and cross-linking solution is 
subsequently added to form MCs. This method uses a large volume of oil phase to form a water-in-
oil emulsion and the prepared MCs are usually washed by organic solvents to remove the oil phase.  
2. Preparation of NPs from Eudragit® polymers 
The Eudragit
®
 series of polymers are esters of acrylic and methacrylic acid and have different pH-
dependencies of solubilities as determined by the monomer compositions and their functionalities. 
A wide range of Eudragit
®
 polymers is commercially available for applications including enteric 
coating and preparation of controlled drug release systems. Eudragit
®
 L100, S100 dissolve above 
pH 6 and 7, respectively and Eudragit
®
 RS is insoluble in aqueous media. Because of their varied 
solubilities, these polymers have been extensively used, either alone or in combination with each 
other, as coating or matrix bases of colon-specific delivery systems (e.g. tablets, pellets, 
MCs).
92,94,163-167
  
Drug release from Eudragit
® 
NPs largely depends on the type of Eudragit
®
 polymer used. Yoo et 
al.
168
 loaded Eudragit
®
 S100 NPs with hydrophilic sodium fluorescein and hydrophobic nile red, 
respectively and compared their in vitro release kinetics from the NPs. Both compounds was 
released slowly in pH 4.0 buffer but were completely released within 2 h in pH 7.4 phosphate buffer. 
In contrast, ciprofloxacin-loaded Eudragit
® 
RS NPs prepared by Kathleen et al
169
 showed a 
sustained release for 25 h in pH 7.4 buffer. The different solubilities between Eudragit
®
 S100 and 
RS resulted in the different drug release profiles in these two studies. Because of the high variable 
pH conditions in the colon, combination of Eudragit
®
 NPs with other delivery systems utilising a 
different colon- targeting mechanism would be a promising strategy to achieve colon-specific drug 
delivery. Table 1-5 lists different methods for production of Eudragit
®
 NPs.  
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Table 1-5 Methods of preparing NPs Eudragit
®
 S100 or RS polymer 
Method 
Eudragit 
Polymer 
Compound encapsulated Size(nm) Ref 
Nanoprecipitation 
 
RS Salmon calcitonin 247.3 170 
S100 Curcumin 100 171 
Emulsion-solvent 
evaporation 
RS100 Ciprofloxacin 170 172 
RS low molecular weight heparin 241.6 173 
Emulsion-solvent 
diffusion 
S100 Sodium fluorescein 241.9 168 
RS100 Sodium ibuprofen 100 174 
RS100 Glutathione 156 175 
Interfacial polymer 
deposition 
S100 Melatonin 241 176 
 
2. Characterisation of MCs and NPs 
Characterisation of drug-loaded MCs or NPs include measurement of size distribution and surface 
charge, surface morphology and chemistry, physical and chemical status of the drug within the 
carrier systems, drug loading and encapsulation efficacy. Commonly used techniques for particle 
size analysis are laser light scattering, optical microscopy (for MCs), scanning electron microscopy 
(SEM), atomic force microscopy (AFM) and transmission electron microscopy (TEM). In general, a 
uniform particle size is desired but may be difficult to achieve due to the preparation process. SEM 
and AFM can also provide information on surface morphology. AFM has higher resolution than 
SEM and thus is more useful for examining the surface of NPs.
177
 The surface chemistry analysis of 
NPs or MCs is usually carried out to confirm the successful coating on particles or drug 
incorporation. Available methods for this are X-ray photoelectron spectroscopy or the Fourier 
transform infrared spectroscopy. Differential scanning calorimetry (DSC) is often used to examine 
the physical state of the drug in NPs or MCs and access possible drug-excipient.
155,178
 Normally the 
thermogram of drug-loaded particles is compared to that of raw drug and blank particles (without 
drug incorporated). For example, Mu and Feng used DSC to compare the influence of different 
emulsifiers on the physical state of paclitaxel encapsulated in the PLGA mcirospheres.
179
 The drug 
loading of a drug delivery system is defined as the weight ratio of the active drug to the total 
formulation while the encapsulation efficiency is the weight ratio of the drug successfully 
encapsulated in the formulation to that of initial drug used in the preparation process. Both indexes 
are useful in formulation optimization: a carrier system with a high drug loading will reduce the 
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quantity of excipients required for dosing sufficient amount of drug; the higher encapsulation 
efficiency of a formulation is, the less drug has been wasted during the preparation process. These 
characterisation methods validate the composition of particulate carriers (especially the drug 
encapsulation) thus are usually conducted to ascertain the optimal formulation for in vitro/vivo 
efficacy evaluation. 
3. In vitro evaluation of colon-specific delivery systems 
Compared to other in vivo evaluation methods based on animal use, in vitro drug release study is a 
relatively simple model to evaluate the potential of carrier systems for colon-specific delivery. It 
utilises different buffers and incubation times to simulate the gastrointestinal conditions that a test 
formulation may encounter after oral administration. The colon presents a highly complex 
biochemical environment in both pH terms and dosage transit time. The reported pH in the human 
terminal ileum of 7.5±0.5 drops to 6.4±0.6 in the ascending colon and rises to a final value of 
7.0±0.7 in the descending colon,
115,180
 and the maximum mean colonic transit time in humans is 
reported to be as high as 33 h in men and 47 h in women.
181
 Currently, there is no standard recipe 
for simulated colonic fluid (SCF) and pH 7.4 phosphate buffer is conventionally used to simulate 
the near neutral pH condition in the colon.
95
 Different timelines for colonic release study have been 
utilised by researchers depending on their own experimental considerations. For example, Glavas et 
al.
182
 performed release study of chitosan-alginate MCs in pH 7.4 phosphate buffer for 24 h to 
simulate ileo-colon conditions. In contrast, Xing et al.
183
 assessed drug release from alginate MCs 
in the same buffer for 3 h and Thakral et al.
155
 tested Eudragit
®
 S100-coated chitosan microspheres 
for 6 h. To evaluate the susceptibility of microflora-activated systems to the in vivo colonic 
microflora environment, rat caecal content or colonic enzymes can be included in the simulated 
colonic fluid. With this model, a number of studies
6,158,184-186
 have shown the colon-targeting 
capacity of the carrier systems investigated, for the drug release from the carrier was significantly 
enhanced in the presence of rat caecal content or colonic enzymes. Although the in vitro release 
model cannot represent the full factors of in vivo conditions, it is still a useful tool for formulation 
development by comparing the response of different formulations to mimic biological factors (e.g. 
transit time, pH or colonic enzymes). 
4. In vivo evaluation of colon-specific delivery systems 
Although a number of in vitro models exist to mimic biological conditions for evaluation of drug 
delivery systems, an improved understanding of drug delivery efficiency can only be achieved using 
in vivo models where the full complement of biological factors is encountered. In vivo evaluation 
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methods for colon-specific delivery systems can be roughly classified as two categories according 
to the experimental design: 1) to investigate the overall therapeutic/biological effects and 2) to 
determine the tissue distribution of the loaded drug and/or the carrier following oral administration.  
Evaluation methods of therapeutic efficacy of colon-specific delivery systems depend on the disease 
studied and the aim of delivery systems. For example, formulations designed to improve 
chemotherapy of colorectal cancer can be assessed by animal survival profile, tumour growth, 
expression of inflammation biomarkers in tumour-surrounding area and incidence of toxicity caused 
by anti-cancer drugs.
96,187
 Indexes for assessing potential treatment of ulcerative colitis include 
myeloperoxidase activity, colon/body weight ratio and damage score. 
6,153
 These measurements are 
often combined with pharmacokinetic study to gain a better understanding of the efficacy of test 
formulations.  
Drug distribution study of colon-specific delivery systems is conventionally performed by 
measuring drug concentration in excised organs, especially the different sections of animal 
gastrointestinal tract. It has been a classical method for evaluating colon-targeting capacity of drug 
delivery systems and a number of examples could be found in the literature.
93,188
 However, this 
study measures the average drug concentration of each organ. For organs like the small intestine 
and colon, it can hardly give details on drug distribution along the intestinal tract unless small 
sections of these organs are analysed separately. One possible solution to this issue is to encapsulate 
contrast agents (e.g. radioisotopes
189
) as model drug in the carrier systems and use imaging 
technique to monitor the distribution of the contrast agent following administration. Another 
limitation of drug distribution study is that the sample preparation and analysis process can be 
complicated and time-consuming, for a large batch of organ samples are often involved and the 
collected organs need to be homogenized to release drug to the extraction phase for sample analysis.  
Understanding the in vivo fate of colon-specific carrier systems is essential for a full evaluation of 
the formulations because 1) residence of carriers in each section of gastrointestinal tract directly 
relates to the drug delivery to the colon and 2) a prolonged retention of drug carriers within the 
gastrointestinal tract may induce side effects to healthy tissues. Besides, the in vivo distribution of 
particulate systems can be used to predict their potential for delivering drug specifically to the 
cellular target. For example, Lamprecht et al.
190
 examined the distribution of fluorescent NPs and 
MCs in inflamed tissue to that in healthy tissue and demonstrated their potentials for targeted drug 
delivery to inflamed colonic mucosal areas. In vivo imaging techniques currently used for drug 
delivery research are introduced in the following section. 
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1.3.6 Animal imaging technique for in vivo evaluation of drug delivery systems 
Imaging modalities such as X-ray computed tomography (CT)
191,192
,  gamma scintigraphy
193
, single 
photon emission computed tomography (SPECT)
194
, positron emission tomography (PET)
195
, 
magnetic resonance imaging (MRI)
196
 and fluorescence optical imaging technique
196
 have been 
used to track functional contrast agents or drug delivery systems in live animals following 
administration and provide comparative analysis between tissues. These technologies are based on 
different imaging mechanisms and their application in cancer detection and treatment has been 
explored extensively in the literature.
15,82,88,91,197
 They allow the non-invasive whole-body imaging 
of a live animal at various time points after drug administration. This is particularly useful in 
biodistribution studies, where natural physiological variation among animals impacts the results, in 
addition to the fact that utilising imaging reduces the number of animals needed to obtain a 
particular data set in comparison to conventional ex vivo organ analysis. 
CT is based on the difference in X-ray absorption between tissues when an X-ray is emitted from an 
outside source. It provides information on anatomic structure and has been widely used in the 
diagnosis of diseases in head, lung, heart and skeletal structures. Contrast agents currently used are 
iodinated molecules which have a high X-ray absorption coefficient. However, their rapid clearance 
by kidney within seconds to a few minutes post-injection
198
 remains a problem as the imaging time 
is very short. To overcome this, Kim et al.
191
 prepared a novel CT contrast agent consisting of PEG-
coated gold NPs which had a prolonged blood circulation time compared to the conventional 
iodine-based agent. However, this is a specialised contrast agent that is applicable only to select 
disease states which are in the well-perfused organs such as heart and liver. 
Gamma scintigraphy, SPECT and PET, measures gamma rays emitted from the body generated by 
radioisotopes after administration. These approaches utilise different mechanisms for signal 
detection. Both gamma scintigraphy and SPECT instrumentations capture photon emission from 
radiotracers directly and the available radioisotopes
199
 include technetium-99m (
99m
Tc), 
123
I,
 125
I and 
133
I, while 
11
C, 
13
N, 
15
O, 
18
F and 
64
Cu are currently in use for PET imaging
200,201
, in which positron 
emission from radiotracers is captured. Another difference between these imaging modalities is that 
gamma scintigraphy creates two-dimensional images while SPECT and PET provide three-
dimensional images with high resolution and correction of attenuation.
199
 These imaging techniques 
provide functional imaging, showing for example metabolic or biochemical activity in the body; a 
companion CT scan is often employed to generate cross-sectional images of anatomical structures. 
The potential of these different techniques for monitoring novel chemotherapeutic strategies has 
been demonstrated in a number of studies. For example, gamma scintigraphy has been used to study 
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the effect of particle size of 
99m
Tc-labelled PMMA microcapsules on their gastric emptying
193
 while 
SPECT/CT has been utilised to monitor the release of radio-labelled proteins or drugs from 
cellulose hydrogels in mice
202
. PET/CT imaging of 
18
F-flourinated deoxyglucose and 
64
Cu(II) 
diacetylbis(N
4
-methylthiosemicarbazone) in tumour-bearing BALB/c mice has been used to 
demonstrate increased metabolism and glucose uptake in tumours compared with healthy tissues.
195
 
Because of its excellent soft tissue contrast properties, MRI has been used for the clinical diagnosis 
of soft-tissue pathologies including diseases of the central nervous system, neoplastic structures, 
cardiovascular diseases and musculoskeletal diseases. In pharmaceutical research developing 
therapeutic agents for cancer detection or targeted drug delivery,
203,204
 MRI has advantages over 
other imaging modalities as it can be used to track and locate contrast agent-labelled drug 
formulations in living animals, while simultaneously showing anatomical features. Jain et al.
203
 
utilised MRI to determine the in vivo clearance kinetics of magnetic iron-oxide NPs in mice while 
Rolfe et al.
205
 developed a multifunctional hyperbranched polymer suitable for simultaneous 
19
F 
MRI and fluorescence imaging of tumours in mice. 
Fluorescence optical imaging is being increasingly used for in vivo evaluation of drug delivery 
systems in small-animal models. Depending on the questions to be addressed, fluorescent dyes (as 
model ‘drugs’) can be physically encapsulated in drug delivery systems to predict in vivo drug 
release kinetics from carriers; they can also be covalently conjugated to drug carriers to monitor 
distribution and site-specific accumulation in animal tissues. Due to the low autofluorescence in the 
animal body at emission wavelength above 650 nm,
206
 fluorescence optical imaging offers a high 
signal-to noise ratio which is beneficial for in vivo analysis and a number of examples have been 
published. For example, Pinkerton et al.
98
 reported the targeted distribution of fluorescent dye-
loaded PEG gel microparticles in a lung capillary of CD1 mice after i.v. injection, while Na et al.
196
 
demonstrated that the long circulation time of Cy5.5 dye labelled glycol chitosan NPs enabled NP 
accumulation in tumour tissues through the EPR effect. Pearce et al.
15
 labelled with a fluorescent 
Cy5 dye to demonstrate the tumour-targeting efficiency of ligand-conjugated hyperbranched 
polymer in a mouse prostate cancer model.  
In conclusion, these imaging techniques offer an effective means of monitoring drug delivery in 
vivo, with clear advantages for understanding the efficacy of candidate formulations by providing 
information on the tissue biodistribution, tumour uptake and retention, and pharmacokinetics. 
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1.4 Thesis objectives 
Current treatment regimens for CRC chemotherapy are far from satisfactory, owing to the low 
efficacy of conventional anti-cancer drugs that are typically administered via i.v. injection. This 
results in low drug concentrations in the colon for interaction with cancer cells, as well as causing 
significant toxicity for healthy tissues. While delivery of anti-cancer drugs to the colorectal region 
has shown potential for improved chemotherapy, most anti-cancer drugs still lack selectivity 
towards cancer cells, so their release within the colon can cause acute toxicity to healthy cells in the 
colorectal region. This problem may be addressed by the combination of a colon-targeted carrier 
and therapeutic nanoparticles that directly interact with cancer cells in the colon to deliver drugs 
specifically to the intended tumour sites. Targeted delivery of individual drug-loaded NPs to the 
colon has not been well explored for improving CRC chemotherapy, therefore the objectives of this 
thesis are as follows: 
1) to develop a colon-targeted carrier for model NPs. This includes NP characterisation, in 
vitro NP release study and optimization of carrier formulation; 
2)  to investigate the in vivo NP release from colon-targeted carriers; this includes preparation 
of dual fluorescently-labelled NPs and carriers, and subsequent study of tissue distribution of both 
NP and carriers in mice using animal imaging techniques; 
3) to investigate the potential of the designed system for targeted drug delivery to colon cancer 
cells. This includes preparation of drug-loaded NPs, incorporation of drug-loaded NPs in the colon-
targeted carrier, in vitro drug and NP release from the carrier and analysis of NPs cytotoxicity on 
cancer and healthy cells. 
This thesis includes six chapters to describe research conducted towards achieving the above 
objectives. The experimental plan is shown schematically in Scheme 1-1. Chapters 2 and 3 present 
the formulation design of colon-targeted carriers prepared from alginate, hypromellose and/or 
chitosan, with Eudragit
®
 RS NPs incorporated as a model NP load. Chapter 2 focuses on alginate-
based carriers, including microcapsules and Eudragit
®
 S100 NP-encapsulated alginate pellets for 
colon-targeted delivery of Eudragit
®
 RS NPs and indomethacin, respectively. Acting on the 
knowledge gained as a result of the poor performance of the materials that were designed in Chapter 
2, Chapter 3 describes the development of hypromellose capsules and chitosan-hypromellose 
microcapsules for delivery of model Eudragit
®
 RS NPs. Following from promising in vitro 
characterisation of the materials described in Chapter 3, Chapter 4 presents an in vivo evaluation of 
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chitosan-hypromellose microcapsules for delivering Eudragit
®
 RS NPs to the colon, including 
fluorescent labelling of NPs and microcapsules and the use of optical animal imaging techniques for 
the study of their in vivo fate after oral administration in mice. Chapter 5 describes the incorporation 
of three model drugs (5-FU, indomethacin and curcumin) into the Eudragit RS NP-loaded chitosan-
hypromellose microcapsules and in vitro analysis of their release. Chapter 6 summarizes the main 
findings of this project and discusses future directions of the research. 
 
Scheme 1-1 Contents of each experimental Chapter (Chapters 2 to 5). 
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This Chapter is presented as an accepted, peer reviewed manuscript and describes an investigation 
of alginate-based carrier systems for delivering model nanoparticles (NPs) and small molecule 
drugs to the colon. Commercial Eudragit
®
 RS NPs were used as model NPs because 1) they exhibit 
the required stability in simulated gastric, intestinal and colonic fluids (neither dissolved nor 
aggregated when dispersed in these fluids) and 2) their concentrations in release samples can be 
determined by UV-visible spectrophotometry, which is a convenient tool for analysing release 
samples to assess the amount of NP released from carriers. Alginate microcapsules were 
investigated for delivering Eudragit
®
 RS NPs to the colon in the first part of this chapter. For 
comparison purpose, the potential of alginate for colon-specific delivery of small molecule drugs 
was also investigated. Indomethacin was used as a model anti-cancer drug and loaded into pH 
responsive Eudragit
®
 S100 NPs, which were further encapsulated into alginate pellets. The work on 
delivering indomethacin to the colon formed the second part of this chapter.  
The performance of the alginate carrier systems on colon-specific release of encapsulated NP or 
drug was evaluated by an in vitro release study, which was conducted in simulated gastric, intestinal 
and colonic fluids to mimic gastrointestinal environments encountered by the carrier system during 
its transit in vivo. The ideal carriers were required to have negligible release of their cargo in 
simulated gastric and intestinal fluid, but exhibit increased release of the model NPs or drug in 
simulated colonic fluid.  
Therefore, the aims of this chapter are as follows: 
1) To encapsulate Eudragit® RS NPs in alginate microcapsules and determine NP loading in 
microcapsules;  
2) To investigate in vitro release of Eudragit® RS NPs from alginate microcapsules; 
3) To examine the stability (aggregation behaviour) of Eudragit® RS NPs in alginate solution 
and the release medium using dynamic laser light scattering (DLS) and transmission 
electron microscopy (TEM) 
4) To prepare and characterise indomethacin-loaded Eudragit® S100 NPs; 
5) To incorporate indomethacin-loadedEudragit® S100 NPs in alginate pellets and determine 
drug loading in Eudragit
®
 S100 NP-loaded alginate pellets; 
6) To investigate in vitro release of indomethacin from Eudragit® S100 NPs and Eudragit® 
S100 NP-loaded alginate pellets. 
The investigation of alginate microcapsules for delivering model NPs to the colon showed that less 
than 2% of the encapsulated Eudragit
®
 RS NPs were released from alginate microcapsules in 
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simulated gastrointestinal fluids. Furthermore, aggregation of the NPs in release samples was also 
observed. NP-alginate aggregation occurred upon mixing prior to microencapsulation and this 
subsequently retarded nanoparticle release from alginate microcapsules in the release medium, thus 
preventing presentation of individual, non-aggregated NPs in the tumour site for ultimate uptake by 
cancer cells. Therefore, alginate microcapsules were found to be unsuitable carriers for delivering 
Eudragit
®
 RS NPs to the colon using this formulation approach. 
For delivering indomethacin to the colon, Eudragit
®
 S100 NPs released almost 100% of the loaded 
drug in simulated intestinal fluid before transfer to the simulated colonic fluid. The encapsulation of 
indomethacin-loaded NPs into alginate pellets prevented burst drug release in simulated intestinal 
fluid and resulted in a significantly higher fraction of drug load being available for release in 
simulated colonic fluid. 
The findings of this chapter showed that alginate-based carriers could potentially deliver small 
molecule drugs to the colon but failed to deliver NPs. These results demonstrated the importance of 
maintaining the colloidal stability of NPs during the incorporation of NPs into colon-specific carrier 
systems. Elimination of NP-excipient aggregation is essential for enabling the presence of isolated 
nanoparticles in the colon for interaction with colorectal cells. Therefore, negatively-charged 
polymers like alginate would not be suitable for fabricating carrier systems for delivering the 
Eudragit
®
 RS NPs to the colon. The later Chapters of this thesis will investigate other carrier 
systems to overcome the NP-carrier aggregation issue observed for alginate microcapsules. 
This Chapter has been published in Journal of Biomedical Materials Research Part A. 
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Chapter 3. Enteric-coated hypromellose capsules and chitosan-
hypromellose microcapsules for delivering nanoparticles to the colon: 
formulation design and in vitro evaluation 
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3.1 Introduction and aims 
3.1.1 Introduction 
In Chapter 2, alginate microcapsules were investigated for delivering Eudragit
®
 RS NPs to the 
colon and an issue of NP-carrier aggregation was observed. Negligible NP release from alginate 
microcapsules in simulated gastrointestinal fluid was observed and NPs in release samples were 
found in an aggregated form. It was proposed that this was caused by electrostatic complexation 
between the positively charged NPs and negatively charged alginate. Thus, it was deduced that the 
NP-carrier aggregation problem would occur during preparation of carrier systems if 1) carriers are 
prepared from negatively-charged polymers and 2) positively-charged NPs and negatively-charged 
polymers are in ionized state and are mixed during NP encapsulation into carriers. Therefore, 
carriers based on non-charged and/or positively charged polymers could potentially be a means to 
avoid Eudragit
®
 RS NP aggregation with carriers.  
Hypromellose (HPMC) and chitosan were selected in this study as representative non-charged and 
positively charged polymers, respectively. They are very common excipients in pharmaceutical 
industry and oral formulations based on them (capsules
1,2
, pellets
3
, tablets
4
, microparticles
5
) have 
been shown to achieve colon-specific release of drugs in vitro and in vivo. HPMC capsules (product 
name: DRcaps
®
 capsules, Figure 3-1) are commercially available from Capsugel (a Division of 
Pfizer Inc.). Scintigraphy in human subjects showed that they started to disintegrate in the human 
stomach 45 minutes later than gelatine capsules that typically show immediate degradation, and 
released the contents completely in the intestine of most subjects.
6
 In this study, DRcaps
®
 capsules 
were investigated for colon-specific delivery of Eudragit
®
 RS NPs. Meanwhile, microcapsules 
prepared from the mixture of chitosan and hypromellose were studied for delivering Eudragit
®
 RS 
NPs to the colon, as an example of a carrier combining non-charged and positively charged 
polymers.  
 
Figure 3-1 DRcaps
®
 capsules (size 1) 
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To ensure that no aggregation occurred between NPs and the carrier polymers, the stability of 
Eudragit
®
 RS NPs suspended in DRcaps
®
 capsule or hypromellose-chitosan solution was examined 
using dynamic laser light scattering (DLS) and transmission electron microscopy (TEM). The 
capsules and microcapsules disintegrated rapidly at gastric pH, thus enteric coating was used to 
prevent them from disintegration and premature NP release in the stomach. Two different pH 
responsive coating materials were chosen for use in this study, Eudragit
®
 polymers (Eudragit
®
 
L100-55 or S100) and alginate hydrogel cross-linked by Ca
2+
. Both coating materials are insoluble 
at acidic gastric pH and provide a protective shell for the carriers. Eudragit
®
 L100-55 and S100 
dissolve above pH 5.5 and 7.0, respectively, and cross-linked alginate hydrogels typically dissolve 
in basic medium due to the displacement of Ca
2+
 by ions such as Na
+
 and K
+
. In this study, the aim 
was to utilise a coating that would dissolve in the small intestine or colon and subsequently enable 
NP release from DRcaps
® 
capsules or chitosan-HPMC microcapules in the colon. 
3.1.2 Aims 
This Chapter focuses on formulation design of enteric-coated DRcaps
®
 capsules and chitosan-
HPMC microcapsules at lab-scale. In vitro evaluation of carrier systems for delivering Eudragit
®
 
RS NPs to the colon is also described. Specific aims are as follows: 
1) To examine the stability of Eudragit® RS NPs suspended in DRcaps® capsule or chitosan-
hypromellose solution using dynamic laser light scattering (DLS) and transmission electron 
microscopy (TEM); 
2) To prepare Eudragit® RS NP-loaded DRcaps® capsules, coat capsules with Eudragit® L100-
55 or alginate and investigate in vitro NP release from coated DRcaps
®
 capsules;  
3) To encapsulate Eudragit® RS NPs in Eudragit® S100-coated chitosan-HPMC microcapsules 
and investigate in vitro NP release from coated microcapsules. 
3.2 Materials and methods 
3.2.1 Materials 
Eudragit
®
 RS30D, Eudragit
®
 L100-55 and Eudragit
®
 S100 were provided by Evonik Industries 
(Darmstadt, Germany). Eudragit
® 
RS 30D is an aqueous dispersion of insoluble NPs at a 
concentration of 30% w/w. Hypromellose capsules (DRcaps
®
 capsules, size 1, clear) were provided 
by Capsugel Australia Pty. Ltd. Sodium alginate (Protanal
®
 LF200FTS, viscosity of 1% aqueous 
solution: 200-400 mPa•s) was provided by FMC BioPolymer (PA, USA). Hypromellose (HPMC, 
Methocel
TM
 E50 premium LV) was provided by Colorcon Asia Pacific Pty. Ltd. Medium molecular 
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weight chitosan (75–85% deacetylated, molecular weight 190,000-310,000 Da), sodium phosphate 
tribasic dodecahydrate and monobasic potassium phosphate were purchased from Sigma Aldrich. 
Calcium chloride (UNILAB), hydrochloride acid (UNIVAR) and sodium hydroxide were purchased 
from Ajax Finechem Pty Ltd (NSW, Australia).  Phosphate buffered saline (PBS) tablets were 
purchased from Amresco Inc. (Solon, OH). Tropaeolin OOO (pH 11.0-13.0) was purchased from 
British Drug Houses Ltd. Dichloromethane of analytical grade was obtained from Thermo Fisher 
Scientific (VIC, Australia). Ethyl acetate and ethanol of analytical grade were purchased from 
Chem-supply (SA, Australia).  
3.2.2 Stability of Eudragit® RS NPs dispersed in solution of carrier polymers 
1) Stability of Eudragit® RS NPs in DRcaps® capsule solution  
DRcaps
®
 capsules were weighted and dissolved in deionized water to prepare a capsule solution (40 
mg/mL). Eudragit
®
 RS 30D and deionized water were then added to produce a final nanoparticle 
and HPMC concentration of 10 mg/mL and 7 mg/mL, respectively. The Z-average size (Z-ave), 
polydispersity index (PDI) of Eudragit
®
 RS NPs dispersed in capsule solution was measured three 
times using a Zetasizer Nano ZS (Malvern Instruments, Malvern, UK) at an angle of 173°. A NP 
suspension in deionized water (10 mg/mL) was measured under the same conditions for 
comparision. To examine the presence of individual Eudragit
®
 RS NPs in capsule solution using a 
Jeol 1010 transmission electron microscope (TEM), a diluted NP suspension in capsule solution 
was prepared with final concentration of NPs and HPMC at 100 µg/mL and 70 µg/mL, respectively. 
A drop of NP-capsule suspension was placed onto a carbon coated copper grid (100 mesh), the 
excess fluid was blotted with a filter paper 5 min later and the grid was stained with 1% uranyl 
acetate. After 5 min of staining, excess stain was removed by a filter paper. The grid was air-dried 
and examined by TEM at 100 kV. 
2) Stability of Eudragit® RS NPs in chitosan-hypromellose solution  
Stock solutions of polymers used for microcapsule preparation were prepared as follows: chitosan 
was dissolved in acetic acid solution (1%, v/v) at a final concentration of 10 mg/mL and 
hypromellose (Methocel
TM
 E50 LV) was dissolved in deionized water at 20 mg/mL. Eudragit
®
 RS 
30D was mixed with chitosan solution and Methocel
TM
 E50 solution to make final concentration of 
each component as follows: 50 µg/mL of Eudragit
®
 NPs, 100 µg/mL of chitosan and 200 µg/mL of 
Methocel
TM
 E50. Acetic acid was added to fix the concentration at 1% (v/v) to ensure complete 
disolution of chitosan. The Z-average size (Z-ave), polydispersity index (PDI) of Eudragit
®
 RS NPs 
dispersed in chitosan- Methocel
TM
 E50 solution was measured using a Zetasizer Nano ZS as 
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described above. The size distribution of Eudragit
®
 NPs (50 µg/mL) dispersed in deionized water, 
Methocel
TM
 E50 solution (200 µg/mL) and Methocel
TM
 E50 (200 µg/mL)-chitosan (100 µg/mL) 
solution was measured under the same conditions for comparision. Samples of Eudragit
®
 NPs 
suspended in different solutions were examined by TEM and are listed in Table 3-1. Grid 
preparation for all samples was conducted as described above except for Methocel
TM
 E50 solution 
(1 mg/mL). Due to the poor absorption of uranyl acetate to Methocel
TM
 E50, the grid was stained 
overnight to produce enough contrast between Methocel
TM
 E50 and background in its TEM image. 
Table 3-1 Composition of Eudragit
®
 RS NP suspension sample examined by TEM 
Sample Concentration of NP Dispersion solution 
1 300 µg/mL Deionized water 
2 N/A 1 mg/mL Methocel
TM
 E50 (1 mg/mL) 
3 100 µg/mL 
Methocel
TM
 E50 (200 µg/mL)-chitosan (100 
µg/mL) solution 
4 100 µg/mL Chitosan solution (1 mg/mL) 
3.2.3 Preparation of enteric-coated DRcaps® capsules loaded with Eudragit® RS NPs 
Eudragit
®
 RS NPs were filled into DRcaps
®
 capsules in the form of aqueous dispersion Eudragit
®
 
RS30D. To protect capsules from dissolution upon contact with NP suspension, the inner wall of 
capsules was coated by Eudragit
®
 S100 in ethanol (10%, w/v) before NP filling. The Eudragit
®
 
S100 coating was performed manually by filling each capsule body and cap with Eudragit
®
 S100-
ethanol, removing the coating solution and subsequently leaving a thin layer of Eudragit
®
 S100-
ethanol solution on the capsule inner wall. The capsule components were left in air overnight and 
after the evaporation of ethanol, the Eudragit
®
 S100 coating formed a hardened layer on the inside 
wall of capsule bodies and caps. The stability of the coated capsules was confirmed by filling with 
Eudragit
®
 RS30D and incubating at 37 ⁰C for 16 h. The capsules remained intact over 16 h without 
leakage of NP suspension over this time period. 
The capsules were sealed by applying Eudragit
®
 S100-ethanol solution (30%, w/v) on the closure of 
each capsule body and overlaying it with the cap. Sealed capsules were left in vacuum oven 
overnight. Eudragit
®
 S100 sealing hardened after drying and bound the capsule bodies and caps 
tightly to prevent capsule parts from falling apart. A hole was punched in the middle of the capsule 
body using a 26G needle and 0.8 mL of Eudragit
®
 RS30D was injected to fill each capsule. To seal 
the hole and improve capsule resistance to intestinal fluid, the capsules were coated by enteric 
Eudragit
®
 L100-55 or alginate.  Eudragit
®
 L100-55 (10%, w/v) in 0.1 M NaOH solution or alginate 
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solution (1.5%, w/v) was brushed onto the outer surface of the filled capsules. Eudragit
®
 L100-55-
coated capsules were air-dried overnight before use. Alginate coating on capsules was completed by 
brushing CaCl2 solution (1 M) to cross-link the alginate layer and drying overnight in air. 
3.2.4 Preparation and characterisation of Eudragit® S100-coated Eudragit® RS NP-loaded 
chitosan-hypromellose microcapsules  
Eudragit
® 
RS NPs were encapsulated into chitosan-hypromellose microcapsules using an ionotropic 
gelation technique
7
 combined with aerosolization. 5 mL of Eudragit
®
 RS 30D was added to 7.5 mL 
of HPMC (40 mg/mL) under stirring at 500 rpm. 750 mg of chitosan was dissolved in 37.5 mL of 
acetic acid aqueous solution (1%, v/v) and then mixed with the Eudragit
®
 RS NP-HPMC 
suspension. The mixture was sprayed through a spray nozzle into a 1:4 mixture of ethanol in a 5% 
w/v trisodium phosphate cross-linking solution (100 mL) at a flow rate of 17 mL/min at 25 psi air 
pressure. The spray conditions were adjusted beforehand to obtain desirable microcapsule size. The 
resulting suspension of microcapsules was stirred overnight to allow complete cross-linking 
between chitosan and trisodium phosphate. The microcapsules were collected by centrifugation at 
2000 rpm for 3 min (Allegra
® 
X-15R, Beckman Coulter) and washed twice with distilled water. The 
concentration of collected MC suspension was determined by freeze drying aliquots of the 
suspension and weighting lyophilised microcapsules. The NP loading of dried chitosan-HPMC 
microcapsules was measured using a slightly modified Tropaeolin OOO method reported by Melia 
et al.
8
. Tropaeolin OOO was dissolved in 0.1 M NaCl solution at a concentration of 150 µg/mL. A 
0.5 mL aliquot of the microcapsule suspension was added to 0.1M hydrochloric acid (0.5 mL) in a 
centrifuge tube and vortexed for 3 min to break down microcapsules and release their NP load. 
Samples in triplicate were added with NaOH (0.1 M) to adjust the pH to around 7 and acetone (3 
mL) was added to precipitate chitosan. After centrifugation at 3000 rpm for 5 min, the supernatant 
was placed in a vacuum oven for 24 h to evaporate acetone. 0.4 mL of the tropaeolin OOO solution 
and 3.5 mL of ethyl acetate were added and vortexed for 10 min to extract tropaeolin OOO-
Eudragit
®
 RS complex into ethyl acetate. Samples were centrifuged at 4000 rpm for 10 min and the 
ethyl acetate layer was analyzed using a UV-visible spectrophotometer (Cary 4000 UV-Vis) at 477 
nm. Absorbance readings were compared with a calibration curve produced using a series of known 
concentrations of Eudragit
®
 RS NPs (50-250 µg/mL) in 0.1M hydrochloric acid. The NP loading of 
microcapsules was expressed as a weight percentage of Eudragit
®
 RS NPs in the dried 
microcapsules. 
Coating of Eudragit
®
 RS NP-loaded microcapsules was carried out at a weight ratio of Eudragit
®
 
S100 to microcapsules at 2.5:1 using a slightly modified coating process reported by Li et al.
9
. 4 
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mL of microcapsule suspension in distilled water containing 80 mg microcapsules was added to 
Eudragit
®
 S100 in methanol solution (4 mL, 5 % w/v). After 1 h incubation, distilled water (30 mL) 
was added to the suspension and the methanol was evaporated overnight. Coated microcapsules 
were collected by centrifugation at 3000 rpm for 3 min and distilled water was added to re-suspend 
the microcapsules and made a final suspension volume to be 4 mL.  
The size distribution of Eudragit
® 
RS NP-loaded chitosan-HPMC microcapsules before and after 
Eudragit
®
 S100-coating was determined by dynamic laser light scattering (Malvern Mastersizer 
2000, Malvern, UK). The sample was measured three times at 25 °C. The morphology of uncoated 
and coated microcapsules suspended in distilled water was examined by optical microscopy 
(Olympus CKX41 inverted microscope in conjunction with an Olympus DP21 camera, Japan). 
3.2.5 In vitro release of Eudragit® RS NPs from enteric-coated DRcaps® capsules or 
chitosan-hypromellose microcapsules  
To evaluate the potential of the coated capsules and microcapsules for delivering NPs to the colon, 
an in vitro release study was performed to mimic the in vivo pH environments and transit times that 
oral dosages would encounter in the human gastrointestinal tract after oral administration. The 
selection of release media and incubation times is explained in Chapter 2 under ‘Eudragit® RS NP 
release from alginate microcapsules’ section. Briefly, three replicates of one coated capsule or 1 mL 
of microcapsule suspension was incubated with 4 mL of simulated gastric fluid (SGF, 0.05 M HCl, 
pH 1.2) for 2 h at 37 °C, then transferred to 1.5 mL simulated intestinal fluid (SIF, pH 6.8, PBS) for 
6 h, and finally to 1.5 mL of simulated colonic fluid (SCF, pH 7.4 PBS) for 6 h. 4 mL of release 
medium was collected every hour and replaced with fresh medium. In the release study of coated 
microcapsules, release medium was collected using a pipette tip wrapped with mesh cut from a 
Falcon™ cell strainer (mesh size: 40 µm) to avoid infiltration of microcapsules into the collected 
release samples. 
 Eudragit
® 
RS NP concentration in the release media was determined by the Tropaeolin OOO 
method
8
 and sample preparation procedure was slightly different from that described in section 
3.2.4 and 0.2 mL of tropaeolin OOO solution (150 µg/mL) were added to each sample. The 
absorbance of organic phase after extraction of tropaeolin OOO-Eudragit
®
 RS complex from 
aqueous phase was reported to be independent of pH over the range of 4.5-9.0.
8
 Therefore, the pH 
of each SGF release sample (3 mL) was adjusted to approximately 7 with 4 M NaOH before adding 
tropaeolin OOO solution and ethyl acetate (3.5 mL). In the collected SIF and SCF release samples, 
dissolved coating materials (alginate and Eudragit
®
 L100-55 for capsules, Eudragit
®
 S100 for 
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microcapsules) may bind with positive Eudragit
®
 RS NPs and hinder complex formation between 
tropaeolin dye and Eudragit
®
 RS NPs during the partitioning process between the aqueous and ethyl 
acetate phases. Therefore, 3 mL of each release sample was acidified by adding 100 µL of HCl (1 
M) and the precipitated coating polymer was removed by centrifugation. The pH was re-adjusted to 
approximately 7 with 1 M NaOH before adding ethyl acetate (3.5 mL) to extract tropaeolin OOO-
Eudragit
®
 RS complex. Sample absorbance readings were compared to calibration standards of 
Eudragit
®
 RS NPs in each release medium prepared using same procedures. The NP release rate 
was calculated as the ratio of released Eudragit
®
 RS NPs against the initial loading in capsules or 
microcapsules and expressed as cumulative release (% w/w) versus time (h).  
The size distribution of NPs in representative release samples collected from capsule release study 
was measured by Zetasizer Nano ZS (Malvern Instruments, Malvern, UK) as described in section 
3.2.2 and compared to that of Eudragit
®
 RS NPs dispersed in in simulated intestinal and colonic 
fluid at 3.75 mg/mL. Release samples from microcapsule release study were not examined because 
peaks arising from chitosan on the nanoscale overlapped with NP peaks, making data interpretation 
difficult. 
3.3 Results and discussion 
3.3.1 Stability of Eudragit® RS NPs in DRcaps® solution  
The aggregation between Eudragit
® 
RS NPs and alginate was the major limiting factor of the 
alginate microcapsules studied in Chpter 2 of this thesis. To assess the propensity for the Eudragit
® 
RS NPs to aggregate with the capsule carrier, dynamic laser scattering was utilised. DLS revealed 
that Eudragit
® 
RS NPs (10 mg/mL) dispersed in water had a Z-ave diameter of 122 nm and a 
polydispersity index (PDI) of 0.198. The same concentration of Eudragit
® 
RS NPs dispersed in 
DRcaps
® 
capsule solution (7 mg/mL) showed a Z-Ave diameter of 321.9 nm and PDI of 0.389. 
Figure 3-2 shows the size distribution of capsule solution and NPs dispersed in water and capsule 
solution by intensity, volume and number. Eudragit
® 
RS NPs dispersed in deionized water exhibited 
a major peak around 100 nm. After dispersion in DRcaps
® 
capsule solution, this major peak 
increase to approximately 300 nm. The sharp peaks on the microscale in Figure 3-2 A and B did not 
show corresponding peak in the size distribution curve by number (Figure 3-2 C), implying that 
there was no significant aggregation between Eudragit
® 
RS NPs and hypromellose. Indeed, 
DRcaps
®
 capsule solution in the absence of NPs showed a similar peak on the microscale in its size 
distribution by intensity curves, indicating dissolved HPMC from capsules resulted in the peaks on 
the microscale. Furthermore, TEM images (Figure 3-3) confirmed the presence of individual 
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Eudragit
® 
RS NPs following dispersion in DRcaps
®
 capsule solution. This is in contrast to the TEM 
imagings observed for the alginate microcapsules described in Chapter 2 (Figure 3). These results 
together implied the potential of DRcaps
®
 capsules as NP carrier without causing NP aggregation 
due to nanoparticle-carrier interactions. 
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Figure 3-2 Size distributions of RS NPs (10 mg/mL) dispersed in deionized water or in 
DRcaps
®
 capsule solution (7 mg/mL).  
A: distribution by intensity; B: distribution by volume; C: distribution by number. 
 
Figure 3-3 TEM images of Eudragit
® 
RS NPs (100µg/mL) dispersed in DRcaps
®
 capsule 
solution (70 µg/mL). (Individual Eudragit
® 
RS NPs shown by arrows) 
3.3.2 Stability of Eudragit® RS NPs dispersed in MethocelTM E50 and chitosan solution  
Figure 3-4 shows size distribution of Eudragit
® 
RS NPs dispersed in deionized water or Methocel
TM
 
E50 (HPMC) solution. Compared to NPs dispersed in water, NP- Methocel
TM
 E50 solution showed 
similar peaks in the nanoscale range with a size increase by 200 nm. No peaks on the microscale 
range were observed in three distribution curves of NP- Methocel
TM
 E50 solution, indicating that no 
aggregation between the non-charged Methocel
TM
 E50 and positively-charged Eudragit
® 
RS NPs 
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occurred. Initial TEM analysis was not successful for examining NPs dispersed in Methocel
TM
 E50 
solution, since contrast between Methocel
TM
 E50 and background in the images was not high 
enough to show morphology of Methocel
TM
 E50 when the grid was stained for 5 min. This is 
possibly due to poor absorption of uranyl acetate onto the Methocel
TM
 E50. An overnight grid 
staining was used to improve contrast between Methocel
TM
 E50 and background in the TEM images 
and HPMC films were observed to be smaller than 300 nm in length (Figure 3-5). The morphology 
of Methocel
TM
 E50 films was quite different from the HPMC polymer chains shown in the image of 
DRcaps
®
 capsules (Figure 3-3), and this could possibly explain the different size peaks on the 
microscale in their size distribution curves measured by DLS. However, the prolonged staining step 
was not suitable for simultaneous imaging of NPs and Methocel
TM
 E50 in one grid, as it caused 
excess staining of NPs by uranyl acetate at the same time and clumps of NPs and uranyl acetate 
were observed under TEM.  
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Figure 3-4 Size distributions of Eudragit
® 
RS NPs (50 µg/mL) dispersed in deionized water 
or in Methocel
TM
 E50 solution (200 µg/mL). A: distribution by intensity; B: distribution by 
volume; C: distribution by number. 
 
Figure 3-5 TEM image of 1 mg/mL Methocel
TM
 E50 solution prepared by overnight grid 
staining with uranyl acetate (1%, w/v) 
 
Size distribution of chitosan solution and Eudragit
® 
RS NPs dispersed in chitosan- Methocel
TM
 E50 
solution is shown in Figure 3-6. Both samples exhibited peaks in the range of 20-100 nm and 300-
2000 nm. The chitosan solution showed one additional peak at around 5 µm in the intensity and 
volume distribution curves while its number distribution did not have a corresponding peak at the 
same size range, due to the different mathematical models used for calculating the three distribution 
curves of dissolved chitosan chains in acetic acid solution
10
. As dispersion of Eudragit
® 
RS NPs in 
Methocel
TM
 E50 solution did not give rise to peaks above 1000 nm (Figure 3-4), the increased size 
of NPs suspended in chitosan- Methocel
TM
 E50 solution could be largely due to the presence of 
chitosan.  
The TEM image of NPs dispersed in chitosan (100 µg/mL) - Methocel
TM
 E50 solution (Figure 3-7B) 
showed the presence of discrete Eudragit
® 
RS NPs together with chitosan chains (Methocel
TM
 E50 
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was invisible because of the 5 min grid staining step). NPs dispersed in a more concentrated 
chitosan solution (1 mg/mL) were also examined to see if there would be concentration-dependent 
aggregation. In a grid area covered by a dense layer of chitosan and NPs (Figure 3-7C), Eudragit
® 
RS NPs could be discerned without being masked by the chitosan layer. In another area close to the 
edge of the same grid, where less chitosan and NPs had precipitated (Figure 3-7D), NPs distributed 
evenly in the imaging field and a dark chitosan layer could be observed in the bottom half of the 
image. Unlike the aggregation between Eudragit
® 
RS NPs and alginate shown in Chapter 2 (Figure 
3), Eudragit
® 
RS NPs dispersed in chitosan solution were not enclosed or masked by the chitosan 
network. These images showed the presence of non-aggregated Eudragit
® 
RS NPs in chitosan 
solution, which is probably due to the repulsive charge properties between the NPs and chitosan. 
All the DLS data and TEM images indicate that the non-charged Methocel
TM
 E50 and positively-
charged chitosan could avoid NP-excipient aggregation and thus were suitable for fabricating a 
colon-specific carrier for Eudragit
® 
RS NPs.  
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Figure 3-6 Size distributions of chitosan solution (100 µg/mL) in acetic acid (1%, v/v) and 
50 µg/mL Eudragit
® 
RS NP in Methocel
TM
 E50 (200 µg/mL) -chitosan (100 µg/mL)- acetic 
acid (1%, v/v) solution . 
A: distribution by intensity; B: distribution by volume; C: distribution by number. 
 
Figure 3-7 TEM image of 300 µg/mL Eudragit
® 
RS NPs dispersed in deionized water (A); 
100 µg/mL RS NPs in chitosan (100 µg/mL) - Methocel
TM
 E50 (200 µg/mL) solution(B); and 
100 µg/mL NPs in 1 mg/mL chitosan solution(C and D). 
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3.3.3 Characterisation of Eudragit® S100-coated Eudragit® RS NP-loaded chitosan-
hypromellose microcapsules  
In order to control the encapsulation of NPs into microcapsules, chitosan was cross-linked to form a 
stable matrix as carriers for NPs. Chitosan has abundant amino groups and can be cross-linked to 
form microcapsules either physically through electrostatic interaction with polyanions (e.g. 
tripolyphosphate,
7
 gelatin,
11
 and alginate
12
) or chemically by reacting with agents like 
glutaraldehyde
13
 and genipin
14
. In this study, chitosan-hypromellose microcapsules were prepared 
by utilising ionotropic gelation between chitosan and Na3PO4. Selection of the cross-linking agent 
and preparation procedure was based on two considerations: 1) preventing Eudragit
®
 RS NPs from 
aggregation as a result of the excipients used; 2) minimizing the use of organic solvents during 
formulation which may cause deformation of Eudragit
®
 RS NPs. Alginate has shown to aggregate 
with Eudragit
®
 RS NPs even at low concentrations in my previous study (under the section 
‘stability of Eudragit® RS NPs in alginate solution’ in Chapter 2), suggesting that negatively 
charged macromolecules may induce aggregation of Eudragit
®
 RS NPs, thus their use in fabricating 
carrier systems for the NPs should be avoided. Glutaraldehyde and genipin are water insoluble and 
emulsion crosslinking method is often used for producing chitosan microcapsules
15
. This method 
uses a large volume of oil phase to form a water-in-oil emulsion and includes a subsequent washing 
process using organic solvents to remove the oil phase and unreacted crosslinking agent. The 
exposure of Eudragit
®
 RS NPs to the oil phase and organic solvents may cause NP dissolution 
during formulation preparation, which would deteriorate the microcapsules designed for delivering 
individual NPs to the colon. To avoid the use of oil or organic solvents in microcapsule preparation, 
Na3PO4 solution was used as the cross-linking agent in this study and ethanol was added to decrease 
particle agglomeration by decreasing surface tension and specific gravity of the Na3PO4 solution
7
. 
Nitrogen gas was utilised to form a spray of Eudragit
®
 RS NP-hypromellose-chitosan mixture 
containing droplets in the size range of tens to hundreds of microns. The microcapsules were simply 
collected by low speed centrifugation after washing with distilled water without using any organic 
solvents.  
The loading of Eudragit
®
 RS NPs in the lyophilised chitosan-hypromellose microcapsules 
calculated by Tropaeolin OOO method was 21.4 ± 3.7 % (w/w). This fairly high NP loading was 
due to the high weight ratio of Eudragit
®
 RS NPs to microcapsule components (chitosan and 
hypromellose) in the microcapsule formulation (1.4:1) to ensure excess NPs available for 
encapsulation. The encapsulation efficiency of Eudragit
®
 RS NPs was 5.7 ± 1.0 % and yield of 
microcapsules was 15.8 ± 0.6 % (w/w). The relatively low yield of microcapsules and NP 
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encapsulation efficiency was due to the ineffective contact between droplets of NP-chitosan-
hypromellose suspension and the cross-linking solution. It is expected that the NP encapsulation 
would be improved with optimized microcapsule formulation and spray conditions such as 
decreased flow rate of the suspension feed and spray pressure. 
The chitosan-hypromellose microcapsules were coated by enteric Eudragti
®
 S100 to prevent 
microcapsules dissolution and NP release in the stomach. Li et al.
9
 demonstrated the successful 
Eudragit
®
 S100 coating on layered double hydroxides using water as the dispersing phase of the 
NP-Eudragit
®
 S100-ethanol mixture. In this study, stability of Eudragti
® 
RS NPs needs to be 
maintained during the coating process, thus a modification of their coating process was made in this 
study by dissolving Eudragit
®
 S100 in methanol instead of ethanol. This was to shorten the 
incubation time for coating NP-loaded microcapsules with Eudragit
®
 S100, for methanol has a 
faster evaporation rate at room temperature than ethanol resulting from their different boiling points. 
The TEM examination of in vitro release sample described in Chapter 4 (Figure 4-5) revealed the 
release of NPs from coated microcapsules in simulated colonic fluid, indicating that Eudragti
® 
RS 
NPs remained in the particulate state after coating.  
Dynamic light scattering measurements (Table 3-2) revealed that 80% of the microcapsules were 
within the size range of 35-220 µm and microcapsules coated by Eudragit
®
 S100 showed a d (0.9) 
of approximately 280 µm, indicating a slightly wider size range compared to the uncoated 
microcapsules which had a d (0.9) of 220 µm. Optical microscopy (Figure 3-8) revealed that the 
majority of the uncoated and coated Eudragit
®
 RS NP-loaded chitosan-hypromellose microcapsules 
were less than 200 µm in size. Particle adhesion was observed under microscope for both uncoated 
and coated microcapsule samples and this could possibly result in the wide size ranges of the 
microcapsules measured by dynamic light scattering.  
Table 3-2 Size distribution of uncoated Eudragit
®
 RS NP-loaded chitosan-hypromellose 
microcapsules and Eudragit
®
 S100-coated microcapsules measured by dynamic light 
scattering (µm) 
Sample d (0.1)
a
 d (0.5)
b
 d (0.8)
c
 d (0.9)
d
 
uncoated microcapsules 35.578 90.334 161.736 219.824 
Eudragit
®
 S100-coated 
microcapsules 
24.365 86.639 187.692 280.582 
a
 d (0.1): 10% of particles smaller than this value; 
b
 d (0.5): 50% of particles smaller than this value; 
c
 d (0.8): 80% of particles smaller than this value; 
d
 d (0.9): 90% of particles smaller than this value. 
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Figure 3-8 Optical micrograph of Eudragit
®
 RS NP-loaded chitosan-hypromellose 
microcapsules. (A) uncoated microcapsules; (B) microcapsules coated by Eudragit
®
 S100 . 
3.3.4 In vitro NP release from enteric-coated DRcaps® capsules  
The NP release from Eudragit
®
 L100-55 or alginate coated DRcaps
®
 capsules investigated using 
simulated gastrointestinal fluids is shown in Figure 3-9 and provides an indication of the efficiency 
of carriers for delivering NPs to the colon. Both coated DRcaps
®
 capsules showed negligible NP 
release during 2 h incubation in simulated gastric fluid, indicating a protective effect of acid-
resistant Eudragit
®
 L100-55 or alginate coating on the capsules. In the following 6 h in simulated 
intestinal fluid, Eudragit
®
 L100-55-coated capsules released approximately 30% of the NP load and 
a further 65% of NP load was released in 6h in simulated colonic fluid. At 5h post-incubation of 
Eudragit
®
 L100-55-coated capsules in simulated intestinal fluid, a leakage of white NP suspension 
into the release medium through the hole punched in capsules was observed and continued in the 
following 7 h. This implied that Eudragit
®
 L100-55 coating had dissolved upon incubation with 
simulated intestinal fluid, subsequently making the NP load available for release from capsules. 
Compared to the NP release profile of Eudragit
®
 L100-55 coated capsules, alginate-coated DRcaps
®
 
capsules showed a more colon-specific release of NPs. The cumulative NP release in simulated 
gastric and intestinal fluid was limited to 16%, while 73% of the NP load was released in simulated 
colonic fluid in 6 h. During the 6 h in the simulated intestinal fluid and the first 2 h in simulated 
colonic fluid, NPs were released constantly and slowly. The restricted NP release from capsules in 
this period most likely resulted from diffusion of the NPs through the alginate hydrogel with 
decreasing cross-linking strength during incubation with the release media. The alginate coating 
was formed through ionic interactions between guluronic acid blocks in alginate and Ca
2+
 ions. It is 
stable at low gastric pH and slowly eroded in simulated intestinal and colonic fluid by displacement 
of Ca
2+
 with ions such as Na
+
 and K
+
, leading to gradual release of the NPs from capsules. After 2 h 
incubation in simulated colonic fluid, around 30% of the NP load was released from alginate-coated 
capsules in the following first h and the cumulative NP release was accordingly increased greatly 
(Figure 3-9). This result indicated the complete dissolution of alginate coating in simulated colonic 
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fluid (pH 7.4) after 2 h incubation, which accelerated NP release from capsules. Over the 14 h 
studied, Eudragit
®
 L100-55 coated capsules showed a higher NP release than their alginate-coated 
counterpart, which was in line with the lower dissolution threshold of Eudragit
®
 L100-55 (pH 5.5) 
than alginate (above 7). The pH of simulated intestinal and colonic fluid was 6.8 and 7.4, 
respectively, therefore the dissolution of Eudragit
®
 L100-55 coating started earlier than alginate 
coating in the release study and resulted in a higher NP release from capsules in simulated intestinal 
fluid. Overall, both coated-DRcaps
®
 capsules showed potentials for protecting their NP load from 
release in the stomach and small intestine and delivering the majority of their NP load to the colon. 
Figure 3-9 Cumulative Eudragit
® 
RS NP release from DRcaps
®
 capsules coated by 
Eudragit
®
 L100-55 or alginate in simulated gastric fluid (SGF), intestinal fluid (SIF) and 
colonic fluid (SCF) (mean±S.D, n=3).  
Table 3-3 and Figure 3-10 present the size distribution of Eudragit
® 
RS NPs released from 
Eudragit
® 
L100-coated DRcaps
®
 capsules. Samples collected at 6 h incubation in simulated 
intestinal fluid and 1 h incubation in simulated colonic fluid showed a slightly increase in Z-ave 
diameter and PDI compared to NPs dispersed in release media. Also, peaks around 100 nm could be 
observed in the size distribution curves of both samples, indicating that released NPs remained non-
aggregated in the release media. Peaks on the microscale were probably caused by the presence of 
dissolved HPMC from capsules and were similar to results shown in the section 3.3.1 where NP 
stability in capsule solution was examined. 
Size distribution of Eudragit
® 
RS NPs released from alginate-coated DRcaps
®
 capsules is presented 
in Table 3-4 and Figure 3-11. For release sample collected at 2 h in simulated colonic fluid, sharp 
peaks around 600 nm could be found (Figure 3-11 A-C) and PDI of the sample was 1.0, indicating 
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that aggregation occurred between the released NPs and dissolved alginate. Samples collected at 3 h 
and 4 h in simulated colonic fluid (Figure 3-11 D-F) exhibited peaks around 200 nm with a PDI of 
0.4, indicating the presence of non-aggregated NPs in the release medium. The different size 
distribution of the NPs in these release samples is probably due to the gradual removal of dissolved 
alginate from the incubation system during sample collection and NP release at higher 
concentrations after 2 h incubation in simulated colonic fluid than previously described. Taking the 
size analysis together, it could be concluded that both Eudragit
®
 L100-55-coated and alginate-
coated DRcaps
®
 capsules have showed potential for delivering separated NPs to the colon enabling 
NP interaction with colorectal cancer cells. 
Table 3-3 Size distribution of Eudragit
® 
RS NPs released from Eudragit
® 
L100-coated 
DRcaps
®
 capsules 
Sample Z-ave diameter (nm) PDI 
Eudragit
® 
RS NPs dispersed in SIF 127.8 0.179 
release sample at SIF 6h 136.5 0.251 
Eudragit
® 
RS NPs dispersed in SCF 124.1 0.185 
release sample at SCF 1h 131.7 0.269 
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Figure 3-10 Size distribution of Eudragit
® 
RS NPs released from Eudragit
® 
L100-coated 
DRcaps
®
 capsules after 6 h incubation in simulated intestinal fluid (SIF) and 1 h in 
simulated colonic fluid (SCF) by intensity (A), volume (B) and number (C). 
  
Table 3-4 Size distribution of Eudragit
® 
RS NPs released from alginate-coated DRcaps
®
 
capsules 
Sample Z-ave diameter (nm) PDI 
Eudragit
® 
RS NPs dispersed in SCF 124.1 0.185 
release sample at SCF 2h 3156 1.000 
release sample at SCF 3h 183.2 0.355 
release sample at SCF 4h 245.6 0.411 
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Figure 3-11 Size distribution of Eudragit
® 
RS NPs released from alginate-coated DRcaps
®
 
capsules after 2, 3 and 4 h incubation in simulated colonic fluid (SCF) (by intensity, volume 
and number). A-C: SCF 2 h sample, D-F: SCF 3 and 4 h samples. 
3.3.5 In vitro NP release of Eudragit® S100-coated chitosan-HPMC microcapsules  
The in vitro NP release from Eudragit
® 
S100-coated chitosan-HPMC microcapsules is shown in 
Figure 3-12. The cumulative NP release was less than 1 % of the NP load during 2 h incubation in 
simulated gastric fluid followed by 6 h in simulated intestinal fluid. In simulated colonic fluid, NP 
release occurred gradually and approximately 7% of the NP load was released over 6 h, suggesting 
that 99% of the NP load would be potentially available for release in the colon. The NP release 
profile correlates well with the pH-responsive dissolution of Eudragit
® 
S100, implying that 
Eudragit
® 
S100 coating could protect chitosan-HPMC microcapsules from disintegration in the 
stomach, dissolve gradually during formulation transit along the gastrointestinal tract and finally 
enable NP release from microcapsules upon their arrival in the colon. The coating thickness was 
shown to impact the NP release greatly during the development of the microcapsule formulation. 
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Eudragit
® 
S100-methanol solution used at a weight ratio of 0.5:1 of microcapsules for coating failed 
to form a protective shell on the microcapsules, because colourful precipitates were observed after 
adding tropaeolin solution to collected simulated gastric fluid, resulting from the complexation 
between dissolved chitosan and the dye. In contrast, for Eudragit
® 
S100 coating applied at a high 
weight ratio of microcapsules (5:1), NP release was not observed over the in vitro release study. 
Alginate also showed traits that would make it a promising coating for capsules (presented in 
section 3.3.4), however, coating microcapsules with alginate was difficult, because the 
microcapsules suspended in alginate solution became a microcapsule-alginate film after vacuum 
drying and coated microcapsules could not be recovered in the form of separated particles. 
 
Figure 3-12 Cumulative Eudragit
®
 RS NP release from Eudragit
® 
S100-coated chitosan-
HPMC microcapsules in simulated gastric fluid (SGF), intestinal fluid (SIF) and colonic 
fluid (SCF) (mean±S.D, n=3). 
3.4 Conclusions 
Eudragit
®
 RS NPs were encapsulated in DRcaps
®
 capsules or chitosan-HPMC microcapsules 
without NP-carrier polymer aggregation observed before formulation. Eudragit L100-55-coated and 
alginate-coated DRcaps
®
 capsules released 65% and 73% of the NP load in 6h in simulated colonic 
fluid, respectively and dynamic laser scattering measurement indicated that NPs in representative 
release samples remained separated in the release medium. Chitosan-HPMC microcapsules coated 
by Eudragit
®
 S100 showed potential for delivering 99% of the NP load to the colon. These findings 
demonstrate the potential for delivering individual nanoparticles to the colon from enteric-coated 
capsules or microcapsules to achieve colorectal tumour targeting for improved chemotherapy. The 
production of Eudragit
® 
S100-coated chitosan-HPMC microcapsules described in this chapter forms 
a useful foundation for preparing fluorescently-labelled nanoparticle-loaded microcapsules for in 
Chapter 3 
 
 78 
vivo evaluation of nanoparticle delivery by microcapsules using small animal optical imaging as 
described in the following Chapter. 
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Chapter 4. Delivery of nanoparticles to the colon from oral 
microcapsule carriers: an in vivo investigation using multispectral 
small animal optical imaging 
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4.1 Introduction and aims 
4.1.1 Introduction 
The potential for enteric-coated hypromellose capsules and chitosan-hypromellose microcapsules to 
deliver non-aggregated Eudragit
®
 RS nanoparticles (NPs) to the colon has been demonstrated using 
an in vitro release model in Chapter 3. Although a number of in vitro models exist to mimic the 
gastro-intestinal tract, an improved understanding of colon specific delivery can only be achieved 
by testing candidate formulations using in vivo models where the full complement of biological 
factors are encountered. Therefore, this chapter presents an in vivo investigation on release of 
nanoparticles from Eudragit
®
 S100-coated chitosan-hypromellose microcapsules in mice. The 
hypromellose capsules (DRcaps
®
) described in Chapter 3 were not tested in vivo because of 
limitations on sample size for oral administration in mice.  
In order to investigate the release of Eudragit
®
 RS NPs from Eudragit
®
 S100-coated chitosan-
hypromellose (HPMC) microcapsules (MCs) in vivo, determination of the concentrations of both 
the MC carrier and its NP cargo in each section of the animal gastrointestinal tract after oral 
administration is necessary. Optical fluorescence imaging is a sensitive imaging modality and has 
been explored as a direct and non-invasive tool for tracking NPs in live animals, and providing 
qualitative and quantitative analysis of tissue distribution
1-5
. In this study, NPs were labelled with a 
specific fluorophore (Cy5 dye) and loaded into MCs which had been pre-labelled with a second 
fluorophore (IR750 dye). Thus, the NP-loaded MCs exhibited two different fluorescent signatures 
and their distribution in animals after oral administration could be monitored by multi-spectral 
fluorescence imaging.  
As Eudragit
®
 RS PO lacks the functionality for attachment of fluorescent dyes, a companion 
polymer with similar properties (poly(methyl methacrylate), (PMMA)) pre-labelled with Cy5 dye 
was synthesized. Cy5-labelled PMMA was mixed with Eudragit
®
 RS PO to produce fluorescent 
model NPs (Cy5 NPs). The MC carrier system was labelled with IR750 dye through amidation of 
chitosan prior to blending with hypromellose to prepare MCs. This strategy enabled a quantitative 
analysis of the biodistribution and relative ratios of each component of the carrier system (NPs and 
MCs) along the full length of the mouse gastrointestinal tract after oral administration. 
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4.1.2 Aims 
This Chapter utilises an in vivo model and multi-spectral fluorescence imaging to evaluate the 
delivery of model NPs from Eudragit
®
 S100-coated chitosan-HPMC MCs to the colon. Formulation 
of the multispectral system is described in Scheme 4-1. Specific aims are as follows: 
1) To prepare model fluorescent NPs (Cy5 NPs) from Eudragit® RS PO and Cy5-labelled 
PMMA; 
2) To encapsulate Cy5-labelled NPs into IR750-labelled MC carriers; 
3) To investigate the in vivo NP release from coated MCs in the various regions of the 
gastrointestinal tract using multi-spectral fluorescence imaging and compare with NP release 
kinetics derived from the in vitro model; 
4)  To examine Cy5 NP uptake by model lines of colorectal cancer cells and normal cells. 
 
Scheme 4-1 Design and preparation of a multi-spectral carrier system for delivery of 
nanoparticles to the colon. 
4.2 Materials and methods 
4.2.1 Materials 
Eudragit
®
 RS PO and Eudragit
®
 S100 were provided by Evonik Industries (Darmstadt, Germany). 
Hypromellose (HPMC, Methocel
TM
 E50 premium LV) was provided by Colorcon Asia Pacific Pty. 
Ltd. Medium molecular weight chitosan (75–85% deacetylated, molecular weight 190,000-310,000 
Da) and sodium phosphate tribasic dodecahydrate were purchased from Sigma Aldrich. Cyanine5 
amine (Cy5-NH2) was purchased from Lumiprobe Corporation, USA and IRDye
®
 750 NHS Ester 
from LI-COR Biosciences, USA. Phosphate buffered saline (PBS) tablets were purchased from 
Amresco Inc. (Solon, OH). Tropaeolin OOO (pH 11.0-13.0) was purchased from British Drug 
Houses Ltd. Dimethyl sulfoxide (DMSO) and ethyl acetate of analytical grade were purchased from 
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Chem-supply (SA, Australia). Pentafluorophenol was purchased from Matrix Scientific (South 
Carolina, USA). Methacrylic acid and methyl methacrylate (Sigma Aldrich) were passed through 
basic alumina before use to remove inhibitor. All other chemicals were purchased from Sigma 
Aldrich and used as received. Mouse embryonic fibroblast cells (NIH/NIH/3T3; ATCC
®
 CRL-
1658
TM
) and human colon adenocarcinoma cells (HT-29; ATCC
®
 HTB-38
TM
) were cultured in 
Dulbecco's modified Eagle medium (DMEM) (Lonza, Australia) and RPMI Medium 1640 (Gibco) 
respectively containing 10% fetal bovine serum (Moregate BioTech, Australia), 
penicillin/streptomycin and glutamine (Gibco) in an atmosphere of 5% CO2 in air.  
4.2.2  Synthesis and characterization of Cy5-labelled poly(methyl methacrylate) polymer  
4.2.2.1 Synthesis of Pentafluorophenol-activated Methacrylic Acid.  
Methacrylic acid (2.2 g, 25.6 mmol), 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide 
hydrochloride (EDC.HCl, 8.4 g, 43.8 mmol) and dimethylaminopyridine (DMAP, 61 mg, 0.5 mmol) 
were combined and dissolved in 45 mL of dichloromethane (DCM).  This was stirred in an ice bath 
for 20 minutes to which was added drop-wise a solution of pentafluorophenol (7.9 g, 43.0 mmol, 
PFP) in DCM (5 mL). This was left to stir overnight. After the reaction, the solvent was removed 
and the crude product was purified by silica gel column chromatography using hexane:ethyl acetate 
(90:10) as eluent yielding a slightly yellow liquid (4.62 g, 72% yield). 
1
H NMR (500 MHz, CDCl3) 
δ (ppm): 6.45 (m, 1H), 5.90 (m, 1H), 2.08 (m, 3H). 19F NMR (471 MHz, CDCl3) δ (ppm): -152.9 (d, 
2F), -158.23 (t, 1F), -162.62 (dd, 2F). 
4.2.2.2 Synthesis of Cy5-Methacrylamide Monomer (Cy5-MA).  
Cy5-amine.2Cl (9.6 mg, 0.0147 mmol) was dissolved in DMF (0.5 mL) to which was slowly added 
triethylamine (1.55 mg, 0.0153 mmol). Then pentafluorophenol-activated methacrylic acid (4.5 mg, 
0.0178 mmol) was added drop-wise to the solution and left to stir overnight (17 h). The product was 
purified by silica gel column chromatography using first ethyl acetate:hexane (10:90) to remove the 
pentafluorophenol, TEA and DMF. Then the column was flushed with DCM:Ethyl acetate:MeOH 
(85:10:5) resulting in 10.8 mg (>95% yield) of a blue waxy solid. 
1
H NMR (500 MHz, CDCl3) δ 
(ppm): 7.85 (dd, 2H), 7.79 (m, 1H), 7.36 (dt, 4H), 7.22 (m, 2H), 7.14 (d, 2H), 7.08 (d, 2H), 6.84 (t, 
1H), 6.68 (m, 1H), 6.48 (d, 1H), 6.24 (d, 1H), 5.74 (s, 1H), 5.26 (s, 1H), 4.08 (t, 2H), 3.59 (s, 3H), 
3.28 (m, 2H), 3.21 (m, 2H), 2.35 (t, 2H), 1.95 (s, 3H), 1.82 (m, 2H), 1.74 (m, 2H), 1.69 (m, 12H), 
1.53 (m, 6H), 1.35 (m, 4H). No signal was detected in the 
19
F spectrum. ESI-MS: Calculated [M]
+
 - 
649.45 g mol-1; measured [M]
+
 - 649.82 g mol
-1
. 
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4.2.2.3 Synthesis of Cy5-labelled poly(methyl methacrylate) (PMMA-Cy5).  
Methyl methacrylate (0.15 g, 1.33 mmol, MMA), 2,2′-Azobis(2-methylpropionitrile) (0.4 mg, 
0.0024 mmol, AIBN) and reversible addition−fragmentation chain-transfer (RAFT) agent, 4-
Cyano-4-(phenylcarbonothioylthio)pentanoic acid (3.3 mg, 0.0120 mmol, CTA) were combined in 
a Schlenk tube and dissolved in toluene (2 mL). Cy5-MA (1.2 mg, 0.00185 mmol) was dissolved in 
tetrahydrofuran (0.5 mL) and added to the reaction mixture. This was degassed with nitrogen for 45 
minutes then sealed and placed in a thermostated oil bath at 80
o
C for 24 h. At the conclusion of 
polymerization, the blue polymer was precipitated into an excess of n-hexane (200 mL). The 
polymer was filtered, washed with additional n-hexane and dried in a vacuum oven overnight.   
The Cy5 content of PMMA was determined by fluorescence spectrophotometry (Horiba 
Fluoromax-4, Ex=648 nm, Em=670 nm) following dissolution of the Cy5-labelled PMMA in 
DMSO and expressed as the molar ratio of Cy5 dye per PMMA chain. A calibration curve was 
produced using a set of known concentrations of Cy5-NH2 dye in DMSO in a linear range of 0.025-
0.4 µg/mL. The Cy5 content of PMMA was also determined using UV-visible spectrophotometry 
(Cary 4000 UV-Vis) by comparison of the absorbance of Cy5 at 648 nm against calibration 
standards. All UV-visible measurements were performed in acetonitrile.  
4.2.3 Chitosan labelling using IRDye® 750 NHS Ester 
The conjugation of IRDye
®
 750 NHS Ester to chitosan was performed by reacting the primary 
amino groups of chitosan with NHS-activated ester groups in the fluorescent dye. Chitosan (160 mg) 
was dissolved in 32 mL of 1% (v/v) acetic acid and the pH was adjusted to 6.5 by slow addition of 
0.1M NaOH. DMSO (40 mL) containing 0.5 mg IRDye
®
 750 NHS Ester was then added to react 
with the chitosan and the mixture was stirred overnight at room temperature. After incubation, the 
product was washed with acetone to remove free dye molecules and finally washed with distilled 
water. IRDye
®
 750-labelled chitosan (IR750 chitosan) was collected by centrifugation and freeze 
dried. The labelling efficiency was expressed as the weight ratio of IRDye
®
750 in labelled chitosan 
and determined by fluorescence spectrophotometry (Horiba Fluoromax-4, Ex=760 nm, Em=778 nm) 
following IR750 chitosan dissolution in a 10:90 mixture of DMSO and 1% v/v acetic acid. A 
calibration curve was produced using a set of known concentrations of IRDye
®
 750 NHS Ester in 
the same solution mixture in the linear range of 0.15-2.1 µg/mL. 
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4.2.4 Preparation and characterization of Cy5-labelled PMMA-Eudragit® RS PO 
nanoparticles (Cy5 NPs) (Scheme 4-1 (1)) 
Cy5 NPs were prepared from a mixture of Cy5-labelled PMMA and Eudragit
®
 RS PO using a 
modified emulsification-diffusion method reported by Nguyen et al.
6
. Cy5-labelled PMMA (25 mg) 
and Eudragit
®
 RS PO (225 mg) were dissolved in 5 mL n-butanol and the solution was added to 
distilled water (20 mL) using a 30G needle at a rate of 1.5 mL/min (Harvard Apparatus PHD 2000 
Syringe Pump) under magnetic stirring at 1500 rpm. The resulting emulsion was stirred for 4 days 
at room temperature to evaporate the n-butanol completely and then centrifuged at 4000 rpm for 5 
min to remove any polymer precipitate. The supernatant was collected and the NP yield was 
obtained by freeze drying aliquots of the Cy5 NP suspension. The labelling efficiency in dried Cy5 
NPs was determined by fluorescence spectrophotometry (Horiba Fluoromax-4, Ex=648nm, 
Em=670 nm) following dissolution of a known weight of NPs in DMSO and expressed as the 
weight ratio of Cy5 dye to NPs. A known set of concentrations of Cy5 dye dissolved in DMSO in 
the linear range of 0.025-0.25 µg/mL was used to produce the calibration curve.  
The Z-average size (Z-ave), polydispersity index (PDI) and zeta potential of Cy5 NPs were 
determined in triplicate at a final concentration of 1 mg/mL using a Zetasizer Nano ZS (Malvern 
Instruments, Malvern, UK) at an angle of 173°. To examine the morphology of Cy5 NPs, a drop of 
NP suspension (100 µg/mL) was placed on a carbon coated copper grid (100 mesh). After five 
minutes, the excess fluid was blotted with a filter paper and the grid was negatively stained with 
uranyl acetate (1%, w/v). Excess stain was removed by further blotting. The grid was air-dried and 
examined by transmission electron microscopy (TEM, Jeol 1010, USA) at 100 kV. 
4.2.5 Preparation and characterisation of Cy5 NP-loaded IR750 chitosan-hypromellose 
microcapsules coated with Eudragit
®
 S100 (Scheme 1-1 (2) and (3)) 
Cy5 NPs were encapsulated in chitosan-hypromellose microcapsules using the conventional 
ionotropic gelation technique
7
. Nitrogen gas was used to aid the formation of MCs by modifying 
the lab-scale spray equipment reported by Si et al.
8
. Briefly, 1 mL of Cy5 NP suspension (30 
mg/mL) was mixed with 0.5 mL of HPMC (40 mg/mL) at 500 rpm and then added to 1.5 mL of 
IR750 chitosan solution (30 mg/mL). The suspension was sprayed through a 23G needle into a 1:4 
mixture of ethanol in a 5% w/v trisodium phosphate cross-linking solution (65 mL) at a flow rate of 
0.15 mL/min. The spray pressure generated by the nitrogen gas was optimized beforehand to 
provide MC sizes smaller than 300 µm. The resulting suspension of MCs was stirred overnight to 
ensure complete cross-linking of the MC shell. The Cy5 NP- IR750 MCs were collected by 
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centrifugation at 3000 rpm for 4 min and washed twice with distilled water to remove excess 
trisodium phosphate on the MC surface. The concentration of the MC suspension was determined 
by freeze drying aliquots of the suspension and weighing lyophilised MCs. Cy5 NP loading of dried 
IR750 MCs was measured by slightly modifying the Tropaeolin OOO method reported by Melia et 
al.
9
. Briefly, Tropaeolin OOO forms an ion-pair complex with the quaternary ammonium groups in 
Eudragit
®
 RS PO. When extracted into an organic phase, the complex gives rise to an absorbance at 
487 nm which is linearly related to polymer concentration. Tropaeolin OOO was dissolved in 0.1 M 
NaCl solution at a concentration of 2.25 mg/mL. A 200 µL aliquot of the Cy5 NP-IR750 MC 
suspension was added to 0.1M hydrochloric acid (200 µL) in a centrifuge tube and vortexed for 3 
min. This resulted in break-down of the MC structure and thus released the Cy5 NPs. Then 
chloroform (0.5 mL) was added to extract the Eudragit
®
 RS PO. After an additional 5 min vortex, 
the sample was centrifuged at 4000 rpm for 10 min and the supernatant was discarded. Tropaeolin 
OOO in NaCl solution (150 µL) was added and vortexed for 10 min to obtain extraction into the 
Eudragit solution in chloroform. After centrifugation at 4000 rpm for 10 min, the bottom 
chloroform layer was dried in a vacuum oven overnight to remove chloroform. The resulting 
Tropaeolin OOO-Eudragit
®
 RS PO complex was dissolved in 10 µL of DMSO and analysed using a 
UV-visible spectrophotometer (NanoDrop 2000, Thermo Scientific, Australia) at a wavelength of 
487 nm. Absorbance readings were compared with a calibration curve produced using a series of 
known concentrations of Eudragit
®
 RS PO (12.5-62.5 µg/mL) in 0.1M hydrochloric acid. Samples 
were prepared in triplicate and the NP loading of MCs was expressed as a weight percentage of 
Eudragit
®
 RS PO in the dried MCs. 
Coating of Cy5 NP-IR750 MCs was carried out using Eudragit
®
 S100 at a weight ratio of 1.5:1 of 
MCs. 5 mL of MC suspension in distilled water containing 100 mg MCs was added to Eudragit
®
 
S100 in methanol solution (5 mL, 3 % w/v) under gentle magnetic stirring. After 1 h incubation, 
distilled water (20mL) was added to the suspension and the methanol was evaporated overnight. 
Coated MCs were collected by centrifugation at 3000 rpm for 3 min and finally re-suspended in 4 
mL of distilled water.  
The size distribution of Cy5 NP-IR750 MCs after Eudragit
®
 S100 coating was determined using 
dynamic light scattering (Malvern Mastersizer 2000, Malvern, UK). The sample size was measured 
three times at 25 °C. The Cy5 NP distribution in hydrated Eudragit
®
 S100-coated IR750 MCs was 
examined using confocal microscopy (LSM 710, Carl Zeiss Inc., Germany).  
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4.2.6 In vitro Cy5 NP release from Eudragit® S100-coated IR750 chitosan-HPMC MCs 
The in vitro NP release experiment was conducted using a procedure described in Section 3.2.5. 
Simulated gastric and intestinal fluids and incubation times were used to mimic the in vivo pH 
environments and transit times that MCs would encounter as they travel along the human 
gastrointestinal tract
10-14
. The selection of release media and incubation times is explained in 
Chapter 2 under Section ‘Eudragit® RS NP release from alginate microcapsules’. Briefly, 1 mL of 
the Eudragit
®
 S100-coated Cy5 NP- IR750 MC suspension was centrifuged at 2500 rpm for 5 min 
after which the supernatant was removed to avoid its dilution effect on the release medium. 
Sedimented microcapsules were incubated with 1.5 mL of simulated gastric fluid (SGF, 0.05 M 
HCl, pH 1.2) for 2 h at 37 °C, then transferred to 1.5 mL simulated intestinal fluid (SIF, pH 6.8, 
PBS) for 6 h, and finally to 1.5 mL of simulated colonic fluid (SCF, pH 7.4 PBS) for 6 h. Samples 
were prepared in triplicate and 1 mL of release medium was collected every hour using a pipette tip 
wrapped with mesh cut from a Falcon™ cell strainer (mesh size: 40 µm) to avoid infiltration of 
MCs into the collected release samples. Centrifugation was not utilised for release sample collection 
since multiple centrifuge steps were proviously shown to accelerate the disintegration of alginate 
MCs
15
. Cy5 NP concentration in the release media was assayed by the Tropaeolin OOO method and 
compared to calibration standards of Eudragit
®
 RS PO in each release medium. In the collected SIF 
and SCF release samples, dissolved Eudragit
®
 S100 from the MC coating may bind with positive 
Eudragit
®
 RS PO and hinder complex formation between tropaeolin dye and Eudragit
®
 RS PO 
during partition between the aqueous and chloroform phases. Therefore, 400 µL of each release 
sample was acidified by adding 20 µL of HCl (1 M) and precipitated Eudragit
®
 S100 was removed 
by centrifugation. The pH was re-adjusted to approximately 7 with NaOH (1 M) before adding 
chloroform to extract the Eudragit
®
 RS PO NPs. The NP release rate was calculated as the ratio of 
released Eudragit
®
 RS PO NPs against the initial loading in IR750 MCs and expressed as 
cumulative release (% w/w) versus time (h). Representative release samples were examined by 
TEM to check the presence of individual (separated) Cy5 NPs which showed successful staining 
with uranyl acetate. 
4.2.7 In vitro cellular uptake of Cy5 NPs 
Mouse fibroblast NIH/NIH/3T3 cells and human colon adenocarcinoma HT29 cells (respectively) 
were cultured in DMEM and RPMI medium supplemented with 1 % penicillin/streptomycin, 4 mM 
L-Glutamine and 10 % fetal bovine serum at 37 ⁰C in a humidified atmosphere of 5 % CO2 in air. 
For flow cytometric analysis, both cell lines were seeded in 6-well plates at a density of 2×10
5
 
cells/well in 2 mL of complete medium. NIH/NIH/3T3 cells were incubated for 24 h and HT29 
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cells overnight to allow cell attachment. Cells were washed with PBS and incubated with Cy5 NPs 
suspended in 1 mL culture medium for 1, 2 or 4 h. Cy5 NP concentrations were 50, 100 and 300 
µg/mL and samples were prepared in triplicate. Afterwards, cells were washed with PBS to remove 
unbound Cy5 NPs, trypsinised and then fixed in 1 % paraformaldehyde for 15 min prior to analysis 
using flow cytometry (BD Accuri™ C6, BD Biosciences, Australia). The student's unpaired t test 
was used to compare the uptake of Cy5 NPs between the two cell types at each incubation condition. 
All p values resulted from the use of two-sided tests and p < 0.05 was considered significantly 
different. 
For confocal microscopy examination, cells were seeded on coverslips in a 24-well plate at a 
density of 5×10
4
 cells/well in 0.5 mL of culture medium and incubated for 16 h (HT29 cells) or 24 
h (NIH/NIH/3T3 cells) to allow attachment. Cy5 NP suspension (1 mL, 1.5 mg/mL) was added to 
each plate. After 4 h incubation, cells were washed with PBS, fixed with 4 % paraformaldehyde and 
nuclei were stained with Hoechst 33342 before observation under a confocal microscope (Zeiss 710 
Confocal LSM). 
4.2.8 In vivo biodistribution of Eudragit® S100-coated Cy5 NP loaded-IR750 chitosan-
HPMC MCs examined by small animal optical imaging 
A total of 20 BALB/c female mice (17-22 g, eight weeks) were used in this study. Animal ethics 
clearance was approved by the University of Queensland ethical committee (AEC Approval 
Number: AIBN/288/13/ARC).  All animals were fed with a suspension of DietGel
®
 Boost (Clear 
H2O
®
) overnight prior to administration of the MCs to avoid any possible food fibre effects on 
gastric emptying. The abdomen of each animal was carefully shaved to improve acquisition of the 
fluorescence signals emitted by Cy5 NPs and the IR750 MC carriers during their transit through the 
mouse gastrointestinal tract.   
The 20 mice were divided randomly into two groups: a MC group (9 mice) and a control group (11 
mice). The MC group was dosed via oral gavage with Eudragit
®
 S100 coated Cy5 NP-IR750 MCs 
suspended in distilled water (0.3 mL, equivalent to 0.75 mg Cy5 NPs). Prior to imaging, animals 
were anaesthetised (3 % isofluorane in oxygen, 1.5 L/min) and placed in an imaging cradle. 3 
animals were imaged at 0.5, 2, 5, 8 and 24 h after oral administration and then euthanased. To gain 
further insight into the pattern of biodistribution of MCs, two additional sub-groups of 3 animals 
each were euthanased at 5 and 8 h, respectively (n=3). The gastrointestinal tracts and major organs 
(liver, kidney, lung, heart, spleen) of all animals were removed following euthanasia and imaged 
immediately. Images were acquired using a Carestream MS FX PRO (Bruker/CareStream, 
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Rochester, NY) in conjunction with Carestream Imaging Software MI. Fluorescence images were 
collected with excitation/emission at 620 ±10 / 700 ±17.5 nm (Cy5 NP signal) and 720 ±10 / 790 
±17.5 nm (IR750-labelled chitosan signal), 4 × 4 binning, f-stop 2.80, FOV 190 mm and 60 s 
acquisition time. X-ray images were also recorded using the following instrument settings: f-stop 
2.80, X-ray filter 0.2 mm, FOV 190 mm and 10 s acquisition time. All images were batch exported 
as 16-bit TIFF images and image processing was completed using Image-J (National Institutes of 
Health). Fluorescence images were false coloured and overlaid onto X-ray images. 
The control group was dosed with a suspension of NPs in distilled water (0.3 mL, 1.5 mg Cy5 NPs) 
via oral gavage to elucidate the biodistribution and transit timeline of un-encapsulated Cy5 NPs in 
mice. The NP dose was doubled compared to the MC group above in order to achieve an acceptable 
signal/noise ratio in the fluorescence images. This NP dose adjustment was necessary, since our 
trial experiment showed that Cy5 NPs in suspension were widely distributed and thus diluted within 
the mouse gastrointestinal tract, leading to problems in detection and measurement of Cy5 intensity 
due to animal auto-fluorescence. Five mice were imaged at 0.5, 2, 5, 8 and 24 h after oral 
administration, with 1 mouse being euthanased at each time point for further ex vivo analysis. Two 
additional mice were euthanased at each of 5, 8 and 24 h, respectively (n=3) to improve 
fluorescence quantitation at these timepoints. For all animals, the gastrointestinal tracts and major 
organs were removed and imaged as described above. 
4.3 Results and Discussion 
This study aimed to develop MCs capable of protecting their cargo (in this case Cy5-labelled NPs) 
during passage through the upper gastrointestinal tract with release in the colon to improve the 
treatment of colorectal cancer. Production of a multi-labelled system provided a means to 
unambiguously ascertain whether the designated function of the MC carrier in delivering NPs to the 
colon had been achieved and whether NP release had occurred at the target site. Formulation of the 
multispectral system is described in Scheme 4-1. 
4.3.1 Characterization of Cy5-labelled PMMA and IR750-labelled chitosan 
In order to effectively quantify the biodistribution and corresponding concentration of NPs and 
MCs in the mouse gastrointestinal tract, precise analysis of NP and MC labelling efficiency is 
essential. The molar mass of the Cy5-labelled PMMA was determined using 
1
H NMR and UV-
visible spectrophotometry. The former analysis was performed by comparing the proton signals in 
the NMR spectrum resulting from the CTA end-groups to the proton signals originating from 
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PMMA repeat units (Mn = 18 kDa). Similarly, the molar mass was calculated using UV-visible 
spectrophotometry of the CTA end-groups (Molar absorptivity: 13200 M
-1
cm
-1 
in acetonitrile) to 
give a Mn of 17.8 kDa. The molar ratio of Cy5 dye to PMMA polymer was determined by both 
fluorescence and UV-visible spectrophotometry (Molar absorptivity: 177200 M
-1
cm
-1
). It was 
determined that the PMMA contained approximately one Cy5 dye molecule per 20 polymer chains 
(1.67 ± 0.28 µg of Cy5 dye per mg of PMMA measured by fluorescence spectrophotometry). The 
IR750-labelled chitosan had a conjugation loading of approximately 2.97 ± 0.15 µg of IR750 dye 
per mg of chitosan as measured by fluorescence spectroscopy. 
4.3.2 Preparation of Cy5-labelled PMMA-Eudragit® RS PO NPs (Cy5 NPs) and Cy5 NP-
loaded IR750 chitosan-HPMC MCs coated by Eudragit
®
 S100  
Cy5-labelled NPs were used as model NPs to evaluate the design and performance of colon-targeted 
chitosan-HPMC MCs as carriers for NPs functioning as drug carriers or diagnostic agents. A major 
challenge in NP preparation was the need to obtain a high NP yield with sufficiently high 
fluorescence intensity to allow detection and quantitative analysis along the gastrointestinal tract of 
test animals. Thus, unlabelled Eudragit
®
 RS PO was used alone in preliminary studies to optimize 
NP formulation before incorporation of Cy5-labelled PMMA. Most published nanoprecipitation or 
emulsion methods
16-18
 for Eudragit
®
 RS PO NP preparation involve polymer dissolution in solvents 
such as acetone and dichloromethane and use of surfactants to stabilize the polymer-organic 
solution droplets in the aqueous phase to prevent NP aggregation after solvent evaporation. 
However, application of this conventional approach typically produced a low yield of Eudragit
®
 RS 
NPs (3-12%, w/w, unpublished data) due to the difficulty in recovering NPs from the viscous, 
surfactant-containing aqueous phase by ultracentrifugation. In the present study, n-butanol was used 
as the organic phase to overcome this issue. Owing to the low interfacial tension between n-butanol 
with water, NPs could be prepared without using surfactants
6
.  
Eudragit
®
 RS PO NPs were recovered with a high yield of around 70% (w/w) simply by 
evaporating n-butanol completely and subsequently removing polymer flakes by low speed 
centrifugation. Cy5-labelled NPs prepared in the same way using the mixture of Cy5-labelled 
PMMA and Eudragit
®
 RS PO had a satisfactory yield of around 76% (w/w). Laser light scattering 
revealed a Z-ave diameter of 198.7 nm, a PDI of 0.201 and a Zeta potential of 50.0 ± 6.24 mV for 
Cy5-labelled NPs. The TEM image (Figure 4-1) reveals a NP size range of 30-200 nm without 
significant aggregation. The weight ratio of Cy5 dye to total polymer in the final dried NPs was 
(0.0043 ± 0.0005) %. 
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Figure 4-1 TEM image of Cy5-labelled PMMA-Eudragit
®
 RS PO NPs (Cy5 NPs) (scale bar 
200 nm). 
The Cy5 NPs were loaded into IR750-labelled chitosan-HPMC MCs using spray-aided ionotropic 
gelation. Ethanol was added to the Na3PO4 cross-linking solution (20 % v/v) to enhance the 
formation of spherical MCs and decrease inter-particle interaction
7
. The loading of Cy5 NPs in the 
lyophilised IR750 MCs was calculated by UV-Vis and found to be fairly high, 10.5 ± 0.4 % (w/w) 
with an encapsulation efficiency of 17.4 ± 0.7 %. The yield of IR750 MCs was 58 ± 1.0 % (w/w). 
The spray technique was found to be the main factor leading to the relatively low yield of 
microcapsules and NP encapsulation efficiency, whereby the high spray pressures employed 
decreased the efficiency of mixing between the droplets of Cy5 NPs-HPMC-chitosan suspension 
and the cross-linking solution. NP encapsulation is expected to be improved by modifying process 
parameters such as solvent, cross-linking solution and spray pressure. 
 Optical microscopy (Figure 4-2A) revealed that the majority of the uncoated Cy5 NP-IR750 MCs 
were less than 100 µm in size while dynamic light scattering measurements revealed that 70% of 
the particles were within the size range of 50-410 µm in diameter with a surface weighted mean 
diameter of around 100 µm, respectively. The MC diameter slightly increased following coating 
with Eudragit
®
 S100: 70 % of the particles were in the range of 50-430 µm with a surface weighted 
mean diameter of around 110 µm. Some agglomerates and irregular shaped MCs were evident 
under the microscope (Figure 4-2B) which explains the broad particle size range measured by laser 
light scattering. Confocal microscopy (Figure 4-3) revealed an even distribution of Cy5 
fluorescence throughout the MCs following coating with Eudragit
®
 S100, suggesting successful 
incorporation of the model NPs into the MCs. We concluded that the size of the coated Cy5 NP-IR 
750 MCs obtained here would be suitable for oral gavage in mice. The mouse pylorus diameter was 
estimated to be 250 µm
19
, and a recent report by Jang et al.
20
 showed that PMMA MCs (80-300 µm 
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in diameter) were emptied from the stomach of male ICR mice with most of the particles reaching 
the intestine in less than 4 h.  
 
Figure 4-2 Optical micrograph of Cy5 NP-loaded IR750 chitosan-HPMC MCs. (A) 
uncoated and (B) Eudragit S100-coated. (scale bar 200 µm) 
Figure 4-3 Confocal microscopic image of Cy5 NP (red)-loaded IR750 MCs coated by 
Eudragit
®
 S100. 
4.3.3 In vitro Cy5 NP release from Eudragit® S100-coated IR750 MCs 
The in vitro release behaviour of Cy5 NPs from Eudragit
®
 S100-coated IR750 MCs is shown in 
Figure 4-4. The cumulative NP release was typically confined to less than 4 % during 2 h 
incubation in simulated gastric fluid and subsequent 6 h in simulated intestinal fluid. Over the 
following 6 h in simulated colonic fluid, a further 9 % of the Cy5 NP load was released from the 
MCs, corresponding to a total cumulative release of approximately 13 %. The low release rate may 
result from slow dissolution of the Eudragit
®
 S100 coating in simulated colonic fluid (pH 7.4). 
TEM analysis of simulated colonic release medium at 4h revealed discrete spherical regions on the 
size scale expected for nanoparticles (50-200 nm) suggesting that the released NPs existed 
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predominantly in an individual (non-aggregated) state (Figure 4-5), while the MC polymeric 
materials are likely the large, diffuse stained regions of soluble polymer in the image. The in vitro 
release study predicted that the chitosan-HPMC MC carriers would release approximately 9% of 
NPs in the colon corresponding to early transit times. Watts et al.
21
 reported a mean residence time 
of 11.0 ± 4.0 h in the human ascending colon for 0.2 mm ion-exchange Amberlite
®
 IR120 resin 
particles following oral administration and around 80% of dosed particles resided in the colon after 
24 h post-administration. Thus the MCs described here are potentially suitable for in vivo delivery 
of non-aggregated NPs to the colon for uptake by cancer cells or local delivery of anti-cancer drugs. 
Figure 4-4 Cumulative Cy5 NP release from Eudragit
®
 S100-coated IR750 MCs in 
simulated gastric fluid (SGF), intestinal fluid (SIF) and colonic fluid (SCF) (mean±S.D, n=3). 
Figure 4-5 TEM images of non-aggregated Cy5 NPs released from MCs after 4h incubation 
in simulated colonic fluid (SCF). Highlighted are the NPs stained with uranyl acetate 
clearly showing discrete particles released from the MCs. Dark, diffuse area is the MC 
polymer dissolved in SCF and stained by uranyl acetate. White area is the background. 
4.3.4 Cellular uptake of Cy5 NPs by colon cancer HT29 cells and fibroblast NIH/3T3 cells 
Following successful demonstration that Cy5 NPs could be released from chitosan-HPMC 
microcapsules in SCF, it was necessary to confirm their uptake by human colon adenocarcinoma 
(HT29) cells. We also tested mouse embryonic fibroblast (NIH/NIH/3T3) cells in a comparative 
experiment since these are widely used for in vitro cytotoxicity evaluation of biomaterials and 
NPs
22-24
. Flow cytometric analysis showed that Cy5 NP uptake by HT29 cells and NIH/NIH/3T3 
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cells increased with NP concentration and incubation time (Figure 4-6a). HT29 cells exhibited 
slightly higher uptake of Cy5 NPs than NIH/NIH/3T3 cells under all incubation conditions 
examined and significant difference between these two cell types was shown when the Cy5 NP 
concentration or incubation time (alone or both) was used at sufficiently high levels (Cy5 NP 
concentration 50 µg/mL for 4 h, 100 µg/mL for 2 or 4 h, and 300 µg/mL for all three incubation 
times) (Figure 4-6a). This behaviour was attributed to the higher proliferation rate of cancerous 
HT29 cells compared with normal NIH/NIH/3T3 cells observed during cell culture. The uptake of 
Cy5 NPs in both cell lines was confirmed by confocal microscopy (Figure 4-6b). The high cellular 
uptake of the NPs shown in the present study may be attributed not only to their small size, but also 
to their hydrophobicity. Cellular uptake of hydrophobic, polymeric NPs has been widely 
reported.
25,26
 Our in vitro data add to the existing body of knowledge that confirms the efficient yet 
non-specific uptake of NPs by cancerous and normal cells. Conjugating targeting ligands (folate, 
hyaluronc acid, humanized A33 monoclonal antibody) to NPs has been widely reported in the 
literature to enhance NP uptake by cancer cells and avoid side effects due to uptake by healthy 
cells.
27,28
 The present study of carrier design for NP delivery paves the way for in vivo trials of these 
promising nanotechnologies for improved treatment and diagnosis of colorectal cancer. 
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Figure 4-6 a) Flow cytometric analysis of Cy5 NP uptake following incubation with HT29 
human colon cancer cells and NIH/NIH/3T3 mouse fibroblasts for 1, 2, 4 h. Cells were 
incubated with Cy5 NPs at 50, 100 or 300 µg/mL in complete medium (mean±S.D, 
n=3/group). Student unpaired t-test was used to assess statistical difference between the two 
cell types under each incubation conditions (*p value <0.05). b) Confocal microscopic 
images of HT29 (top) and NIH/NIH/3T3 cells (bottom) after 4 h incubation with Cy5 NPs 
(1.5 mg/mL). Left: cell nuclei stained with Hoechst 33342 (blue); middle: Cy5 NP signal 
(red); right: merged images showing nuclei and Cy5 NPs. 
4.3.5 Biodistribution of Cy5 NPs and Eudragit® S100-coated IR750 MCs following oral 
administration in mice 
Investigations of the biodistribution of Cy5 NPs and the carrier microcapsules along the mouse 
gastrointestinal tract following oral administration were conducted using multispectral optical 
imaging to provide evidence for the specificity of NP delivery to the colon. To my knowledge, there 
are no comparable commercialized microcapsule formulations available for such a comparison. 
Marketed products are mostly capsules which cannot be administered to mice due to size limitations. 
The progression of Cy5 NP-IR750 MCs along the mouse gastrointestinal tract was recorded by 
whole-body imaging over 24 h (Figure 4-7A and B). At 0.5 h, the fluorescence signal arising from 
both MCs and NPs was predominantly in the stomach and both signals were detected in the 
abdominal region over 24 h. Owing to the coiling of the large and small intestine within the 
abdominal cavity, it was difficult to distinguish between the different sections of the gastrointestinal 
tract. Hence, in order to accurately assess particle biodistribution, the mouse gastrointestinal tracts 
and major organs were removed at different time points and imaged for quantitative ex vivo analysis 
(Figure 4-7C and D). In vivo biodistribution was not assessed at 2 h post administration, as the 
microcapsules remained intact in the mouse gastrointestinal tract at 5 h post administration 
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(explained on Page 96) and the data at 2 h would provide little information regarding release 
kinetics of nanoparticles from the microcapsules. It was found that the IR750 MC carriers were 
cleared more rapidly from the mouse gastrointestinal tract compared to the released Cy5 NPs, 
probably due to the MC size and hydrophilicity of the chitosan polymer which would be exposed 
after dissolution of the Eudragit
®
 S100 coating in the intestinal environment. This observation is 
significant since it confirms release of NPs from the MC carrier in vivo. The other major organs 
(liver, kidney, lung, heart, spleen) gave rise only to very weak fluorescence signals at all timepoints, 
typically equivalent to the levels of autofluorescence detected in control mice (Figure 4-8). This 
indicates that there is minimal absorption of NPs, MCs or ‘free’ dye molecules into the bloodstream. 
In contrast, Lee et al.
4
 reported some accumulation of Cy5.5-conjugated ZnO nanoparticles around 
20 nm and 100 nm in rat kidneys and liver at 7 h following oral administration, illustrating the 
importance of NP material and size factors in determining the in vivo fate of NPs designed for oral 
drug delivery. 
Figure 4-7 Mouse whole body images (4A and 4B) at 0.5, 2, 5, 8 and 24 h after oral 
administration of Eudragit
®
 S100-coated Cy5 NP-IR750 MCs. (4A) Cy5 NP signal (4B) 
IR750 MC signal. Fluorescence images of gastrointestinal tract (4C and 4D) following 
excision from mice at 5, 8 or 24 h after oral administration of Eudragit
®
 S100-coated Cy5 
NP-loaded IR750 MCs. (4C) Cy5 NP signal (4D) IR750 MC signal. 
 
Figure 4-8 Mouse major organs at 5, 8, 24 h after oral gavage of Eudragit
®
 S100-coated Cy5 
NP-IR750 MCs. (a)Cy5 NP signal in blue; (b) IR750 MC signal in red.  
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The relative fluorescence intensity ratio of Cy5 NPs to IR750 MCs was used as an indicator of NP 
residence or accumulation in different regions of the mouse gastrointestinal tract. For example, a 
higher Cy5-to-IR750 ratio indicates NP release from the MCs and possibly interaction with mouse 
intestinal mucosa, resulting in longer retention in gastrointestinal tract than if NPs remained 
encapsulated by the MC carrier. The initial Cy5 NP-IR750 MCs were imaged in an eppendorf tube 
prior to oral administration and the relative intensity of Cy5:IR750 was used as the zero time point 
control where all NPs were encapsulated within the MCs (1.86 ± 0.19, n=3, orange dashed line 
shown in (Figure 4-9). 
Figure 4-9 Fluoroscence intensity ratio (Cy5 to IR750) in mouse stomach, small intestine, 
caecum, colon and faeces at 5, 8 and 24 h after oral administration of Cy5 NP-IR750 MCs 
coated by Eudragit
®
 S100. The dotted orange line shows the relative ratio prior to 
administration (1.86 ± 0.19 (mean±S.D.; n=3)). 
The ratio of the two different fluorophores in each section of the mouse gastrointestinal tract and 
faecal pellets was measured at 5, 8 and 24 h. At all time points the stomach showed consistently low 
fluorescence ratios (1.1-2.3), indicating restricted release of NPs due to the Eudragit
®
 S100-coating, 
remaining intact at gastric pH and thus preventing MC disintegration and premature release of NPs 
in the stomach. The average Cy5:IR750 ratios in the stomach, small intestine, caecum, colon and 
faecal pellets at 5 h were similar to the zero time point control, indicating that a fraction of the MCs 
transited rapidly through the GI tract but were largely intact and NP release was minimal. At 8 h, 
however, the small intestine, caecum and colon exhibited marked increases in average fluorescence 
intensity ratios to around 15, 10 and 8, respectively indicating significant NP release from the MCs 
occurs in the small intestine and lower gastrointestinal tract between 5 h and 8 h. These findings 
parallel the in vitro release data presented in (Figure 4-4). Compared to the stomach and faecal 
pellets, the Cy5:IR750 ratio in small intestine, caecum and colon had a relatively high standard 
deviation. The sample preparation and animal dosing procedures were carefully-performed to 
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minimize possible variations caused by experimental error(s), thus the variation in the in vivo data 
highlighted the complex influence and interplay of physicochemical and physiological factors on 
NP release. Such factors include dissolution of the Eudragit
®
 S100 coating on MCs, release of NPs 
from MCs and the intra-animal variation of transit time within the gastrointestinal tract. In vivo 
results of oral formulations reported by other researchers had similarly high intra-animal 
variability.
29,30
 For example, Mayank and Mansoor
30
 reported the variation in transit times of 
poly(epsilon-caprolactone) microspheres (diameter less than 5 µm) through the gastrointestinal tract 
of Wistar rats. At 8 h in the present study, the Cy5:IR750 ratio measured in faecal pellets was 
similar to the zero time-point control and remained much lower than ratios in the small and large 
intestine, indicating that a fraction of the NP-loaded MCs was excreted intact. At 24 h, however, the 
intensity ratios in faecal pellets increased to around 8.3 indicating excretion of released NPs. The 
ratios in the small intestine, caecum and colon at 24 h remained elevated and were similar to the 8 h 
interval, clearly indicating the potential for increasing NP residence time in the colon for targeting 
tumours and local release of chemotherapeutic drugs.  
In order to achieve a greater understanding of the effect of the MC carrier on NP biodistribution, 
mice were administered with an oral suspension of un-encapsulated Cy5 NPs to mice. Figure 4-10 
shows a comparison of the fluorescence intensity of Cy5 NPs in each section of mouse 
gastrointestinal tract and faecal pellets after oral administration of both formulations (free and 
encapsulated NPs, respectively). This data is extracted from the ex vivo fluorescence images of 
mouse gastrointestinal tract following oral administration of unencapsulated Cy5 NPs suspensions 
at various time points (Figure 4-11). At 0.5 and 2 h post-administration (Figure 4-11a), Cy5 NPs 
were mostly located within the stomach and the small intestine. At 5 h (Figure 4-10), their 
distribution in the lower gastrointestinal tract (caecum, colon) and faecal pellets was noticeably 
higher than NPs loaded in our MC formulation, reflecting a shorter transit time of unencapsulated 
NPs throughout the lower gastrointestinal tract and implying a reduced time period for drug 
delivery in the colon. 
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Figure 4-10 Fluoroscence intensity of Cy5 NPs at 5, 8 and 24 h following oral 
administration of Cy5 NP suspension (a) and Eudragit
®
 S100-coated Cy5 NP-IR750 MCs 
(b). (mean±S.D, n=3/group). The Cy5 NP dose administered in NP suspension group was 
doubled compared to that of the MCs. 
 
 
Figure 4-11 Mouse gastrointestinal tract (a) and organs (b) removed at 0.5, 2, 5, 8 and 24 h 
after oral gavage of Cy5 NP suspension. Cy5 NP signal in blue. 
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NP-loaded MCs showed a stable mean fluorescence intensity of Cy5-labelled NPs in the colon over 
a 24 hour time period and at 24 h was higher than the unencapsulated NPs. It should be noted that 
these values are indicative only, since the fluorescence intensity of Cy5 NPs initially dosed in un-
encapsulated NP form was 1.85 times that of NPs loaded in IR750 MCs, suggesting that the NPs 
would have a limited distribution in the colon if administered in un-encapsulated form. NP 
encapsulation in Eudragit
®
 S100-coated chitosan-HPMC MCs avoided rapid transit along 
gastrointestinal tract and excretion of NPs in faeces, resulting in an increased accumulation of NPs 
in the colon from 8 h to 24 h post-administration. This behaviour may be expected to facilitate NP 
interaction with the colorectal wall and localised release of anti-cancer drugs at tumour sites.  
Interestingly, both NP-loaded MCs and the un-encapsulated NPs showed significant retention in the 
stomach over 24 h. Gastric emptying of NPs in rodents typically occurs within 6 h post-
administration.
31,32
. In the present study, prolonged retention of NP suspensions and NP-loaded 
MCs in the mouse stomach may be attributed to their adhesion to the gastric mucosal surface, which 
is a continuously secreted protective coating containing proteins, carbohydrates, lipids, salts, 
antibodies, bacteria, and cellular debris
33
. Particle interaction with gastric mucosa is known to occur 
via electrostatic, hydrophobic, and van der Waals interactions, polymer chain interpenetration or a 
combination of these mechanisms
34
. The gastric mucosal surface of many mammals has been 
shown to be hydrophobic due to its mucin glycoproteins
35
 and lipidic constituents, especially the 
presence of surface-active phospholipids
34
. Additionally, the extensive negatively charged sugar 
moieties on mucins can bind to positively charged particles through electrostatic interactions
33
. 
Sakuma et al.
36
 reported that polystyrene NPs with cationic polymer chains on the surface exhibited 
a slower gastric emptying rate in rats compared with their neutral or anionic counterparts. In the 
present study, the considerable amount of Cy5 NPs in the stomach at 24 h post-administration could 
be explained by a combination of hydrophobic and electrostatic interaction with gastric mucus (Cy5 
NPs are positively charged with a zeta potential of around 50.0 mV). Chickering et al.
37
 reported 
the carboxyl groups of Eudragit
® 
S100 coating on MCs may form hydrogen bonds with mucus 
glycoproteins, a mechanism that could lead to the observed prolonged retention of the MCs in the 
stomach. Gastric retention of particulate systems in the stomach should be assessed in the future 
development of colon-targeting systems. 
It is worthwhile noting that the simple in vitro release study of colon-targeted drug delivery does 
not take particle adhesion with stomach mucosa into account (which leads to prolonged particle 
rention within gastointestinal tract) and is therefore not the optimum predictor of a delivery system's 
in vivo performance.  
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4.4 Conclusions  
 We have prepared Eudragit
®
 S100-coated chitosan-hypromellose microcapsules suitable for oral 
delivery of model PMMA- Eudragit
® 
RS PO nanoparticles to the colon. The microcapsule carrier 
and the NP load were successfully labelled with different fluorescent dyes to provide a multispectral 
animal imaging approach for quantitative in vivo evaluation of the biodistribution of the carrier and 
released NPs in the mouse gastrointestinal tract. Despite in vitro evidence that Eudragit
®
 S100-
coated chitosan-hypromellose MCs restricted the release of encapsulated Eudragit
®
 RS NPs,  
complete NP release from MCs was shown in the lower part of the mouse small intestine in the 
animal experiments. Moreover, encapsulation of NPs by MCs resulted in higher NP concentration 
in the colon from 8 h to 24 h post-administration compared to the NP suspension alone. These 
results demonstrated the feasibility of such MCs as a carrier for delivering drug-loaded NPs to the 
colon and increasing NP residence time for tumour targeting and local release of chemotherapeutics. 
Encapsulation of ligand-conjugated therapeutic or diagnostic NPs in the MCs would provide a 
means for targeted delivery to colorectal tumours for improved chemotherapy and detection. The in 
vitro testing model provides a first-hand approach for evaluating formulations, but the efficiency of 
the MC delivery system must be examined by in vivo experiments to gain a comprehensive 
understanding. 
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Chapter 5. Eudragit
®
 S100-coated chitosan-hypromellose 
microcapsules for delivering drug-loaded nanoparticles to the 
colon  
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5.1 Introduction and aims 
5.1.1 Introduction  
Chapter 4 utilised small animal optical imaging to validate the efficiency of Eudragit
®
 S100-coated 
chitosan-hypromellose (HPMC) microcapsules (MCs) for delivering Eudragit
®
 RS-PMMA 
nanoparticles (NPs) to the colon. This Chapter investigates the potential of the optimised MCs for 
delivering drug-loaded NPs to the colon. Preparation of drug-loaded NPs encapsulated in MCs (NP-
MCs) includes three steps which are similar to the procedure presented in Scheme 4-1(Chapter 4): 1) 
encapsulation of small drug molecules in Eudragit
®
 RS NPs, 2) incorporation of drug-loaded NPs in 
chitosan-HPMC microcapsules and 3) coating drug-loaded NP-MCs with Eudragit
®
 S100. As drug 
loss inevitably occurs during each formulation step as a result of drug partitioning within the 
preparation medium, it was hypothesized that the solubility properties of drug candidates would 
influence their encapsulation efficiency in NPs and MCs. Similarly, drug release from carriers is 
affected by their solubility in the release medium, where diffusion from carrier matrix to the release 
medium is enhanced with increasing solubility.
1,2
 In order to investigate the feasibility of utilising 
the NP-MCs for delivering drugs of different solubility to the colon, fluorouracil (5-FU), 
indomethacin and curcumin were selected as model drugs, because they are known to inhibit 
proliferation of human colorectal cancer cells
3-5
 and are reported to have different solubilities in 
different pH buffers (Table 5-1). The solubilities of 5-FU, indomethacin and curcumin under 
different pH conditions predicted using Advanced Chemistry Development (ACD/Labs) Software 
V11.02 are shown in Appendix 1-3. Although the models used to predict the solubility for each 
drug under a specific pH may show significant variation from model to model, they reveal 
indicative pH-dependencies of drug solubilities that can aid in improving formulation design. Being 
a hydrophilic drug, 5-FU has a very high solubility in the pH range of 1-10 (Appendix 1). In 
contrast, the solubility of indomethacin below pH 6 is less than 1 mg/mL, but increases to be above 
20 mg/mL in neutral and basic media (Appendix 2). Of the three drugs, curcumin has the lowest 
solubility in water at any pH, but is expected to show enhanced solubility at or above pH 9 
(Appendix 1).  
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Table 5-1 Solubilities of 5-FU, indomethacin and curcumin in water and different aqueous 
buffers reported in the literature 
Drug 
Water or aqueous buffers 
used 
Solubility 
5-FU water 10 mg/mL
6
, 11.8 mg/mL
7
 
Indomethacin 
water 27.1 µg/mL
8
 
pH 1.0 citric acid-phosphate 5 µg/mL
9
 
pH 3.0 citric acid-phosphate 15 µg/mL
9
 
pH 3.3 phosphate buffer 1.3 µg/mL
2
 
pH 5.0 citric acid-phosphate 30 µg/mL
9
 
pH 6.8 1 mg/mL
9
 
pH7.4 phosphate buffer 1.3 mg/mL
9
, 1.5 mg/mL
2
 
Curcumin water insoluble
10
, 0.6 µg/mL
11
 
 
pH 5 phosphate buffer lower than 11 ng/ mL
 12
 
 
pH 7.4 phosphate buffer lower than 15 µg/mL
13
 
5.1.2 Aims  
The aim of this study was to prepare NP-MCs with sufficiently high drug loading where the coated 
MCs could release drug-loaded NPs in the colon for improved anti-cancer activity of the drug 
against colorectal cancer cells. The performance of MCs for releasing drug-loaded NPs in the colon 
was evaluated by monitoring the in vitro release of both drug and NPs from the system. The 
potential of Eudragit
®
 RS NPs as carriers for enhanced delivery of chemotherapeutic drugs to 
colorectal cancer was then investigated by analysing the cytotoxicity of drug-loaded NPs on 
colorectal cancer cell lines and normal cells. 
5.2 Materials and methods  
5.2.1 Materials  
Eudragit
®
 RS PO and Eudragit
®
 S100 were provided by Evonik Industries (Darmstadt, Germany). 
Hypromellose (HPMC, Methocel
TM
 E50 premium LV) was provided by Colorcon Asia Pacific Pty. 
Ltd. Medium molecular weight chitosan (75–85% deacetylated, molecular weight 190,000-310,000 
Chapter 5 
 
 106 
Da), fluorouracil, indomethacin, curcumin and sodium phosphate tribasic dodecahydrate were 
purchased from Sigma Aldrich, USA. Hydrochloric acid (UNIVAR) and sodium hydroxide were 
purchased from Ajax Finechem Pty Ltd (NSW, Australia). Phosphate buffered saline (PBS) tablets 
were purchased from Amresco Inc. (Solon, OH). Tropaeolin OOO (pH 11.0-13.0) was purchased 
from British Drug Houses Ltd. Acetone, ethyl acetate, ethanol and methanol of analytical grade 
were purchased from Chem-supply (SA, Australia). All other chemicals were purchased from 
Sigma Aldrich, USA and used as received. Mouse embryonic fibroblast cells (NIH/NIH/3T3; 
ATCC
®
 CRL-1658TM) and human colon adenocarcinoma cells (HT-29; ATCC
®
 HTB-38TM) were 
cultured in Dulbecco's modified Eagle medium (DMEM) (Lonza, Australia) and RPMI Medium 
1640 (Gibco, Australia) respectively containing 10% fetal bovine serum (Moregate BioTech, 
Australia), 1% penicillin/streptomycin and 4 mM glutamine (Gibco) in an atmosphere of 5% CO2 in 
air. CellTiter 96
®
 AQueous One Solution for cell proliferation MTS Assay was purchased from 
Promega, USA. 
5.2.2 Preparation and characterization of Eudragit® RS NPs loaded with 5-FU, 
indomethacin or curcumin  
5-FU-loaded Eudragit
® 
RS NPs (5-FU NPs) were prepared by the emulsification-diffusion method. 
Eudragit
®
 RS PO (50 mg) was dissolved in 5 mL 2-butanone and the solution was injected through 
a 30G needle into 5-FU solution (10 mg/mL, 5 mL) at a rate of 1.5 mL/min (Harvard Apparatus 
PHD 2000 Syringe Pump) under magnetic stirring at 1500 rpm. The resulting suspension was 
stirred overnight at room temperature to evaporate 2-butanone and then centrifuged at 4000 rpm 
(Allegra
® 
X-15R, Beckman Coulter) for 5 min to remove any polymer precipitate. The supernatant 
was transferred to dialysis tubing (molecular weight cut-off: 3500 Da) and dialyzed against distilled 
water (80 mL) for 4 h under magnetic stirring at 500 rpm to remove un-encapsulated 5-FU. The 
water was replaced once after 2 h dialysis. Aliquots of collected 5-FU-loaded Eudragit
®
 RS NP 
suspension were freeze dried to determine NP concentration. 5-FU loading of Eudragit
®
 RS NPs 
was measured by UV spectrophotometry at an absorbance wavelength of 265 nm (Cary 4000 UV-
Vis) following NP dissolution in methanol and compared to a calibration curve produced using a 
series dilution of 5-FU in methanol in a linear range of 2.5-15µg/mL. The drug loading, drug 
encapsulation efficiency and yield of 5-FU-loaded NPs were calculated using the equations (1-3) 
below. The Z-average size (Z-ave), polydispersity index (PDI) of 5-FU-loaded Eudragit
®
 RS NPs 
dispersed in distiled water (100 µg/mL) was measured three times using a Zetasizer Nano ZS 
(Malvern Instruments, Malvern, UK) at an angle of 173°. 
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Eudragit
®
 RS NPs were loaded with either indomethacin or curcumin by dissolving 50mg of 
indomethacin or curcumin and Eudragit
®
 RS PO (500 mg for indomethacin and 1.5 g for curcumin, 
respectively) in acetone (10 mL), then injecting each mixture into distilled water (20 mL) at a rate 
of 1.0 mL/min under magnetic stirring at 1500 rpm. The resulting suspensions were stirred 
overnight at room temperature to evaporate acetone and then centrifuged at 4000 rpm (Allegra
® 
X-
15R, Beckman Coulter) for 5 min to remove any polymer precipitate. Indomethacin loading of 
Eudragit
®
 RS NPs was measured by UV spectrophotometry using an absorbance wavelength of 324 
nm (Cary 4000 UV-Vis) following NP dissolution in ethanol and compared to a calibration curve 
produced using a series dilution of indomethacin in ethanol over a linear range of 10-50 µg/mL. 
Curcumin loading of Eudragit
®
 RS NPs was measured by UV spectrophotometry using an 
absorbance wavelength of 429 nm (Cary 4000 UV-Vis) following NP dissolution in ethanol and 
compared to a calibration curve produced using a series dilution of curcumin in ethanol over a 
linear range of 1-5 µg/mL. Drug loading assay and size measurement of indomethacin- or 
curcumin-loaded NPs were conducted as described above for 5-FU-loaded NPs.  
5.2.3 Encapsulation of drug-loaded Eudragit® RS NPs in Eudragit® S100-coated 
chitosan-HPMC microcapsules  
Drug-loaded Eudragit
® 
RS NPs were encapsulated into chitosan-HPMC microcapsules using an 
ionotropic gelation technique combined with aerosolization as described in Section 4.2.5. To 
investigate the impact of the pH of cross-linking solution on drug encapsulation efficiency, the 
cross-linking solution used in this study was prepared by adjusting the pH of trisodium phosphate 
solution (5%, w/v) to approximately 8.0 or 10.0 with phosphoric acid, then mixing with ethanol at a 
volume ratio of 4:1. Chitosan was dissolved in acetic acid aqueous solution (1%, v/v) at 24 mg/mL 
and HPMC was dissolved in distilled water at 40 mg/mL. The concentrations of 5-FU-, 
indomethacin- and curcumin-loaded NPs in each suspension were 5, 16 and 36 mg/mL, respectively. 
For each drug-loaded Eudragit
®
 RS NP suspension, a volume of 6 mL was mixed with HPMC 
solution (1.5 mL) and chitosan solution (15 mL) under magnetic stirring. The suspension was 
sprayed through a 23G needle into the cross-linking solution (60 mL) at a flow rate of 0.15 mL/min. 
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The spray pressure generated by the nitrogen gas was optimized beforehand to provide MC sizes 
smaller than 300 µm. The resulting suspension of MCs was stirred overnight to ensure complete 
cross-linking of the MC shell. The drug-loaded NP-MCs were filtered and washed twice with 
distilled water to remove excess trisodium phosphate on the MC surface, and the concentration of 
MCs in the collected suspension was determined by freeze drying aliquots of the suspension and 
weighing lyophilised MCs.  
In order to measure drug loading of each drug NP-loaded chitosan-HPMC MCs, samples were 
prepared in triplicate. A 0.25 mL aliquot of each MC suspension was added to an equal volume of 
0.1M hydrochloric acid, then vortexed for 2 min to dissolve chitosan-HPMC MCs to release drug-
loaded NPs. Methanol (3.5 mL) was added to precipitate chitosan and the sample was centrifuged at 
4000 rpm for 5 min to remove chitosan. The supernatant was analysed at the absorbance 
wavelength of each drug using UV spectrophotometry (Cary 4000 UV-Vis) and compared to a 
calibration curve produced using a series dilution of each drug in methanol. Drug loading of each 
MC suspension was expressed as a weight percentage of drug in the dried MCs. The Eudragit
®
 RS 
NP loading of each MC suspension was measured using the Tropaeolin OOO method as described 
in Section 3.2.4 and expressed as a weight percentage of Eudragit
®
 RS NPs in the dried MCs. 
Chitosan-HPMC MCs incorporating indomethacin- or curcumin-loaded NPs prepared using pH 10 
trisodium phosphate solution were coated by Eudragit
®
 S100 at a weight ratio of 1.5:1 of MCs to 
Eudragit
®
 S100. 5 mL of MC suspension in distilled water containing 80 mg MCs was added to 
Eudragit
®
 S100 in methanol solution (5 mL, 2.4 % w/v) under gentle magnetic stirring. After 0.5 h 
incubation in a vacuum oven at room temperature, distilled water (15 mL) was added to the 
suspension and the methanol was evaporated overnight. Coated MCs were collected by 
centrifugation at 1000 rpm for 2 min and a 4 mL aliquot of supernatant was freeze dried and 
dissolved in ethanol or tropaeolin solution for UV-VIS analysis as described above to check loss of 
drug or Eudragit
®
 RS NPs during coating. Coated MCs were prepared in triplicate and finally re-
suspended in 5 mL of distilled water for analysis of in vitro release. Eudragit
®
 S100 coating was not 
applied to MCs prepared at pH 8 since the MCs showed incomplete cross-linking of chitosan under 
the microscope and were found to disintegrate after coating. In addition, the low loading efficiency 
for 5-FU NP-loaded MCs meant that it was difficult to determine drug concentration in release 
samples.  
The size of NP-loaded MCs at 25 °C was measured three times. The morphology of uncoated and 
coated MCs suspended in distilled water was examined by optical microscopy (Olympus CKX41 
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inverted microscope in conjunction with an Olympus DP21 camera, Japan). The size distribution of 
Eudragit
®
 S100 coated indomethacin NP- or curcumin NP-loaded MCs was determined using 
dynamic light scattering (Malvern Mastersizer 2000, Malvern, UK). 
5.2.4 In vitro drug release  
In vitro release of indomethacin or curcumin from drug-loaded Eudragit
® 
RS NPs and Eudragit
®
 
S100-coated NP-loaded Chitosan-HPMC MCs was investigated using a dialysis tubing test 
procedure as described in Chapter 2 (under Section ‘indomethacin release from NPs and alginate 
pellets’). The selection of release media and incubation times is explained in Chapter 2 under 
Section ‘Eudragit® RS NP release from alginate microcapsules’. For all formulations, 1 mL of each 
suspension was placed in a dialysis tube (molecular weight cut-off: 3500Da) and immersed in 
simulated gastric fluid (SGF, 4 mL) for 2 h at 37°C. The dialysis tube was then transferred to 
simulated intestinal fluid (SIF, 4 mL) for 6 h, and finally into simulated colonic fluid (SCF, 4 mL) 
for 6 h. Samples were prepared in triplicate and 4 mL of release medium was collected every hour 
and replaced with fresh medium (4 mL). The concentration of indomethacin in collected release 
samples was measured by UV spectrophotometry at 265 nm for SGF samples and at 267 nm for SIF 
and SCF samples. Absorbance of curcumin in SGF release samples were measured at 429 nm and 
SIF and SCF samples at 432 nm. Calibration curves were prepared by dissolving indomethacin or 
curcumin at a known set of concentrations in each release medium. The drug release rate was 
calculated as the ratio of released drug against the initial drug loading of each formulation and 
expressed as cumulative release (% w/w) versus time (h).  
5.2.5 In vitro Eudragit® RS NP release from Eudragit® S100-coated Chitosan-HPMC 
MCs  
The in vitro NP release experiment was conducted using a procedure described in Section 3.2.5. 1 
mL of MC suspension was centrifuged at 1000 rpm for 1 min after which the supernatant was 
removed to avoid dilution of the release medium. Sedimented microcapsules were incubated with 
SGF (4 mL) for 2 h at 37°C, then transferred to SIF (4 mL) for 6 h, finally to SCF (4 mL) for 6 h. 
Samples were prepared in triplicate and 4 mL of release medium was collected every hour using a 
pipette tip wrapped with mesh cut from a Falcon™ cell strainer (mesh size: 40 µm) to avoid 
infiltration of microcapsules into the collected release samples. Fresh release medium (4 mL) was 
added each time after sample collection to replace the withdrawn volume of medium. Eudragit
® 
RS 
NP concentration in the release medium was determined by Tropaeolin OOO method as described 
in Section 3.2.5. The NP release rate was calculated as the ratio of released Eudragit
®
 RS NPs 
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against the initial loading in MCs and expressed as cumulative release (% w/w) versus time (h). To 
examine drug (indomethacin or curcumin) content in released Eudragit
®
 RS NPs, the remaining 1 
mL aliquots of representative simulated colonic fluid samples were freeze dried, dissolved in 
methanol and subsequently scanned by UV spectrophotometry to check the presence of drug in the 
release samples.  
5.2.6 Cytotoxicity of drug-loaded Eudragit® RS NPs  
The cytotoxicity of drug-loaded NPs was assessed using the MTS assay. This assay determines the 
relative number of living cells by quantifying the formation of a colored formazan at 490 nm, for 
only living cells can reduce MTS reagent to formazan and the absorbance is proportional to the 
number of living cells. A lower absorbance observed in treated cells compared to untreated control 
cells indicates inhibition of cell proliferation by the sample tested, thus suggesting a cytotoxic effect 
of the sample on a particular set of cells.  
Mouse embryonic fibroblast NIH/NIH/3T3 cells and human colon adenocarcinoma HT29 cells 
were seeded in 96-well plates at a density of 5×10
3
 cells/well in 100 µL medium and allowed to 
attach for 24 h. Then the medium was replaced with 100 µL culture medium containing curcumin, 
curcumin NPs and blank Eudragit
®
 RS NPs (without curcumin loaded) at various concentrations 
(Table 5-2). Concentrations of curcumin were selected based on the reported IC50 value of 50±0.015 
μM on HT29 cells5 and curcumin NPs containing equivalent drug amounts to the curcumin 
solutions were investigated. Blank Eudragit
®
 RS NPs (without drug loaded) containing equivalent 
amount of NP materials to curcumin NPs were tested. After 24 h or 48 h incubation, cell viability 
was measured by MTS assay following the manufacturer’s protocol and expressed as the relative 
metabolic activity compared to control cells grown in culture medium. Three independent wells 
were prepared for each sample condition and results were presented as mean ± standard deviation. 
The experimental data were analyzed using GraphPad Prism 6. The cytotoxicity of curcumin-loaded 
NPs under each incubation condition was compared to the corresponding curcumin solution or 
blank Eudragit
®
 RS NPs using two-way ANOVA with a Sidak's multiple comparisons test. The 
cytotoxicity difference between HT29 cells and NIH/3T3 cells treated by each formulation 
(curcumin solution, curcumin-loaded NPs or blank Eudragit
®
 RS NPs) was examined by two-way 
ANOVA. A p value < 0.05 was considered significantly different. 
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Table 5-2 Concentrations of curcumin solution, curcumin NPs and blank Eudragit
®
 RS NPs 
tested for cytotoxicity on NIH/NIH/3T3 and HT29 cells 
Samples of each drug group Concentration (µg/mL) 
Curcumin solution 3.7 (10 µM) 14.75 (40 µM) 29.5 (80 µM) 
Curcumin NPs 40.9 163.75 327.5 
blank Eudragit
®
 RS NPs 37.5 150 300 
5.3 Results and discussion  
5.3.1 Characterisation of Eudragit® RS NPs loaded with 5-FU, indomethacin or curcumin 
Table 5-3 presents size distribution and drug loading analysis of Eudragit
®
 RS NPs loaded with 5-
FU, indomethacin or curcumin. Eudragit
®
 RS NPs loaded with the drugs were prepared under 
different formulation conditions, which had been optimized in preliminary studies to produce NPs 
of similar drug loadings (approximately 10%, w/w shown in Table 5-3). 5-FU has a relatively low 
molecular weight of 130.08 g/mol and its water solubility is approximately 10 mg/mL.
6
 It was 
found that NPs prepared by dissolving 5-FU and Eudragit
®
 RS PO in 2-butanone resulted in low 
drug loading (0.4-2.2%, w/w). It was also observed that 5-FU loading in NPs increased with the 
weight ratio of 5-FU to Eudragit
®
 RS PO, as more drug was available for encapsulation. The 
volume ratio of 2-butanone to water phase was used at 1:1 to minimize 5-FU loss caused by drug 
dissolution in the water phase, while at the same time maintaining an oil-in-water emulsion. This 
approach resulted in the desired 10% (w/w) loading. In contrast to 5-FU, indomethacin and 
curcumin are hydrophobic drugs with low water solubilities, thus injection of a mixture of drug and 
Eudragit
®
 RS PO in acetone to water phase resulted in a satisfactory drug loading of approximately 
10% (w/w) in Eudragit
®
 RS NPs. For both drugs, the encapsulation efficiency by Eudragit
®
 RS NPs 
was much higher than that for 5-FU-loaded NPs, indicating that Eudragit
®
 RS NPs were more 
efficient at encapsulating hydrophobic drugs than hydrophilic drugs. Nonetheless, nanoparticles 
containing approximately 10 % drug by weight were obtained for all three drugs using these two 
formulation approaches. Their Z-average size, PDI and zeta-potential of all drug-loaded NPs was 
similar to those of the Cy5 NPs without drug encapsulation described in Chapter 4 (198.7 nm, 0.201 
and 50.0±6.24 mV, respectively; see Section 4.3.2), implying that incorporation of these drugs did 
not significantly change the size distribution or surface charge of  Eudragit
®
 RS NPs. 
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Table 5-3 Characterisation of Eudragit
®
 RS NPs loaded with 5-FU, indomethacin, 
curcumin 
Drug-loaded Eudragit
®
 
RS NPs 
Size distribution of drug-
loaded NPs 
Drug encapsulation by NPs 
Z-ave 
(nm) 
 
PDI 
zeta 
potential 
(mV) 
drug loading 
(%, w/w) 
encapsulation 
efficiency  
(%, w/w) 
NP yield  
(%, w/w) 
5-FU NPs 153.0 0.184 53.7±4.2 10.7±1.9  6.4±1.3 29.9±4.6   
Indomethacin NPs 210.8 0.301 48.5±9.4 10.8±1.3  57.7±0.8 48.8±5.3 
Curcumin NPs 165.6 0.282 51.7±7.2 9.1±1.8 71.9±2.5 25.6±4.7 
5.3.2 Encapsulation of drug NPs in chitosan-hypromellose microcapsules 
The capacity of MCs to encapsulate drug-loaded NPs was investigated by determining 1) the 
amount of drug and 2) the amount of NPs that were encapsulated. Even though the drug was 
initially encapsulated within the Eudragit
®
 RS NPs, drug diffusion from NPs into the preparation 
medium may occur during microencapsulation, and consequently decrease drug content in the final 
NP-loaded MC formulation. Thus the aims of this section were 1) to examine if the drugs remained 
incorporated in NPs during the process of MC encapsulation and 2) to optimize the formulation 
conditions for an improved encapsulation of drug-loaded NPs in MCs. 
In Chapter 4, chitosan-HPMC MCs were prepared through cross-linking chitosan using Na3PO4. 
The mixture of Na3PO4 solution and ethanol used as preparation medium of MCs had a pH of 
approximately 12.2 due to the presence of phosphate ion in solution. Preliminary experiments for 
incorporating drug-loaded NPs in MCs using the Na3PO4-ethanol solution showed a fairly low drug 
loading (less than 0.2%, w/w) within the MCs, most likely resulting from drug extraction by the 
strongly alkaline preparation medium during the overnight cross-linking step. Thus, in an attempt to 
understand and improve encapsulation of drug-loaded Eudragit
®
 RS NP by chitosan-HPMC MCs 
the pH of Na3PO4-ethanol solution was adjusted to 8 or 10.  
Figure 5-1 presents drug loading and Eudragit
®
 RS NP loading of MCs prepared under different pH 
conditions. Although Eudragit
®
 RS NPs containing approximately 10% (w/w) of each drug were 
used for encapsulation into MCs, the concentrations of 5-FU-loaded NPs, indomethacin-loaded NPs 
and curcumin-loaded NPs in each suspension were different, 5, 16 and 36 mg/mL, respectively, as 
evidenced by the different theoretical loading shown in Figure 5-1. MCs showed the lowest drug 
loading for 5-FU (Figure 5-1A), regardless of the pH of the preparation medium. This can be 
explained by the low 5-FU NP concentration (5 mg/mL) in suspension used for preparing NP-
loaded MCs and the high solubility of 5-FU in water. Nonetheless, encapsulation efficacy of 5-FU 
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NP-loaded MCs was approximately 20%, indicating that NPs were able to protect the loaded 5-FU 
from complete dissolution in the pH 8 preparation medium during the overnight cross-linking 
process. On the other hand, 5-FU NP-loaded MCs prepared in pH 10 medium did not show 
detectable 5-FU loading, implying the complete drug loss during the microencapsulation process. 
Similarly, MCs loaded with indomethacin NPs or curcumin NPs prepared at pH 8 showed a higher 
drug loading than that of MCs prepared at pH 10 due to increased solubility of both drugs at the 
higher pH. MCs exhibited a higher loading of curcumin than indomethacin prepared under same pH 
conditions, because a larger amount of curcumin-loaded NPs were used for encapsulation by MCs 
than indomethacin NPs and curcumin had a lower solubility than indomethacin in the same cross-
linking medium. 
Figure 5-1 Effect of preparation medium pH on drug loading (A) and Eudragit
®
 RS NP 
loading (B) of chitosan-HPMC MCs compared to their corresponding theoretical drug/NP 
loading. The theoretical drug/NP loading was expressed as weight percentage of the 
drug/NPs used in the formulation relative to total weight (drug-loaded NPs plus MC 
materials).  
Analysis of NP encapsulation in MCs (Figure 5-1B) showed that 5-FU NP-loaded MCs had the 
lowest NP loading while curcumin NP-loaded MCs had the highest among the three drug-NP 
loaded MC groups. These values correlated well with the amount of NPs used for preparing the 
MCs. With the exception of 5-FU-loaded NPs, MCs prepared at pH 10 had a slightly higher NP 
loading than those prepared at pH 8, probably due to more efficient crosslinking and hence the 
formation of a more compact microcapsule matrix at higher pH enabling a more efficient 
entrapment of NPs. This was confirmed by microscopic observation of MCs loaded with 
indomethacin- or curcumin-NPs (Figure 5-2), which showed incomplete cross-linking of chitosan in 
the pH 8 preparation medium (Figure 5-2, A and D) and spherical microcapsule formation at pH 10 
(Figure 5-2, B and E). This was likely due to the limited availability of phosphate ions (PO4 
3−
) at 
pH 8 required for cross-linking with chitosan compared to pH 10 medium.  
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Overall, drug or NP loading of MCs was influenced by two major factors: 1) the initial amount of 
drug or Eudragit
®
 RS NPs available for encapsulation by MCs (in this study, 5-FU NPs < 
indomethacin NPs < curcumin NPs) and 2) the extent of drug/NP diffusion through MC matrix to 
the preparation medium (influenced by the efficiency of the cross-linking protocol). Thus, high 
yielding NPs produced with high drug loading would potentially improve the ability for MCs to 
deliver a high payload to the colon. However, this is ultimately influenced by drug solubility in MC 
preparation medium, NP stability during microencapsulation and cross-linking chemistry and 
density of MCs. 
Optical microscopy (Figure 5-2) revealed that the majority of MCs (uncoated or Eudragit
®
 S100-
coated, loaded with indomethacin- or curcumin-NPs) prepared at pH 10 were less than 200 µm in 
diameter. Dynamic light scattering measurements showed that 90% of Eudragit
®
 S100-coated MCs 
loaded with indomethacin NPs and curcumin NPs were less than 130 and 115 µm in size, 
respectively. Importantly, MCs loaded with indomethacin NPs retained their spherical shape after 
Eudragit
®
 S100 coating (Figure 5-2 C), while some MCs loaded with curcumin NPs deformed after 
coating (Figure 5-2 F; non-spherical particles more than 50 µm in size). This implies that curcumin 
NP-loaded MCs were more prone to structural damage caused by centrifugation than their 
indomethacin-loaded counterparts. One possible reason is that at high concentrations, the 
positively-charged curcumin-loaded Eudragit
®
 RS NPs impaired the cross-linking of MCs by 
interfering with ionic interactions between phosphate ions and amino groups of chitosan. During 
coating of MCs, loss of indomethacin into the formulation medium was shown to be negligible. 
Conversely, approximately 8.6% of the curcumin was lost during the coating process. Owing to the 
low 5-FU loading, 5-FU-loaded chitosan-HPMC MCs were not coated for further studies and the 
next section just focuses on carriers loaded with curcumin or indomethicin. 
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Figure 5-2 Optical micrographs show indomethacin NP-loaded MCs (A, B, C) and 
curcumin NP-loaded MCs (D, E, F). MCs prepared at pH 8 cross-linking medium (A, D); or 
pH 10 (B, E); MCs prepared at pH 10 and coated with Eudragit
®
 S100 (C, F). 
5.3.3 In vitro drug release from drug-loaded Eudragit® RS NPs and Eudragit® S100-
coated Chitosan-HPMC MCs 
Release profiles of indomethacin from Eudragit
®
 RS NPs and Eudragit
®
 S100-coated chitosan-
HPMC MCs are presented in Figure 5-3. Indomethacin release from Eudragit® RS NPs began in 
SGF at a low rate, with less than 5% of the indomethacin load released over the first 2 h incubation. 
In comparison, 20% and 25% of the indomethacin load was released over 6 h incubation in SIF (pH 
6.8) and SCF (pH 7.4), respectively, indicating a faster and constant drug release compared with 
SGF (pH 1.2). This could be explained by the higher indomethacin solubilities under higher pH 
conditions, as reported by Munjeri et al.
9
 (solubilities of indomethacin at pH 1, 6.8 and 7.4 were 
0.0005, 1 and 1.3 mg/mL, respectively).  
For Eudragit
®
 S100-coated MCs loaded with indomethacin-NPs, indomethacin release was 
negligible in SGF due to the stability of the Eudragit
®
 S100 coating at low pH. Compared to 
indomethacin-NPs, MCs exhibited a slower drug release in SIF and SCF, possibly because the 
chitosan-HPMC hydrogel impeded drug diffusion into surrounding fluid. However, this in vitro 
release model  was limited to the effect of pH variations in gastrointestinal tract whereas the in vivo 
performance of drug delivery systems is affected by additional biological factors such as particle 
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interaction with gastric mucosa, digestive enzymes in the gastrointestinal tract and particle retention 
in the colon. The in vivo study presented in Chapter 4 demonstrated the superior efficacy of NP-
loaded MCs over un-encapsulated NPs for delivery to the colon, since MCs had a slower transit 
than NPs in mouse gastrointestinal tract and protected NPs from fast excretion in faeces, thus 
increasing NP concentration and residence time in the colon. Also, the observed adhesion of 
unencapsulated NPs to gastric mucosa and their prolonged retention in the stomach (Chapter 4) 
could result in the majority of drug load being released in the stomach.  
In contrast, curcumin release from Eudragit
®
 RS NPs and Eudragit
®
 S100-coated MCs was 
negligible over the time frame investigated, probably due to the very low solubility of curcumin in 
water at acidic or neutral pH.
11,12
 
Figure 5-3 Cumulative indomethacin release from drug-loaded Eudragit
®
 RS NPs and 
Eudragit
®
 S100-coated Chitosan-HPMC MCs in simulated gastric fluid (SGF), intestinal 
fluid (SIF) and colonic fluid (SCF) (mean±S.D, n=3). 
5.3.4 In vitro Eudragit® RS NP release from Eudragit® S100-coated Chitosan-HPMC 
MCs 
To further evaluate the delivery system, the in vitro release behaviour of the drug-loaded Eudragit
®
 
RS NPs from coated MCs was investigated (Figure 5-4). Given that the aim of this study was to 
develop a system where drug-loaded NPs were delivered to the colon, it was important to 
investigate how much of the initially loaded drug was still entrapped in the NP carrier upon 
reaching the colon. Tropaeolin OOO analysis (as described in Section 4.3.3) showed that drug-
loaded NPs were not released from coated MCs into SGF over 2 h incubation. However, in SIF, 
there was a cumulative release of approximately 10% of the NP load from MCs over 6 h. During 
the subsequent 6 h incubation in SCF, 20% and 22% of the NP content were released from 
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indomethacin NP- and curcumin NP-loaded MCs, respectively (Figure 5-4). This release behaviour 
most likely arises from slow dissolution of the Eudragit
®
 S100 coating in SIF and SCF. In the case 
of curcumin, most of the drug remained entrapped within the released NPs owing to the relative 
hydrophobicity of the drug, suggesting that Eudragit
®
 S100 coated-MCs are a useful carrier for 
delivering curcumin-loaded NPs to the colon. In contrast, analysis of indomethacin in release 
samples showed a considerable portion of the indomethacin had been released as free drug in SCF 
instead of remaining in the released NPs. This observation arises through analysis of the cumulative 
drug release in SCF (~ 25% - 60% over 6 hours, Figure 5-3) compared to the cumulative NP release 
calculated by the Tropaeolin OOO analysis shown in Figure 5-4 (~10% - 30%).The different drug 
partition behaviors of indomethacin and curcumin between SCF and released Eudragit
® 
RS NPs 
could be explained by the higher solubility of indomethacin (reported to be 1.3 mg/mL
9
 and 1.5 
mg/mL
2
 in pH 7.4 PBS) compared with curcumin (lower than 15 µg/mL
13
) in SCF, leading to a 
greater drug diffusion from NPs into the release medium. 
 In summary, solubility of these candidate drugs in gastrointestinal fluids is an important factor, as 
it determines the extent of drug diffusion from NP-loaded MCs into the surrounding gastrointestinal 
enviroment, and thus the amount of drug-loaded NPs reaching the colon. 
Figure 5-4 Cumulative release of indomethacin-loaded Eudragit
® 
RS NPs or curcumin-
loaded Eudragit
® 
RS NPs from Eudragit
®
 S100-coated MCs in simulated gastric fluid 
(SGF), intestinal fluid (SIF) and colonic fluid (SCF) (mean±S.D, n=3).  
 
5.3.5 Cytotoxicity of drug-loaded Eudragit® RS NPs 
In vitro cytotoxicity studies have been widely used for pre-clinical evaluation of drug-loaded NPs 
on their potential for improving efficacy of anticancer drugs.
14,15
 Such studies examine the influence 
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of drug-loaded NPs on growth of cells in vitro. In this study, the MTS assay was used to determine 
the cytotoxicity of curcumin NPs on HT29 human colon adenocarcinoma cells and NIH/3T3 mouse 
embryonic fibroblast with that for curcumin solution and blank Eudragit
®
 RS NPs. This was to 
examine if 1) drug encapsulation by Eudragit
®
 RS NPs affected drug cytotoxicity and 2) whether 
there was any specificity for tumour cells due to physicochemical properties of the NPs and 3) 
whether the drug carriers (Eudragit
®
 RS NPs) by themselves inhibit proliferation of normal cells 
and thus may be potentially toxic to healthy tissues. The corresponding indomethacin samples were 
not tested in this study because of the poor encapsulation of indomethacin within MCs and the high 
rate of drug release from NPs in simulated colonic fluid (Section 5.3.4), and so cytotoxicity studies 
discussed in this section utilised only curcumin as a model drug. 
As shown in Figure 5-5 the cytotoxicity of the three formulations (curcumin, curcumin NPs and 
blank Eudragit
®
 RS NPs) on HT29 and NIH/3T3 cells was found to be dependent on sample 
concentration and incubation time. At 10 µM, there was no significant difference in cytotoxicity 
between curcumin solution and curcumin NPs for either cell type after 24 or 48 h incubation, 
although both formulations were cytotoxic compared with blank NPs. In contrast, at a concentration 
of 40 µM, cytotoxicity of curcumin NPs for both HT29 and NIH/3T3 cells was approximately 10-
20% higher than that for free curcumin after 24 h and 48 h incubation. Curcumin NPs at 80 µM 
showed considerable cytotoxicity against HT29 cells after 48 h incubation, for the cell proliferation 
was reduced to 17% of the value for untreated cells. This compared with reductions in HT29 cell 
proliferation to 50% and 85% of control for free curcumin solution and blank Eudragit
®
 RS NPs 
respectively. Under the same incubation conditions, curcumin solution, curcumin NPs and blank 
Eudragit
®
 RS NPs reduced proliferation of NIH/3T3 cells to 73%, 45% and 84%, respectively. 
These results indicate that encapsulation of curcumin by Eudragit
®
 RS NPs enhances the 
cytotoxicity of curcumin on both cell lines, which may be attributed to NPs enhancing cellular 
uptake of curcumin. This result is in agreement with that of Mohanty et al.
16
 who reported that 
compared to free curcumin, copolymeric micelles prepared from methoxy poly(ethylene glycol) and 
poly-e-caprolactone increased cellular uptake of curcumin by pancreatic cancer cells 2 to 3-fold . 
Similarily, curcumin-loaded solid lipid nanoparticles have shown considerably higher cellular 
uptake and cytotoxicity in MCF-7 breast cancer cells than free drug.
17
 Importantly, the results 
showed that HT29 cells were more susceptible to curcumin solution or curcumin NPs than NIH/3T3 
cells, while there was no significant difference in cytotoxicity of blank Eudragit
®
 RS NPs between 
the two cell types. These results suggest that curcumin may show some selectivity for tumour cells 
compared to normal cells as has been previously reported
18
. The slight toxicity of blank Eudragit
®
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RS NPs on both types of cells reflects similar cellular uptake kinetics of Cy5 NPs by HT29 and 
NIH/3T3 cells, (see Section 4.3.4). These findings suggest that Eudragit
 ®
 RS NPs may cause toxic 
side effects when released in the colon since both normal and tumour cells would endocytose the 
NPs to similar extent. A promising solution for this problem is to conjugate them to targeting 
ligands so that the NPs can be selectively taken up by cancer cells, thus reducing toxicity to normal 
cells
19-21
. Taken together, these results demonstrated that Eudragit
®
 RS NPs have the potential to 
enhance the anticancer activity of curcumin. Strategies to increase their selectivity towards 
colorectal cancer cells will avoid potential side effects resulting from interaction with normal cells. 
 
Figure 5-5 Cytotoxicity of curcumin solution, curcumin NPs and blank Eudragit
®
 RS NPs 
on HT29 (a, b) and NIH/3T3 (c, d) cells after 24 or 48h incubation (mean± S.D, n = 3). The 
X axis shows the curcumin concentration in solution or incorporated in NPs. Blank 
Eudragit
®
 RS NPs were tested at concentrations of 0.295, 1.18 and 2.36 mg/mL, respectively, 
equivalent to the NP concentrations in curcumin-loaded NP formulations. (*p value <0.05; 
two-way ANOVA with Sidak's multiple comparisons test).  
 E q u iv a le n t  c u r c u m in  c o n c e n tr a tio n
R
e
la
ti
v
e
 c
e
ll
 n
u
m
b
e
r
(p
e
r
c
e
n
t 
o
f 
c
o
n
tr
o
l)
1 0  M 4 0  M 8 0  M
0
2 0
4 0
6 0
8 0
1 0 0
1 2 0
1 4 0 * *
* * *
 E q u iv a le n t  c u r c u m in  c o n c e n tr a tio n
R
e
la
ti
v
e
 c
e
ll
 n
u
m
b
e
r
(p
e
r
c
e
n
t 
o
f 
c
o
n
tr
o
l)
1 0  M 4 0  M 8 0  M
0
2 0
4 0
6 0
8 0
1 0 0
1 2 0
1 4 0
*
* * *
*
 E q u iv a le n t  c u r c u m in  c o n c e n tr a tio n
R
e
la
ti
v
e
 c
e
ll
 n
u
m
b
e
r
(p
e
r
c
e
n
t 
o
f 
c
o
n
tr
o
l)
1 0  M 4 0  M 8 0  M
0
2 0
4 0
6 0
8 0
1 0 0
1 2 0
1 4 0 * *
* * *
 E q u iv a le n t  c u r c u m in  c o n c e n tr a tio n
R
e
la
ti
v
e
 c
e
ll
 n
u
m
b
e
r
(p
e
r
c
e
n
t 
o
f 
c
o
n
tr
o
l)
1 0  M 4 0  M 8 0  M
0
2 0
4 0
6 0
8 0
1 0 0
1 2 0
1 4 0
*
* *
H T 2 9  ce lls , 2 4  h H T 2 9  ce lls , 4 8  h
3 T 3  c e lls , 2 4  h 3 T 3  c e lls , 4 8  h
a
d
b
c
C u r c u m in , H T 2 9  c e l ls
C u r c u m in  f r e e  N P s , H T 2 9  c e l l s
C u rc u m in  N P s , H T 2 9  c e l ls
C u rc u m in , 3 T 3  c e l l s C u rc u m in  N P s , 3 T 3  c e l l s
C u rc u m in  f r e e  N P s , 3 T 3  c e l l s
Chapter 5 
 
 120 
5.4 Conclusions 
This chapter studied the incorporation of three drug candidates (5-FU, indomethacin and curcumin) 
with different solubilities into the optimised carrier systems developed in Chapter 4.  The different 
aqueous solubilities of the three drugs resulted in different drug loadings of NPs and MCs; their in 
vitro release kinetics were also different. For each of the three drugs, a loading of approximately 10% 
(w/w) in Eudragit
®
 RS NPs was achieved. Hydrophobic indomethacin and curcumin exhibited a 
more efficient encapsulation by Eudragit
®
 RS NPs than the hydrophilic 5-FU. Encapsulation of 5-
FU into NP-loaded MCs was not successful due to its high solubility in aqueous preparation 
medium of MCs. Moreover, drug loading of NP-encapsulated MCs was dependent on the medium 
used for MC preparation, with the amount of drug loaded decreasing with the increase of drug 
solubility in the preparation medium. Conversely, the in vitro drug release from Eudragit
®
 RS NPs 
or Eudragit
®
S100-coated MCs in simulated intestinal and colonic fluids correlated with drug 
solubility such that, commensurate with its higher solubility, indomethacin had a higher release rate 
than curcumin. Eudragit
®
 RS NPs were released from coated MCs at a similar rate, regardless of 
which drug was encapsulated (indomethacin or curcumin). However, curcumin-NPs released from 
coated MCs retained a higher drug loading than indomethacin-NPs, indicating that the MCs could 
potentially deliver the majority of the curcumin-loaded NPs to the colon without premature drug 
release in the stomach and small intestine. The results also show that Eudragit
®
 RS NPs enhanced 
the cytotoxicity of curcumin on both NIH/3T3 cells and HT29 cells, but lacked specificity for 
cancerous HT29 cells. These results demonstrate the potential of MCs for improving the efficacy of 
chemotherapeutic drugs especially drugs such as curcumin which have limited aqueous solubility.  
Importantly, delivery of drug to the tumour site reduces the amount of drug required and protects 
normal cells from the toxic side-effects associated with systemic delivery. This chapter forms a 
useful foundation for further studies to develop delivery systems for tumour-targeted delivery of 
anticancer drugs. 
5.5 Appendix  Predicted mass solubilities of 5-FU, indomethacin and 
curcumin under different pH conditions using Advanced Chemistry 
Development (ACD/Labs) Software V11.02 
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Appendix 1 Predicted mass solubilities of 5-FU under different pH conditions using Advanced 
Chemistry Development (ACD/Labs) Software V11.02 (data from Scifinder database
22
) 
Chemical properties Value Condition 
Mass intrinsic solubility Soluble (21 g/L) Temp: 25 ⁰C 
Mass solubility Soluble (21 g/L) pH 1 Temp: 25 ⁰C 
Mass solubility Soluble (21 g/L) pH 2 Temp: 25 ⁰C 
Mass solubility Soluble (21 g/L) pH 3 Temp: 25 ⁰C 
Mass solubility Soluble (21 g/L) pH 4 Temp: 25 ⁰C 
Mass solubility Soluble (22 g/L) pH 5 Temp: 25 ⁰C 
Mass solubility Soluble (29 g/L) pH 6 Temp: 25 ⁰C 
Mass solubility Soluble (99 g/L) pH 7 Temp: 25 ⁰C 
Mass solubility Very soluble (604 g/L) pH 8 Temp: 25 ⁰C 
Mass solubility Very soluble (1000 g/L) pH 9 Temp: 25 ⁰C 
Mass solubility Very soluble (1000 g/L) pH 10 Temp: 25 ⁰C 
Mass solubility Soluble (21 g/L) Unbuffered water pH 3.60 Temp: 25 ⁰C 
 
Appendix 2 Predicted mass solubilities of indomethacin under different pH conditions using 
Advanced Chemistry Development (ACD/Labs) Software V11.02 (data from Scifinder 
database
23
) 
Chemical properties Value Condition 
Mass intrinsic solubility Sparingly soluble (6.1E-3 g/L) Temp: 25 ⁰C 
Mass solubility Sparingly Soluble (6.1E-3 g/L) pH 1 Temp: 25 ⁰C 
Mass solubility Sparingly Soluble (6.1E-3 g/L) pH 2 Temp: 25 ⁰C 
Mass solubility Sparingly Soluble (6.8E-3 g/L) pH 3 Temp: 25 ⁰C 
Mass solubility Sparingly Soluble (0.013 g/L) pH 4 Temp: 25 ⁰C 
Mass solubility Sparingly Soluble (0.075 g/L) pH 5 Temp: 25 ⁰C 
Mass solubility Sparingly Soluble (0.68 g/L) pH 6 Temp: 25 ⁰C 
Mass solubility Slightly soluble (5.7 g/L) pH 7 Temp: 25 ⁰C 
Mass solubility Soluble (23 g/L) pH 8 Temp: 25 ⁰C 
Mass solubility Soluble (33 g/L) pH 9 Temp: 25 ⁰C 
Mass solubility Soluble (34 g/L) pH 10 Temp: 25 ⁰C 
Mass solubility Sparingly Soluble (0.022 g/L) 
Unbuffered water pH 4.37 Temp: 
25 ⁰C 
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Appendix 3 Predicted mass solubilities of curcumin under different pH conditions using 
Advanced Chemistry Development (ACD/Labs) Software V11.02 (data from Scifinder 
database
24
) 
Chemical properties Value Condition 
Mass intrinsic solubility Sparingly Soluble (0.044 g/L) Temp: 25 ⁰C 
Mass solubility Sparingly Soluble (0.044 g/L) pH 1 Temp: 25 ⁰C 
Mass solubility Sparingly Soluble (0.044 g/L) pH 2 Temp: 25 ⁰C 
Mass solubility Sparingly Soluble (0.044 g/L) pH 3 Temp: 25 ⁰C 
Mass solubility Sparingly Soluble (0.044 g/L) pH 4 Temp: 25 ⁰C 
Mass solubility Sparingly Soluble (0.044 g/L) pH 5 Temp: 25 ⁰C 
Mass solubility Sparingly Soluble (0.044 g/L) pH 6 Temp: 25 ⁰C 
Mass solubility Sparingly Soluble (0.052 g/L) pH 7 Temp: 25 ⁰C 
Mass solubility Sparingly Soluble (0.096 g/L) pH 8 Temp: 25 ⁰C 
Mass solubility Sparingly Soluble (0.63 g/L) pH 9 Temp: 25 ⁰C 
Mass solubility Soluble (13g/L) pH 10 Temp: 25 ⁰C 
Mass solubility Sparingly Soluble (0.044 g/L) 
Unbuffered water pH 3.60 Temp: 
25 ⁰C 
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Chapter 6. Conclusions and future directions 
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Despite improvements in chemotherapeutic drugs, the efficacy of conventional delivery systems for 
colorectal cancer is limited by non-specific toxic effects on normal non-cancerous tissue. Hence 
there is a need to develop delivery systems capable of delivering high drug concentrations to the 
tumour site, while minimising damage to surrounding normal tissue
1-4
. Of the numerous strategies 
being investigated, drug-loaded nanoparticles (NPs) and colon-specific drug delivery systems show 
particular promise. Although mostly designed for intravenous injection, NPs have been shown in 
animal models to deliver anticancer drugs more effectively to tumour cells than straight injection of 
neat drug.
1,4
 By protecting drugs from release in the upper gastrointestinal tract, colon-specific drug 
delivery systems, such as microparticles
2,3
, pellets
5
, capsules
6,7
 and tablets
8
, have the potential to 
deliver drug at higher concentrations to the colon following oral administration. Recent advances in 
colon-specific delivery systems include the encapsulation of NPs in a microcapsule or pellet matrix 
and these ‘NP-in-particle’ systems have been shown to enhance delivery of anticancer drugs or 
gene-based therapeutics to the colon.
9-11
 These studies used biodegradable NPs for a complete 
release of their cargo in the intestinal tract and focused on the overall therapeutic effect relating to 
the tissue distribution of the drug or gene. However, the fate of those NPs that were encapsulated in 
the microcapsules was not well elucidated in their results.  
Currently, the encapsulation of drug-loaded NPs in colon-specific carriers for achieving specific 
interaction with cancer cells in the colorectal region has not been well investigated. Thus, the aim of 
this thesis was to develop a colon-specific carrier system to deliver drug-loaded nanoparticles to the 
colon. It involves three main components:  
1) Design and formulation of colon-specific delivery vehicles capable of protecting a therapeutic 
cargo from premature release; 
 2) In vitro and in vivo investigation of NP release from the carrier using models that simulate the 
gastrointestinal tract;   
3) Encapsulation of drug-loaded NPs within the carrier and analysis of drug/ NP release from the 
system.  
Thus, this thesis describes the formulation design and preclinical evaluation of colon-specific 
carriers encapsulating NPs, and demonstrates the potential of Eudragit
® 
S100-coated chitosan-
hypromellose microcapsules for improving colorectal cancer chemotherapy.  
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6.1 Production of colon-specific carriers for delivering individual NPs to the 
colon 
In the present study, Eudragit
®
 RS NPs were selected as model nanoparticles for the developmental 
formulation studies of carriers based on several formulation considerations. Firstly, a latex form of 
these NPs at a high concentration (300 mg/mL) is commercially available. The well-established 
industrial scale-production of Eudragit
®
 RS NPs ensures consistency of NP characteristics within a 
batch (e.g. size and surface charge). Minimal variation in these properties is important since they 
determine NP performance and inform on design properties for different carrier systems for 
delivering NPs to the colon. Secondly, previous reports
12-14
 have shown that the water-insoluble 
Eudragit
®
 RS NPs exhibited a sustained drug release and enhanced drug uptake by tumour cells. 
Finally, a simple assay for determining Eudragit
®
 RS100 concentrations reported by Melia et al.
15
 
enables accurate analysis of NP release from the carriers (i.e. the Tropaeolin OOO assay). Therefore, 
Eudragit
®
 RS NPs have been a useful model used in the studies of carrier formulation and NP 
delivery and stability.    
NPs are colloidal systems and have the tendency to aggregate due to their high free surface 
energy.
16,17
 Furthermore, the nano-particulate structure and drug incorporation may be changed 
during harsh formulation processes such as autoclaving
15
 and freeze-drying
18-20
. Thus, extra 
considerations must be taken into account when designing carrier systems suitable for delivering 
NPs. For the case of work described in this thesis, sustained colloidal stability of Eudragit
®
 RS NPs 
was necessary during encapsulation by colon-specific carriers, (i.e. prevent NP from aggregation or 
deformation). This was required to ensure the presence of unmodified NPs in the final formulated 
carriers, which are available for release in the colon and subsequent uptake by tumour cells. Thus, 
rigorous analysis of the NPs before and after encapsulation and release was undertaken to verify the 
structural integrity during formulation. 
The colon-specific carriers investigated in this thesis were prepared from alginate, hypromellose 
and the mixture of chitosan and hypromellose. Analysis of the stability of Eudragit
®
 RS NPs upon 
mixing with the different carrier materials showed that alginate microcapsules were unsuitable for 
delivery of Eudragit
®
 RS NPs because the electrostatic interaction between the two materials caused 
aggregation which in turn retarded NP release. However, Eudragit
® 
RS NPs dispersed in 
hypromellose or chitosan solution did not aggregate, and enteric-coated hypromellose capsules and 
chitosan-hypromellose microcapsules exhibited sustained NP release over time in simulated colonic 
fluid. In this thesis, the ionic properties of NPs and excipients were shown to be a key factor in 
inducing aggregation and this finding was in line with the results reported by other researchers
21,22
. 
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These results demonstrated that carriers produced from non-charged or positively charged polymers 
are suitable for delivering Eudragit
®
 RS NPs to the colon, as they minimize electrostatic 
interactions between NPs and carriers and thus enable release of non-aggregated NPs in the colon. It 
should be noted that other negatively charged polymers such as alginate may be similarly useful in 
fabricating carriers for delivery of negatively charged NPs. These results show that the surface 
charge of carrier materials affect the stability of NPs during the formulation process and hence 
plays a critical role in their aggregation behaviour upon release at the target site.  
6.2 NP release properties from carriers   
In vitro release studies have been widely used for development and evaluation of oral dosage 
forms.
5,7
 In this thesis, DRcaps
®
 capsules (hypromellose capsules) coated by Eudragit
®
 L100-55 or 
alginate (Chapter 3) and Eudragit
®
 S100-coated chitosan-hypromellose microcapsules (Chapter 3, 4 
and 5) were investigated using an established in vitro release model
23
 and have shown potential for 
delivering Eudragit
® 
RS NPs to the colon. The results demonstrated that the pH-responsive 
dissolution of coatings affected NP release kinetics, such that alginate-coated capsules (which do 
not dissolve below pH 7) exhibited a more colon-specific NP release than capsules coated by 
Eudragit
®
 L100-55 (dissolves above pH 5.5). For chitosan-hypromellose microcapsules (described 
in Section 3.3.5), Eudragit
®
 S100 coating restricted the cumulative NP release to approximately 1% 
in simulated gastric and intestinal fluid, implying that 99% of the NP content was potentially 
available for release in the colon. Release was slightly higher when lower amounts of Eudragit
®
 
S100 were used for coating microcapsules. An important characteristic of the formulation process 
was the degree of crosslinking of the microcapsule matrix. Preparation of the microcapsule matrix 
at lower pH (pH 10 (described in Section 5.3.4) compared to pH 12 (Section 4.3.3) )also increased 
the rate of premature NP release, due to a reduction in cross-linking degree of microcapsules. These 
results indicate that the NP release kinetics from the carrier are dependent on the type and amount 
of coating material, as well as the degree of crosslinking of the carrier matrix. To our knowledge, 
there is no investigation on release kinetics of NPs from comparable carrier systems in the literature. 
However, studies on colon-specific delivery of small molecule drugs and proteins have shown that 
the carrier structure and surface coating influenced the release of the content and mechanism of 
diffusion through the carrier matrix was proposed
24-29
. Hence, the dependence of the NP release 
kinetics on carrier formulation described in this thesis may be explained by the interplay of 
dissolution of the enteric-coating layers, swelling of the hypromellose capsules or chitosan 
microcapsules and NP diffusion through these carrier matrixes. 
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The accuracy of predicting efficacy of colonic delivery vehicles using in vitro release studies is 
compromised by the difficulty in replicating physiological conditions that are encountered in vivo, 
such as the presence of gastrointestinal mucus, peristaltic movement of the digestive tract, and 
inherent variations in pH and dosage transit time within the gastrointestinal tract. Animal studies 
provide an improved understanding of colon-specific delivery of NPs release because the full 
complements of gastrointestinal conditions are encountered and variability in these conditions can 
be assessed through multiple animal studies. The in vivo studies of Eudragit
® 
S100-coated NP-
loaded chitosan-hypromellose microcapsules presented in Chapter 4 revealed the complete release 
of NPs from microcapsules in the lower region of the small intestine of mice at 8 h following oral 
gavage. This release data was in close agreement with the in vitro NP release data. The efficacy of 
the designed microcapsule system for delivery of NPs to the colon was also demonstrated, with 
increased NP accumulation in the colon over the course of the study compared to delivery of the 
nanoparticles alone. However, the in vivo data also showed particle adhesion to stomach mucosa, 
resulting in retention of both microcapsules and un-encapsulated NPs in the stomach at considerable 
concentrations after 24 h. Further studies are required to monitor elimination of remaining particles 
from the stomach, and to assess the toxicity of residual particles in the stomach. Although the 
interactions (e.g. bioadhesion and penetration) between particulate systems and the gastrointestinal 
tract have been investigated,
30,31
 more in-depth studies are required to determine how the surface 
properties of particles influence their retention within the different regions of the gastrointestinal 
tract. Future studies should investigate other carrier systems with lower retention times in the 
stomach which could maximise the delivery of NP load to the colon. Promising candidate materials 
include alginate
32
, starch
33
, poly(epsilon-caprolactone)
10
, poly (anhydride)
34
, and silica
35
, for they 
have shown minimal gastric retention in animal models. 
6.3 Encapsulation of anti-cancer drugs in NP-loaded carrier system  
Three drugs with different solubility properties, fluorouracil (5-FU), indomethacin and curcumin 
were selected as model anti-colorectal cancer drugs and successfully loaded in Eudragit
®
 RS NPs. 
Drug hydrophobicity was shown to influence encapsulation by the hydrophobic Eudragit
®
 RS NPs, 
with 5-FU exhibiting a much lower encapsulation efficiency than indomethacin and curcumin. 
Incorporation of three drug-loaded NPs in microcapsules indicated that a high drug loading into 
microcapsules could only be obtained when two conditions are met: 1) the initial drug loading of 
NPs is high, and 2) the drug candidate has limited solubility in the alkaline microcapsule 
preparation medium. In vitro analysis showed that the cumulative release of indomethacin from 
Eudragit
®
 RS NPs was faster than that from the coated microcapsules, implying that the 
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microcapsule matrix impeded drug diffusion from NPs to release media. In contrast, curcumin 
exhibited very limited solubility in the release media, resulting in a negligible curcumin release 
from either NPs or coated microcapsules. However, release of Eudragit
®
 RS NPs from coated 
microcapsules was independent of the drug candidates incorporated in the system. These findings 
indicate the potential for coated microcapsules to deliver Eudragit
®
 RS NPs which are loaded with 
insoluble drugs such as the curcumin to the colon. For drugs like indomethacin which are soluble at 
near neutral pH (the pH range of small intestine and colon), premature drug release from NP-loaded 
microcapsules may occur in the small intestine and thus reduce the amount of drug delivered to the 
colon. Therefore, drug hydrophobicity and solubility in preparation and release media should be 
considered in detail during development of colon-specific drug delivery systems. Characterization 
of the physical status of the entrapped drug in the formulations is lacking in this thesis as the present 
work focused on drug encapsulation by, and release from, free NPs and NP-in-microcapsules. In 
future studies, characterization methods such as differential scanning calorimetry could be used for 
a detailed study of formulation development.  
Eudragit
®
 RS NPs enhanced the cytotoxicity of curcumin on both NIH/3T3 cells and HT29 cells but 
lacked specificity to cancerous HT29 cells. Various strategies exist to overcome this apparent lack 
of specificity for tumours tissue and currently NPs conjugated to targeting ligands have been shown 
specificity towards colorectal cancer cells.
36-39
 Ligands that have been investigated for targeting 
colorectal cancer include folic acid
40
, hyaluronic acid
1
, monoclonal antibody cetuximab
41
, αvβ(3)-
specific RGD peptide
42
, chemical synthetic peptide TCP-1
43
 and animal studies of NPs conjugated 
to these ligands have demonstrated the enhanced and selective accumulation in the tumours. Thus, 
before in vivo testing of our colon-specific carrier systems can be justified, further studies are 
required to identify ligands capable of specific targeting to colorectal tumours and investigate 
encapsulation of targeting-ligand conjugated NPs in the colon-specific carrier systems. 
6.4 Summary 
This thesis presents a comparative study of different carrier systems for delivering Eudragit
®
 RS 
NPs to the colon and ultimately assesses the potential of NP-loaded microcapsule systems for 
targeted drug delivery to cancer cells in the colorectal region. The major findings for each carrier 
system that was investigated are summarized in Table 6-1. 
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Table 6-1 Colon-specific carrier systems investigated in this thesis-in comparison with the 
current research  
1) Alginate microcapsules (Chapter 2)  
Major findings Similar carriers reported 
Alginate aggregated with the Eudragit
®
 RS 
NPs and this behaviour retarded NP release 
from alginate microcapsules. 
Alginate microspheres containing 
oxaliplatin-loaded NPs showed in vivo 
therapeutic effect but the stability and 
release of NPs was not examined in the 
reported study. (Urbanska et al.
9
) 
2) Enteric-coated hypromellose capsules (Chapter 3) 
NP/drug release from the carriers Similar carriers reported 
The in vitro study showed colon-specific 
release of NPs from the capsules and the 
dissolution of enteric coating played a major 
role in determining NP release kinetics. 
To our knowledge, no similar carriers have 
been reported for delivering NPs. 
Formulations prepared from these materials 
have shown potential for delivering drugs 
and proteins to the colon.
6,44,45
 
3) Chitosan-hypromellose microcapsules coated by Eudragit® S100 (Chapters 3, 4, 
5) 
NP/drug release from the carriers Similar carriers reported 
Crosslink density of the microcapsule matrix 
and coating determined NP release rate and 
could be adjusted to obtain controlled NP 
release kinetics. 
Microcapsules improved NP delivery to the 
colon in vivo compared to un-encapsulated 
NPs. Gastric retention of both NPs and 
microcapsules was observed and this issue is 
to be addressed in future studies. 
Hydrophobicity and solubility of drug played 
an important role in drug encapsulation and 
release from NP-loaded microcapsules. This 
carrier system could potentially deliver 
insoluble drugs to the colon. 
Studies on NP or microcapsule systems often 
focused on the tissue distribution of their 
payloads and subsequent therapeutic 
effects
2,46,47
, but few studies have 
investigated release of NPs from oral dosage 
forms. One similar study on ‘NP-in-
microcapsule system’ reported by Bhavsar et 
al.
10
 did not discuss NP release from the 
microcapsules. 
Particle interaction with gastrointestical tract 
has been investigated
31,48
, but a clear 
understanding of this behaviour has not 
developed. One similar observation was 
made by Thakral et al.
49
, where Eudragit
®
 
S100-coated chitosan microspheres showed 
mucoadhesion in excised goat colon. 
 
Since the Eudragit
®
 RS NPs used in this thesis do not specifically target cancer cells, targeting-
ligands conjugated to NPs which can selectively interact with cancer cells would be promising 
candidates for encapsulation by the microcapsule carriers developed in this thesis. Thus, future 
studies on this project are recommended as follows: 
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1) To develop targeting-ligand conjugated NPs and assess their efficiency for targeting 
colorectal cancer cells; 
2) To load anti-cancer drugs in the targeting NPs and incorporate the therapeutic NPs in the  
microcapsule carriers; 
3) To investigate the in vivo fate of the therapeutic NP-loaded microcapsules and evaluate their 
therapeutic effect in colorectal cancer animal models.  
Overall, this thesis described the development of a microcapsule system for delivering NPs to the 
colon. To my knowledge this thesis firstly investigated colon-specific delivery systems for 
delivering nanoparticles (instead of small molecule drugs) to the colon. The attempt to deliver 
particulate nanoparticles to the colon is the novelty of this thesis, as nanoparticles represent a 
different type of payload from small molecule drugs (explained in Section 6.1). The nanoparticle-
excipient can often lead to aggregation resulting from their electrostatic interaction and this should 
be avoided in the formulation process to maintain the colloidal stability of nanoparticles. This rule 
can be applied to the future design of other carrier systems for specific delivery of individual 
nanoparticles to disease sites. This thesis has broadened the application of colon-specific carrier 
systems from delivering small molecule drugs, peptides and proteins up to nanometre-sized 
polymeric NPs. It covers the critical issues to be addressed during the development of such a carrier 
system, including NP-excipient aggregation, carrier matrix formulation and coating, in vivo 
evaluation of the NP release from microcapsules, and release studies of drug-loaded NPs from 
carriers. The findings of this thesis increased our understanding of carrier systems and informed on 
future design of improved systems for delivering NPs to the colon. The microcapsules described in 
this thesis could be a useful carrier for delivering targeting ligand-conjugated NPs to the colon for 
achieving targeted drug delivery to tumour cells and improved cancer chemotherapy. 
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